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ABSTRACT 
 
Gestational age at delivery and birth weight are important predictors of fetal and infant health. 
Preterm infants and infants born with a low birth weight are at risk to a host of adverse health 
effects including neurological disabilities, breathing problems and chronic diseases later in life. 
Puerto Rico has one of the highest rates of preterm birth in the U.S. and the reasons behind this 
elevated rate are unclear. Chemical exposure during pregnancy could impact the mother, leading 
to adverse birth outcomes, or could pass through the placenta and directly impact the fetus. 
These adverse effects could potentially occur with very low concentrations of chemicals due to 
the vulnerable period of development. Phenols, parabens and triclocarban are a group of 
ubiquitous chemicals commonly found in personal care products and household items. These 
chemicals have been detected in the majority of the U.S. population, and a cohort in Puerto Rico, 
PROTECT, has higher concentrations of these chemicals as compared to the U.S. mainland.  
Phenols, parabens and triclocarban have also been linked to a number of growth parameters 
during pregnancy and at birth, including birth weight and gestational length. Endocrine 
disruption is a suspected pathway leading to these health outcomes. This dissertation focuses on 
the associations between urinary biomarkers of phenols, parabens and triclocarban on birth 
outcomes. The association between the exposure biomarkers and maternal hormones is also 
explored as a potential pathway. Maternal stress could modify the association between the 
exposure biomarkers and birth outcomes given the similar pathways involved between stress and 
gestational length. Therefore, the interaction between stress and the exposure biomarkers was 
explored.  
Aim 1 focused on the associations between the exposure biomarkers and maternal hormones in 
two study populations of pregnant women. The exposure biomarkers were associated with 
altered thyroid and reproductive hormones in the mother. Aim 2 and 3 were focused on the main 
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dissertation cohort in Puerto Rico, PROTECT. Aim 2 found changes in gestational length with 
higher concentrations of some of the biomarkers of exposure. Benzophenone-3, bisphenol-A, 
methylparaben and propylparaben were associated with an increase in gestational length, with 
stronger associations observed at the 16-20 weeks gestation time point in comparison to 24-28 
weeks. There was also evidence of a change in birth size with increased concentrations of the 
exposure biomarkers. Triclosan was associated with a higher odds of small for gestational age 
(SGA), and benzophenone-3 was associated with a higher odds of being large for gestational age 
(LGA). The relationship between bisphenol-S and birth size differed by study visit. At 16-20 
weeks gestation, bisphenol-S was associated with LGA; however, at 24-28 weeks gestation, 
bisphenol-S was associated with SGA. Aim 3 examined the modifying effect of maternal stress 
on the association between the exposure biomarkers and gestational length. Associations 
between exposure biomarkers and gestational length were stronger in the presence of an overall 
negative score of the life event survey, indicating maternal stress due to negative life events may 
make pregnancies more vulnerable to chemical exposure. Overall, these results add to the 
growing literature on the effects of phenols, parabens and triclocarban on pregnancy. Further 
studies are required to confirm these findings, particularly the temporal differences observed. 
This is the first study to look into the modifying effect of mater nal stress and these associations, 
and more studies are needed to confirm the findings observed.  
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 Introduction 
 
 
Background 
Gestational age at delivery and birth weight are important predictors of fetal and infant health. 
Preterm birth, defined as gestational length less than 37 weeks, is a leading cause of neonatal 
death in the United States and most high and middle income countries, accounting for over a 
third of the 3.1 million global neonatal deaths every year [1,2]. Preterm infants and infants born 
with a low birth weight (less than 2500 grams at birth) remain at risk to a host of adverse health 
effects. For example, preterm birth is the second leading cause of pneumonia for children below 
the age of five, and the survivors of preterm birth are subject to an increased risk of cerebral 
palsy, neurological disabilities, vision problems, hearing impairment, breathing problems, and 
chronic diseases later in life [2–5]. As such, identifying risk factors of preterm birth to 
implement effective preventative measures is essential. The U.S. preterm birth rate has declined 
since 1997, yet remains at one of the highest rates in the developed world at 9.6% [6,7] . 
On the other hand, pregnancies lasting over 40 weeks are associated with their own risks, to both 
the baby and the mother. The rate of stillbirth, birth injuries, and neonatal complications are 
increased as well as maternal complications including perineal lacerations, postpartum 
hemorrhage, and increase rate of caesarean deliveries [8,9]. In the United States, the post-term 
birth rate incidence was 7% in 2005 [10], but the induction of labor practices is thought to have 
decreased this rate of post-term births [9].  
Puerto Rico has one of the highest rates of preterm birth in the U.S. at approximately 12% of all 
live births [11], and the reasons behind this elevated rate are unclear [12]. The island is a non-
incorporated territory of the U.S.; this ambiguous status leads to political and social issues that 
partly explain Puerto Rico’s health disparities and crumbling health infrastructure [13]. While 
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the social and political aspects are likely to indirectly influence the preterm birth rate, other 
environmental exposures likely play an important role in describing this high rate.  
Hefty tax incentives over the last few decades drove industry and manufacturers to Puerto Rico, 
leading to a subsequent growth in population and urban development in parts of the island. 
However, the rise in industry and their reliance on some hazardous materials also led to 
environmental contamination from accidental and/or deliberate spills in the groundwater [14]. 
Puerto Rico has an area of approximately 3,500 miles (the third smallest territory/state in the 
U.S.), yet currently has 16 active Superfund sites, and over 200 hazardous waste sites. In 
addition, many of these sites lie on unlined limestone aquifers, increasing the chance of exposure 
to contaminants via groundwater. 
The Puerto Rico Testsite for Exploring Contamination Threats (PROTECT) Program, funded by 
the Environmental Health Sciences’ Superfund Research Program, is a multi-disciplinary center 
set up in order to explore the role of environmental contamination with birth outcomes, provide 
insight on environmental routes and exposure pathways, and develop mitigation strategies to 
reduce the levels of contamination. To achieve this, a cohort of pregnant women is being 
followed to birth, and urinary and serum samples are being collected from the women at several 
time points during their pregnancy to account for the varying levels of exposures and biological 
markers throughout gestation. This large cohort provides an opportunity to study the effects of 
prenatal/in-utero exposure to various chemicals on birth outcomes in a vulnerable population. 
Details of the study population are described later in this Chapter.  
The prenatal period is an important window of vulnerability due to the various stages involved in 
rapid development. Chemical exposure during pregnancy could impact the mother, leading to 
adverse birth outcomes, or could pass through the placenta and directly impact the fetus [15,16]. 
This is especially important because even low concentrations could lead to adverse health effects 
that manifest from the fetal stage to adulthood, and potentially to future generations [17,18]. 
Among chemical classes associated with adverse health effects with gestational exposure are 
phenols and parabens. 
Phenols, parabens and triclocarban as exposures of interest. Phenols, parabens and triclocarban 
are a group of ubiquitous chemicals commonly found in personal care products and household 
items. Reports from the National Health and Nutrition Examination Survey (NHANES) show 
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that the majority of the U.S. population have detectable levels of these contaminants in their 
bodies [19], and the levels of phenols and triclocarban found in the PROTECT cohort are higher 
than the levels of women of reproductive age in NHANES [20]. Triclocarban, in particular, was 
found at concentrations 37 times greater in PROTECT compared to NHANES concentrations. 
The exposure biomarkers of interest include: 2,4-dichlorophenol (2,4-DCP), 2,5-dichlorophenol 
(2,5-DCP), bisphenol-A (BPA), bisphenol-S (BPS), bisphenol-F (BPF), benzophenone-3 (BP-3), 
triclosan, triclocarban, and ethyl-  (EPB), methyl- (MPB), butyl- (BPB) and propyl-paraben 
(PPB). 
BPA is a high volume chemical used in the manufacture of polycarbonate plastics and epoxy 
resins in many consumer products such as food containers and cans. BPS and BPF are common 
substitutes for BPA. BP-3 is a UV-filter used in cosmetics and sunscreens and some plastics 
[21]. Triclosan and parabens have anti-microbial properties and are commonly added to personal 
care products to reduce bacterial contamination [21,22]. Triclocarban is not a phenol, but is also 
used in products similar to triclosan due to its antiseptic properties [23]. Conversely, 2,4-DCP is 
a metabolite of the widely used herbicide 2,4-dichlorophenoxyacetic acid, and 2,5-DCP is a 
metabolite of 1,4-dichlorobenzene, a compound used in mothballs and room deodorizers [21]. 
Results from a product use questionnaire administered to the PROTECT cohort also showed that 
the phenol, paraben and triclocarban biomarkers were associated with consumer product use 
[20,24]. The urinary paraben mean concentration was higher among PROTECT women who 
reported using cosmetics and lotions; the urinary triclosan and triclocarban levels were higher 
among those who used toothpaste, hairspray and soap; the urinary BPA level was higher among 
those who used mouthwash; and the urinary BP-3 level was higher among those who reported 
use of sunscreen and lotion.  
Exposure to phenols, parabens and triclocarban could occur in a multitude of pathways given 
these chemicals’ widespread use, most notably through dermal absorption via use of personal 
care products, and ingestion in the case of contamination of food products. Multiple exposure 
science studies have documented these chemicals’ detection in human urine, nails, plasma, breast 
milk, placental tissue and umbilical cord blood [25–31]. 
Although the research is limited, phenols, parabens and triclocarban have also been linked to a 
number of growth parameters during pregnancy and at birth, including birth weight, birth length 
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and gestational length [32–36]. There are, however, many discrepancies across the studies. While 
BPA positively increased the odds of preterm birth among only males in one study [37], another 
reported an association with preterm birth among only females [38]. BPA was also associated 
with low birth weight or smaller size for gestational age [39–45]. 2,4-DCP and 2,5-DCP were 
associated with low birth weight in human and animal studies [36,46–48], whereas BP-3 was 
associated with both low and high birthweight in two separate studies [36,46]. Triclosan was not 
associated with birthweight in human neonates [33,34]; however, an animal study found 
evidence of reduced birthweight after prenatal triclosan exposure to rats [49]. Parabens were 
associated with high birthweight in a human study [34], but animal studies in rats and mice 
found reduced [50] or no effect [51–53] on fetal birthweight.  
There were inherent differences across the studies that may have led to the differences in the 
results. Phenols and parabens are non-persistent and can be highly variable across gender, 
lifestyle and time of day [19,54,55]. The majority of human studies that looked at phenol and 
parabens’ association with adverse birth outcomes were cross-sectional in nature, and included 
urinary samples from a single time point during pregnancy. However, evidence suggests 
biomarker concentrations of these chemicals, particularly BPA and parabens is highly variable 
throughout pregnancy, likely due to the intermittent exposure of these chemicals and their rapid 
metabolism [56]. Pregnancy is not a constant biological state; maternal and fetal hormonal and 
inflammation pathways vary throughout the developmental stages; therefore, exposure to 
environmental chemicals could impact birth outcomes differently depending on the time of 
exposure, which was not accounted for in most epidemiological studies [57–61]. In turn, 
exposure measurement deficiencies, the varying study populations, as well as unaccounted for 
residual confounding could explain the discrepancies observed. The lack of strong study 
methodologies, and limited number of studies in the literature warrant further studies to be 
conducted. The PROTECT cohort provides a unique and rigorous opportunity to do so. 
Hormone disruption as a potential biological mechanism. A potential toxicity pathway for these 
chemicals is through endocrine disruption, and pregnancy is a vulnerable window for endocrine 
disruption due to the varying levels of hormones involved in the growing organism [62]. 
Reproductive hormones have an important role in maintaining pregnancy; in turn, disruption of 
the complex interplay between the hormones could lead to adverse effects during gestation. 
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Estriol is named the “estrogen of pregnancy” because 90% of estriol precursors in maternal 
circulation arise from fetal precursors [63]. Thus, estriol is a marker for fetal adrenal activity, 
wherein elevated levels of estriol in the maternal circulation could indicate fetal distress. At low 
levels, estriol is an inhibitor of estradiol, but the level of estriol increases drastically 
approximately 2-4 weeks before delivery. Once the estriol:estradiol ratio exceeds 10:1, estriol 
becomes an effective agonist of estradiol- which leads to a decrease in progesterone levels and a 
surge in CRH [64,65]. CRH (synthesized by the placenta) is not only associated with myometrial 
contractions, but  stimulates the production  of dehydroepiandrosterone sulfate (DHEAS) – an 
estriol precursor – in the fetal adrenal, causing the feedback loop to produce more estriol [65]. 
Consequently, an exponential rise in CRH correlates with timing of birth. Progesterone is 
normally implicated as the hormone responsible for maintaining pregnancy status, particularly in 
animals. However, evidence suggests that in humans, the ratio between progesterone and estriol 
is more important in maintaining pregnancy, deferring labor by promoting uterine relaxation and 
reducing prostaglandin synthesis, than the level of progesterone on its own [63,66].  
Thyroid hormones also play an important role in pregnancy. Thyroid hormones, triiodothyronine 
(T3) and thyroxine (T4), are produced in the thyroid gland, and their levels are negatively 
controlled by thyroid stimulating hormone (TSH) from the pituitary gland via the hypothalamic-
pituitary-thyroid (HPA) axis [67]. The fetal thyroid only begins to produce hormones at 10-12 
weeks gestation, and is completely dependent on maternal thyroid hormones for 
neurodevelopment in its first weeks of life, particularly T4 [68–70]. Additionally, thyroid 
hormones (maternal and fetal) are essential to the development of fetal tissues, and fetal growth 
promotion [71].  With the rise of estrogens, T3 and T4 rise in early pregnancy, stabilizing by the 
first half of pregnancy [72]. During the second half of pregnancy, maternal thyroid hormones 
help maintain fetal thyroid homeostasis [73]. Subclinical maternal thyroid dysfunction has been 
associated with low birth weight, low Apgar scores, and neurological disabilities [74–76]. 
It is clear that because of this complexity in hormone levels, a slight disruption could potentially 
lead to adverse effects. Endocrine disrupting chemicals could act through several pathways, 
including hormone synthesis, regulation, transport and metabolism, and/or interference with 
receptors. Although research on most of the phenols, parabens and triclocarban mechanism of 
action is limited, a brief summary of the findings is described below. 
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2,4-DCP and 2,5-DCP are suspected endocrine disruptors. 2,4-DCP was associated with an 
increase in progesterone among non-menopausal women [77], and a decrease in serum FT4 
among pregnant woman in a large cohort measured at two time points in pregnancy [78]. There 
was also evidence of altered steroidogenesis with 2,4-DCP exposure to zebrafish, causing lesser 
rates of hatching of eggs [79]. 2,5-DCP, on the other hand, was associated with earlier menarche 
[80] and earlier breast development among a cohort of U.S. girls, pointing to evidence of thyroid 
agonist tendencies and/or reproductive hormone disruption [59]. This was further supported by 
an NHANES study that reported an increase in TSH and hypothyroidism with an increase in 2,5-
DCP among adolescents [81].  
BPA has been associated with changes in thyroid and reproductive hormone levels [82,83]. More 
specifically, BPA has weakly estrogenic properties [19], and increased estradiol and SHBG in rat 
pups and male adults [84,85]. Additionally, BPA increased T4 after perinatal exposure in rats, 
however, pregnant ewes demonstrated lower levels of thyroid hormones with dietary exposure to 
BPA [86–88]. A number of human studies have also been conducted. A review of epidemiology 
studies found relatively consistent results in males, wherein BPA exposure tended to increase 
FSH and testosterone, but decrease estradiol [89]. However, the results pertaining to women were 
more variable. This is likely due to the differences in the ages of women across the studies (pre-
pubertal versus pregnant women) and differences in the reproductive health status (polycystic 
ovary syndrome versus non-polycystic ovary syndrome).  
BPS and BPF are common replacements for BPA, but have also been associated with similar 
effects to BPA [90,91]. Although less researched, BPF and BPS interfered with thyroid hormone 
signaling by binding to thyroid hormone receptors TRα and TRβ, but with lower binding 
potencies [83]. 
BP-3 is suggested to be weakly estrogenic and antiandrogenic [59]. In in vitro studies, BP-3 
exerted an agonist effect on human ERα and ERβ, an antagonistic effect on the androgen 
receptor and progesterone receptors, and thyroid receptor agonistic effects [92–95]. In vivo 
studies mirrored some of these effects. BP-3 altered transcription of hormonal receptors in 
invertebrates [96], and decreased spermatozoa among male fish [97]. The potential endocrine 
disrupting effects of BP-3 is not as well documented in humans; however endocrine-mediated 
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endpoint changes were observed in connection to BP-3, including earlier menarche [80] and 
breast development [59] among girls. 
One of triclosan’s modes of action is disruption of steroidogenesis [22], and this was shown to 
occur in the placenta as well [98]. Triclosan’s chemical structure is similar to that of 
anthropogenic estrogens, and evidence suggests trislocan disrupts hormone metabolism, 
displaces hormones from receptors and disrupts steroidogenic enzyme activity [58]. Moreover, 
triclosan is structurally similar to thyroid hormones T3 and T4, and has been shown to decrease 
T4 in rodent studies [49,99–101]. This effect was also observed, albeit not significantly, in a 
cohort of pregnant women in the U.S. [78].  
Triclocarban has not been studied in detail, although studies have demonstrated its estrogenic 
and androgenic effects in rodents and aquatic animals, and these findings were supported by in 
vitro studies [23]. It was recently described as a “new type” of endocrine disruptor because it is 
thought to augment endogenous hormone action rather than activate hormone receptors [102]. 
With regards to parabens, most animal studies have focused on effects of BPB, likely due to the 
fact that BPB has the highest estrogenic potency [103]. It is important to note that while MPB has 
the lowest estrogenic potency, it also penetrates through the skin at the highest rate as compared 
to other parabens, and can accumulate in skin layers [103]. While parabens have low binding 
affinity to estrogen receptors, they have been documented to have full agonist properties, 
particularly with longer exposure durations [60]. Two rat studies found no difference in estradiol 
levels in dam ovaries after in utero exposure to BPB and iso-butylparaben [104,105]. However, 
estradiol levels decreased after exposing human adrenocortical carcinoma cells (H295R cells) to 
parabens to test their interference with steroid hormone biosynthesis, affirming the weak 
estrogenic properties of parabens [104]. Likewise, researchers found decreases in estradiol and 
progesterone levels after paraben exposure in prepubertal female rats, particularly with ethyl- 
and isopropyl paraben [106]. Other endocrine-mediated effects have been linked to MPB and 
BPB, including decreased odds of live births [107], increases in dam uterine weights [104], and 
changes in various reproductive hormone levels   .  
Given the growing evidence of the endocrine disrupting properties of these exposure biomarkers, 
in addition to the evidence linking the biomarkers to adverse birth outcomes, I was interested in 
exploring the associations between phenols, parabens and triclocarban with maternal hormones, 
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and to look for potential windows of susceptibility. As described below in, this analysis was 
carried out in two pregnancy cohorts to help validate observed associations.   
Interaction between chemical exposure and psychosocial stress. There is a growing interest in 
looking at the combined effect of stressors in the environment on human health, particularly with 
the introduction of the exposome concept [108,109]. In addition to looking at the effect of 
chemical mixtures on health, interactions between chemical and non-chemical stressors are 
important to consider in deepening our understanding on how the environment impacts humans. 
Although this area of research is relatively new and limited, evidence supports the notion of an 
increased risk in the presence of an exposure to high levels of environmental chemicals, as well 
as high psychosocial stress levels, indicating a modifying effect of stress on the relationship 
between chemicals and health. For example, a systematic review found the combined effect of 
chemical exposures such as smoking and traffic pollution in combination with high stress or 
socio-economic stressors were associated with worse fetal growth parameters than with either 
chemical or psychosocial stressors on their own [110].  
With this in mind, I was interested in examining the potential effect of chemical exposure in 
combination with maternal stress as a potential effect modifier, given that maternal stress has 
been associated with adverse birth outcomes in multiple studies. A population-based case control 
study reported a 60% increased odds of a very low birth weight among women who reported 
always feeling stressed as compared to women reporting no stress [111]. Other studies have also 
reported a shortened gestational length with maternal stress or a larger number of negative life 
events [112–115].  
The effects of maternal stress on the fetus could also extend beyond the pregnancy and birth 
experience, and potentially cause long-term adverse effects on the cognitive, behavioral and 
psychomotor development of the child [116,117]. Maternal stress influences the HPA axis [118], 
and this intra-uterine programming of the HPA axis is the suspected mechanism between low 
birth weight and adult HPA axis regulation abnormalities, and adult insulin resistance [119–121].   
In conclusion, this dissertation focuses on the association between phenols and parabens on birth 
outcomes, the association between phenols and parabens and hormones as a potential mechanism 
of action, and the modifying effect of psychosocial factors in the association between phenols 
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and parabens and gestational length. Figure I.1 is a conceptual figure summarizing the study 
aims described below. 
 Aim 1 
Associations between phenols and parabens on hormones during pregnancy is a largely 
understudied area of research. Endocrine disruption is an important pathway that could lead to a 
myriad of adverse health effects, including birth outcomes. Most human studies only looked at 
the associations between phenols and parabens at one time point during pregnancy, particularly 
at the end of pregnancy. However, changes at the start of pregnancy may also be important since 
some maternal hormones play an important role in fetal development in early pregnancy as well.  
To this end, my first aim was to investigate the extent to which urinary concentrations of 
phenols, parabens and triclocarban are individually associated with serum reproductive and 
thyroid hormone levels, including estriol, progesterone, corticotropin-releasing hormone (CRH), 
sex hormone-binding globulin (SHBG), total thyroxine (T4), total triiodothyronine (T3), free 
thyroxine (FT4), and thyroid stimulating hormone.  
A preliminary analysis on the first 106 women in the PROTECT cohort showed some 
associations between the chemical biomarkers and serum hormones. The direction of association 
between the chemical biomarkers and hormone levels was dependent on the specific hormone 
and biomarker. Based on this analysis and existing research, I hypothesized an increase in 
circulating thyroid hormone concentrations in association with BPA and parabens, a decrease in 
thyroid hormones in association with triclosan, a decrease in SHBG in association with phenols 
and parabens, and a change in the direction of associations between the two study visits in 
relationships with progesterone. I was unable to hypothesize directions of associations for the 
remaining associations due to the lack of human health data, so a goal of Aim 1 is to fill this gap 
in the literature.  
For Aim 1, I repeated the analysis on two cohorts: a larger sample of women from the 
PROTECT cohort, and a large sample of women from a second cohort, LifeCodes, based in 
Boston, MA. I ran the analyses in two cohorts to help validate the associations observed. 
However, LifeCodes only had data on maternal thyroid hormones.  
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 Aim 2 
Aim 2 investigated the association between phenols, parabens and triclocarban in relation to the 
birth outcomes, gestational length and birth weight. Studies regarding the associations between 
the exposure biomarkers have varied in their conclusions; therefore I wanted to investigate this 
association in a larger cohort, and investigate how the timing of exposure would impact the 
strength of associations between the chemicals and birth outcomes.  
I hypothesized that phenols were associated with a decrease in gestational length, whereas the 
parabens were associated with an increase in gestational length and birthweight. 
 Aim 3 
In concert with the growing trend of looking at the impact of multiple exposures on birth 
outcomes, I wanted to investigate the interaction between chemicals and a non-chemical stressor. 
Therefore, my third aim examines the extent to which pyschosocial factors modify the 
associations between the chemical biomarkers and gestational length. Preliminary analysis 
showed that gestational length was the outcome most strongly associated with the exposure 
biomarkers, so Aim 3 focused on this birth outcome. I hypothesized that the associations 
between exposure biomarkers and gestational length will be stronger in the presence of high 
levels of psychosocial factors.  
 Study Populations 
 PROTECT [Aims 1-3] 
As mentioned previously, the study included participants from the ongoing prospective cohort of 
pregnant women, PROTECT. The study participants (aged 18-40 years) have been recruited 
from 2010-present at 14 ± 2 weeks gestation from two hospitals (Manatí Medical Center and 
Arecibo’s Cayetano Coll y Toste Hospital) and five affiliated prenatal clinics in Northern Puerto 
Rico. The recruitment target was 1,000 live births, and the recruitment rate was 78% from 2011-
2018. Women received $30 for participating in the study. The exclusion criteria include: women 
who live outside the region, have multiple gestations, used oral contraceptives within three 
months prior to getting pregnant, got pregnant using in vitro fertilization, or have known medical 
health conditions (e.g., diabetes, hypertension, liver/kidney disease). 
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Demographic information was collected via questionnaires at the initial study visit. A nurse-
administered questionnaire was conducted during an in-home visit to collect information on 
household exposures, water source and usage, job history, hobbies, housing characteristics, 
family situation, mental health, and life experiences. Spot urine samples were collected at three 
separate study visits (Visit 1: 16-20; Visit 2: 20-24; Visit 3: 24-28 gestation weeks), and blood 
samples are collected during the first and third visits. Figure I.2 shows the timeline for 
recruitment and data collection from the cohort. The timing of the visits were aimed to coincide 
with routine clinical visits, thus also coinciding with periods of rapid fetal growth and reducing 
costs. This study was approved by the research and ethics committees of the University of 
Michigan School of Public Health, University of Puerto Rico, Northeastern University, and 
participating hospitals and clinics. All study participants provided full informed consent prior to 
participation.  
 LifeCodes [Aim 1] 
Participants were part of a nested case-control study within the LifeCodes cohort. LifeCodes is 
comprised of a prospective birth cohort of pregnant women planning on giving birth at the 
Brigham and Women’s Hospital in Boston, MA. LifeCodes enrolled 1600 women from 2006-
2008, and 1181 were followed to deliver live singletons. Women aged ≥ 18 years old were 
recruited prior to 15 weeks gestation. Relevant health information, urine and blood samples were 
collected at up to four time points, Visit 1: median 10 weeks gestation, Visit 2 median 18 weeks 
gestation, Visit 3 median 26 weeks gestation, and Visit 4 median 35 weeks gestation. The visits 
were meant to coincide with clinically relevant pregnancy characteristics. Demographic and 
lifestyle details were collected at the first study visit. From the LifeCodes cohort, 130 women 
who delivered preterm (< 37 weeks) and 352 randomly selected controls were included in the 
nested case-control study. An additional 41 women were excluded with self-reported pre-existing 
and/or gestational thyroid diseases (such as hyper- or hypothyroidism, Graves’ disease, or 
thyroid cancer). The final study population included 116 cases of preterm birth and 323 controls. 
The study protocols were approved by the ethics and research committees from Brigham and 
Women’s Hospital and the University of Michigan, and all study participants provided written 
informed consent. 
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Figure I.1 Conceptual figure of Dissertation Study Aims 
 
 
 
 
Figure I.2 Study visit timelines by gestational age (weeks) for the PROTECT and LifeCodes cohorts  
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 Associations between Maternal Phenol and Paraben Urinary 
Biomarkers and Maternal Hormones during Pregnancy:  
A Repeated Measures Study (LifeCodes) 
 
 
Abstract: 
Background: A number of phenols and parabens are added to consumer products for a variety of 
functions, and have been found at detectable levels in the majority of the U.S. population. 
Among other functions, thyroid hormones are essential in fetal neurodevelopment, and could be 
impacted by the endocrine disrupting effects of phenols and parabens. The present study 
investigated the association between ten maternal urinary phenol and paraben biomarkers 
(bisphenol S, triclosan, triclocarban, benzophenone-3, 2,4-dichlorophenol, 2,5-dichlorophenol, 
and ethyl, butyl, methyl and propyl paraben) and four plasma thyroid hormones in 439 pregnant 
women in a case-control sample nested within a cohort study based in Boston, MA. Methods: 
Urine and blood samples were collected from up to four visits during pregnancy (median weeks 
of gestation at each visit: Visit 1: 9.64, Visit 2: 17.9, Visit 3: 26.0, Visit 4: 35.1). Linear mixed 
models were constructed to take into account the repeated measures jointly, followed by 
multivariate linear regression models stratified by gestational age to explore potential windows 
of susceptibility. Results: We observed decreased total triiodothyronine (T3) in relation to an 
IQR increase in benzophenone-3 (percent change [%Δ] = -2.07; 95% confidence interval [CI] = -
4.16, 0.01), butyl paraben (%Δ = -2.76; 95% CI = -5.25, -0.26) and triclosan (%Δ = -2.53; 95% 
CI = -4.75, -0.30), and triclocarban at levels above the LOD (%Δ = -5.71; 95% CI = -10.45, -
0.97). A 2.41 % increase in T3 was associated with an IQR increase in methyl paraben (95% CI 
= 0.58, 4.24). We also detected a negative association between free thyroxine (FT4) and propyl 
paraben (%Δ = -3.14; 95% CI = -6.12, -0.06), and a suggestive positive association between total 
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thyroxine (T4) and methyl paraben (%Δ = 1.19; 95% CI = -0.10, 2.47). Gestational age-specific 
multivariate regression analyses showed that the magnitude and direction of some of the 
observed associations were dependent on the timing of exposure.  Conclusion: Certain phenols 
and parabens were associated with altered thyroid hormone levels during pregnancy, and the 
timing of exposure influenced the association between phenol and paraben, and hormone 
concentrations. These changes may contribute to downstream maternal and fetal health 
outcomes. Additional research is required to replicate the associations, and determine the 
potential biological mechanisms underlying the observed associations. 
Introduction 
There are thousands of chemicals found in personal care products (PCP) and household items to 
which humans could potentially be exposed [1,2]. Usage of PCPs continues during pregnancy, 
and this may have unique effects on the mother and/or her developing fetus [3,4].  
Phenols and parabens are among the chemicals used in PCPs, and are regularly found at 
detectable levels in the U.S. population [5]. Phenols regularly detected in exposure 
biomonitoring studies include triclosan (TCS), triclocarban (TCC), benzophenone-3 (BP-3), 
bisphenol-A (BPA), bisphenol-S (BPS), 2,4-dichlorophenol (2,4-DCP) and 2,5-dichlorophenol 
(2,5-DCP). Parabens, TCS and TCC are used in PCPs such as soaps and makeup for their anti-
microbial properties [5]. The phenol BP-3 is a UV-filter, and is used in sunscreen, cosmetics and 
some plastic products [5]. BPS is a common alternative to BPA, and is found in foods, plastics 
and paper products [6].  2,4-DCP and 2,5-DCP are biomarkers of a compound used in mothballs 
and room deodorizers; 2,4-DCP is also a metabolite of a herbicide used as a weed killer [5]. 
Although results have been conflicting, in vitro, animal and human studies have linked a range of 
phenols and parabens with changes in thyroid hormones [7–14].  Studies have also linked these 
exposures to a series of adverse health effects that could potentially be mediated through the 
thyroid hormone system, including changes in pubertal development [15], adverse birth 
outcomes [16,17], male infertility [18], diminished female fecundity [19], increases in oxidative 
stress [20], and childhood adiposity [21], among other health effects.  
Thyroid hormones, triiodothyronin (T3) and thyroxine (T4), are produced in the thyroid gland, 
and their levels are negatively controlled by thyroid stimulating hormone (TSH) from the 
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pituitary gland via the hypothalamic-pituitary-thyroid axis [22]. The fetal thyroid only begins to 
produce hormones at 10-12 weeks gestation, and is completely dependent on maternal thyroid 
hormones for neurodevelopment in its first weeks of life, particularly T4 [23–25]. Additionally, 
thyroid hormones (maternal and fetal) are essential to the development of fetal tissues, and fetal 
growth promotion [26]. Given this, and the complexity in the hypothalamic–pituitary–thyroid 
axis, even slight alterations in thyroid hormones could lead to adverse effects in the child 
[27,28].  In fact, subclinical maternal thyroid dysfunction has been associated with low birth 
weight, low Apgar scores, and neurological disabilities [29–31]. It is, therefore, important to 
understand the effects of in-utero exposure to chemicals such as phenols and parabens on 
maternal thyroid hormones.  
Our group recently reported associations between phenols and parabens and maternal thyroid 
hormones in pregnancy in a small prospective cohort study in Puerto Rico [32]. The present 
study aimed to test these relationships in a larger study of pregnant women recruited in Boston, 
USA. We published a study on the effects of BPA on thyroid hormones in this same cohort since 
BPA was initially the only phenol measured in our samples [33]; the analytical method was 
recently expanded to include additional phenols and parabens, which are the focus of this study. 
 Methods 
 Study Population 
The study population includes pregnant women who were participants in a case-control study 
nested within the longitudinal birth cohort study in Boston, MA, Lifecodes [34,35]. Lifecodes 
enrolled 1,600 women from 2006-2008, of whom 1,181 were followed until delivery to live 
singletons. Women ages ≥ 18 years old were recruited early in pregnancy (< 15 weeks of 
gestation) between 2006 and 2008 and were eligible for participation if they were carrying a 
singleton, non-anomalous fetus and planned to deliver at Brigham and Women’s Hospital. 
Additional information regarding recruitment and eligibility criteria are described in detail 
elsewhere [35,36]. Women were followed through the duration of their pregnancy and relevant 
health information as well as urine and blood samples were collected at  initial study visit (Visit 
1: median 9.64 weeks of gestation [range = 5.43–19.1 weeks]) as well as three subsequent visits: 
Visit 2 (median = 17.9 weeks of gestation [range = 14.9–32.1 weeks]), Visit 3 (median = 26.0 
weeks of gestation [range = 22.9–36.3 weeks]), and Visit 4 (median = 35.1 weeks of gestation 
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[range = 33.1–38.3]). The study protocols were approved by the ethics and research committees 
of the participating institutions, and all study participants provided written informed consent. 
From the parent birth cohort, 130 women who delivered preterm (<37 weeks gestation) and 352 
randomly selected women who delivered after a full term pregnancy (≥ 37 week gestation) were 
included in the case-control study. From these, we excluded participants who had pre-existing 
thyroid conditions such as thyroid cancer, Graves’ disease, and hyper- or hypothyroidism 
(N=41), and excluded those who did not provide any blood samples at any visit (N=2). Our final 
study population (N=439) included 116 preterm birth cases and 323 controls. 
 Phenol and paraben measurement 
Spot urine samples were collected at each of the four visits. After collection, spot urine samples 
were divided into aliquots and frozen at -80oC until they were shipped overnight. The samples 
were analyzed at NSF International (Ann Arbor, MI) for six phenols (2,4-DCP, 2,5-DCP, BP-3, 
BPS, TCS, and TCC) and four parabens (ethyl- (EPB), methyl- (MPB), butyl- (BPB), and 
propyl- (PPB) paraben) using isotope dilution-liquid chromatography-tandem mass spectrometry 
(ID-LC-MS/MS). The analytical method was a modification of a method developed by the 
Centers for Disease Control and Prevention (CDC), as described previously [37–39]. Samples 
below the limit of detection (LOD) were assigned a value of LOD/√2 [40]. Urinary specific 
gravity (SG) was used to account for urinary dilution, and was measured using a digital handheld 
refractometer (AtagoCo., Ltd., Tokyo, Japan). For descriptive, univariate data analysis, phenol 
and paraben concentrations were corrected for SG as follows: Pc = M [ (SGm – 1) / (SGi – 1) ], 
where Pc is the SG-corrected exposure concentration (ng/mL), M is the measured exposure 
concentration, SGm is the study population median urinary specific gravity (1.0196), and SGi is 
the individual’s urinary specific gravity. For bivariate and multivariate analysis, urinary specific 
gravity was included as a covariate in all models. 
To minimize measurement error from the variability in urine dilution, we applied the method 
developed by [41]. In brief, we ran a linear mixed model (LMM) regressing SG on maternal age, 
extracted the predicted values of SG from that regression, calculated the ratio of SG and the 
predicted SG, and used this ratio to standardize the phenol and paraben measurements.  
27 
 
 Thyroid hormone measurement 
Blood samples were collected at each of the four visits. The samples were frozen at -80˚C until 
shipped overnight on dry ice to the analytical laboratory. Blood plasma was analyzed for free 
thyroxine (FT4), total thyroxine (T4), total triiodothyronine (T3), and thyroid stimulating 
hormone (TSH) at the Clinical Ligand Assay Service Satellite (CLASS) lab at the University of 
Michigan (Ann Arbor, MI). TSH, T3 and T4 were measured using an automated 
chemiluminescence immunoassay (Bayer ADVIA Centaur, Siemens Health Care Diagnostics, 
Inc.), and FT4 was measured using direct equilibrium dialysis followed by radioimmunoassay 
(IVD Technologies). Thyroid hormones were highly detected in the study population [42]. TSH 
samples below the LOD (N=5) were assigned a level at the LOD level (0.01 μIU/mL). Given that 
the LOD for FT4 is not biologically feasible, samples <LOD for FT4 were regarded as missing 
values in our statistical analyses. The inter-assay coefficients of variation (CV) for all hormones 
ranged from 2.3% (for T3) to 10.4% (for FT4). The intra-assay CVs ranged from 1.2% (for T3) 
to 12.3% (for FT4). Volume limitations in some of the samples resulted in differences in the 
number of samples. 
 Statistical analyses 
We applied inverse probability weighting to all statistical analyses in order to account for the 
study’s case-control design and over-representation of preterm birth cases in our sample. This 
ensures that the association observed between secondary outcomes (hormone levels) and 
biomarkers (phenols and parabens) in the present study population would be representative to the 
overall cohort population, and enhances the generalizability of our results [43]. We constructed 
the weights as the inverse of the selection probability for cases and controls from the set of 
eligible cases and controls in the entire cohort. Weighted distributions of key demographic 
characteristics were calculated. All biomarkers, and the hormones TSH and FT4, were 
positively-skewed, and were natural log-transformed. The distributions of T3 and T4 
approximated normality and remained untransformed in all analyses. Geometric means and 
standard deviations were calculated for all SG-corrected biomarkers, hormones, and the ratio of 
T3/T4. The ratio between T3 and T4 provides an indication of thyroid homeostasis, specifically 
the peripheral conversion of T4 to T3 in tissues. 
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Two urinary biomarkers, BPS and TCC, were detected in less than 25% of the samples. 
Therefore, we categorized BPS and TCC into dichotomous variables for the statistical models, 
where 1 represented a detectable level (>LOD), and 0 was <LOD. BPS and TCC were analyzed 
as binary variables in all regression models, whereas all other biomarkers were analyzed 
continuously. 
In our repeated measures analysis, we regressed one thyroid hormone on one urinary biomarker 
using Linear Mixed Models (LMM) with a subject-specific random intercept to account for intra-
individual correlation of serial hormone measurements collected over time. The biomarker 
measures across time were treated as time varying variables in the model. Potential confounders 
were identified from the literature. They included socio-economic status, body mass index 
(BMI), alcohol and smoking during pregnancy, and age. The availability of private insurance 
was used as socioeconomic status indicator. Potential confounders that were found to change the 
main effect estimate by >10% were retained in the final models as covariates. Final models were 
adjusted for specific gravity, study visit, BMI at the first study visit, insurance provider, maternal 
age and gestational age at time of sample collection. To explore windows of susceptibility, we 
ran multiple linear regressions (MLR) stratified by gestational age, adjusted for the same 
covariates as those in LMMs. The gestational age groups were <15 weeks, 15-21 weeks, 21-30 
weeks, and >30 weeks gestation. In addition to the visit-specific stratified analysis, to conduct a 
statistical test whether the associations between phenol and/or paraben biomarker varied by study 
visit of sample collection, we included in our repeated measures analysis interaction terms 
between urinary biomarkers and the study visit. We also re-ran our analyses in only term births 
status (>37 weeks gestation) as a sensitivity analysis. To make our results from these models 
including ln-transformed continuous biomarkers and/or outcomes more interpretable, we 
transformed regression coefficients to percent changes (and associated 95% confidence intervals) 
in hormone concentration in relation to the interquartile range (IQR) increase in urinary 
biomarker concentrations. Beta coefficients from models with categorical biomarkers (BPS and 
TCC) were transformed to percent changes (and associated 95% confidence intervals) in 
hormone concentration at biomarker levels above the LOD versus biomarker levels below the 
LOD. The alpha level was set at 0.05.  All statistical analyses were conducted in R Version 3.2.2. 
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 Results 
The mean age of the study participants was 31.8 years, 66% attained at least some college education, 56% 
were White, and less than 20% depended on Medicaid ( 
Table II.1). The women also had low levels of smoking (7%) and alcohol use (4%) during 
pregnancy, and only 22% had a BMI level above 30 kg/m2.  
Table II.2 shows the results of the univariate analyses conducted on the urinary biomarkers and 
hormone levels.  Little variation was observed in urinary biomarker concentrations across 
pregnancy, whereas all hormones showed varied levels across the four time points in pregnancy, 
as was described previously in greater detail [42,44]. MPB was detected at the highest levels 
among all biomarkers, followed by BP-3 (Table II.2).  MPB was strongly correlated with PPB 
(Correlation coefficient= 0.83), whereas BPB and EPB (Correlation coefficient =0.57), and 2,4-
DCP and 2,5-DCP (Correlation coefficient=0.59) were moderately correlated.  No other 
biomarker concentrations strongly correlated with one another. T3 and FT4 were correlated with 
T3/T4 (Correlation coefficients=0.74, -0.44, respectively), but T4 was weakly correlated with 
T3/T4 (Correlation coefficient=0.2) (Figure II.2).  T3 and T4 were also moderately correlated 
(Correlation coefficient=0.46).  
Table II.3 shows the results from LMMs, which included measurements collected at up to four 
time points in pregnancy. 2,4-DCP and 2,5-DCP were not associated with any thyroid hormones, 
although an IQR increase in 2,4-DCP was suggestively associated with 1.4% decrease in the 
T3/T4 ratio (percent change [%Δ] = -1.44; 95% confidence interval [CI] = -3.11, 0.22). There 
were significant 2-3% decreases in T3 in relation to an IQR increase in BP-3 (%Δ = -2.07; 95% 
CI = -4.16, 0.01), and TCS (%Δ = -2.53; 95% CI = -4.75, -0.30). TCC at levels above the LOD 
were also negatively associated with T3 (%Δ = -5.71; 95% CI = -10.45, -0.97). While an IQR 
increase in TCS was associated with a 7.7% increase in TSH (95% CI = 0.01, 16.02), TCC levels 
above the LOD were associated with a suggestive 13% decrease in TSH (%Δ = -12.86; 95% CI = 
-25.6, 2.05). 
There were no consistent associations among the parabens. There were 2.4% (%Δ = 2.41; 95% 
CI = 0.58, 4.24), and 1.2% (%Δ = 1.19; 95% CI = -0.10, 2.47) increases in T3 and T4, 
respectively, with an IQR increase in MPB. BPB was associated with a 2.8% (%Δ = -2.76; 95% 
CI = -5.25, -0.26), and 3.7% (%Δ = -3.70; 95% CI = -5.98) decrease in T3 and T3/T4 ratio. EPB 
30 
 
was also associated with a reduced T3/T4 ratio (%Δ = -1.87; 95% CI = -3.76, 0.02). PPB was 
inversely associated with FT4 (%Δ = -3.14; 95% CI = -6.12, -0.06).  
To further understand these associations and explore the relationships at specific time points, 
multiple linear regressions were conducted stratifying by GA (Table II.5). 2,4-DCP was 
associated with a decrease in T3 (%Δ = -4.05; 95% CI = -7.49, -0.61), and a marginal increase in 
TSH (%Δ = 6.81; 95% CI = -0.74, 14.94) at 21-30 weeks. 2,4-DCP and 2,5-DCP were associated 
with decreases in TSH <21 weeks GA, and increases in TSH >21 weeks GA, although only the 
association between TSH and 2,5-DCP and >30 weeks GA reached statistical association (%Δ = 
10.03; 95% CI = 0.74, 20.19). This change in the direction of the associations between 2,4-DCP 
and 2,5-DCP and TSH by timing in pregnancy was further reflected in the significant interaction 
terms between the phenol and visit in LMMs.  
In contrast to LMM results, BP-3 was associated with all thyroid hormones at at least one time 
point in MLR models. BP-3 was associated with 5-7% decreases in T3 at all gestational ages 
except at 15-21 weeks GA, 3-4% decreases in T4 at all gestational ages except at >30 weeks GA, 
and 8-16% increases in TSH at 15-21 and 21-30 weeks GA. BP-3 was additionally associated 
with a 7.4% decrease in the T3/T4 ratio at >30 weeks GA (%Δ = -7.37; 95% CI = -12.70, -2.04).  
BPS was associated with an increase in FT4 (%Δ = -9.63; 95% CI = -18.10, -0.33), and a 
marginal decrease in TSH (%Δ = 26.02; 95% CI = -3.53, 64.63) at <15 weeks GA, indicating a 
potential window of vulnerability during early pregnancy. TCS and TCC showed no significant 
associations with any thyroid hormone in MLR models stratified by GA.  
Associations between parabens and thyroid hormones also varied by gestational age. EPB was 
not associated with any thyroid hormones, except for a marginal 4% decrease in the T3/T4 ratio 
at 15-21 GA weeks (%Δ = -4.29; 95% CI = -9.24, 0.65). Later time points in pregnancy may be a 
vulnerable time point for associations with BPB, given that BPB was associated with 6-7% 
decreases in T3 at 15-21 and >30 weeks GA, 5-6% decreases in the T3/T4 ratio at 15-21 and >30 
weeks GA, and a 14.7% increase in TSH at >30 weeks GA. In contrast, MPB and PPB were 
associated with changes in thyroid hormones during early pregnancy. An IQR increase in PPB 
was associated with 5-6% decreases in FT4 at <15 weeks and 15-21 weeks GA [(%Δ = -4.60; 
95% CI = -8.88, -0.12), (%Δ = -5.57; 95% CI = -10.74, -0.10), respectively]. At <15 weeks GA, 
an IQR increase in MPB was associated with a 4.2% decrease in FT4 (95% CI: -8.84, 0.69), a 
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3.7% increase in T3 (%Δ = 3.67; 95% CI = -0.33, 7.67), and a 2.7% increase in T3/T4 ratio (%Δ 
= 2.65; 95% CI = 0.09, 5.21). MPB was also associated with a marginal 7.0% decrease in TSH at 
21-30 weeks GA (%Δ = -6.98; 95% CI = -13.91, 0.51). In a sensitivity analysis conducted only 
among term births only, most of the results remained consistent, with the exception of the 
associations involving TCS and TCC with T3 and T4 which were no longer statistically 
significant (Table II.5). 
 Discussion 
In the present study, phenols and parabens were associated with changes in maternal thyroid 
hormone levels during pregnancy. In particular, T3 was most strongly and consistently related to 
phenols and parabens as compared to the other studied thyroid hormones in our analysis. In 
general, BP-3, TCS, TCC, and BPB were associated with a decrease in T3, while MPB were 
associated with an increase in T3.  There was a general positive association between BPS, BP-3, 
TCS and BPB in relation to TSH, and a negative association between TCC in relation to TSH. 
Few associations between the urinary biomarkers and FT4 or T4 were observed, with the 
exception of MPB, PPB and BPS which were negatively associated with FT4 at <21 weeks GA, 
and the negative association between BP-3 and T4 at <30 weeks GA. Windows of vulnerability 
were identified. BPS, MPB and PPB were associated with thyroid hormone at earlier time points 
in pregnancy, whereas BPB was associated with thyroid hormone later in pregnancy.   
An IQR increase in 2,5-DCP was associated with a suggestive 9% decrease in TSH at 15-21 
weeks GA, and a 10% increase in TSH at >30 weeks GA. 2,4-DCP was associated with increases 
in T3/T4 ratio at 15-21 weeks GA and TSH at 21-30 weeks GA, and a decrease in T3 at 21-30 
weeks GA. Few studies have looked into the effect of either phenol on thyroid hormones, and it 
is unclear why the associations between the dichlorophenols change direction from one time 
point to the next. No associations were observed between 2,4-DCP or 2,5-DCP and thyroid 
hormones in our previous small cohort study in Puerto Rico [32]. 2,5-DCP was associated with 
increased TSH and hypothyroidism in a subsample of adolescents in NHANES, and negatively 
associated with FT4 among a large Belgian adolescent population [45,46], while chlorophenols 
(including 2,5-DCP) were found to interfere with the T4 binding site of a T4 carrier in an in vitro 
study [47].  
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In the present study, there were consistent negative associations between BP-3 with T4 and T3, 
and positive associations with TSH. Given the concurrent negative associations between BP-3 
and bound T4 and T3 hormones, it is possible that BP-3 could be reducing the thyroxine-binding 
globulin (TBG) level [48]. The lower levels in T4 and T3 alongside the elevated level of TSH in 
association with BP-3 could also indicate a situation of slight hypothyroidism, stimulating an 
increase in TSH. While BP-3 has shown anti-estrogenic and anti-androgenic effects in vitro [49], 
and caused cytotoxicity in yeast cells and developmental disorders in zebrafish [50], few studies 
have studied the effect of BP-3 on thyroid hormones, and study designs, hormones measured, 
and results have varied. Our previous study of a smaller pregnancy cohort in Puerto Rico found a 
significant negative association of BP-3 and free T3, but no significant associations with TSH 
[32]. After topical application of sunscreen containing BP-3, there were small changes in thyroid 
hormone levels in young men (n=15) and older women (n=17) after two weeks, but the authors 
concluded that this was a chance finding, and attributed no effect of sunscreen on thyroid 
hormone levels [51].  
BPS, which is used as a replacement chemical for BPA, was associated with a suggestive 
increase in TSH, particularly <15 weeks GA, as well as a decrease in FT4 at <15 weeks GA. 
BPS was observed to induce uterine growth in rats [52], affect the feedback regulatory circuits in 
parental zebrafish hypothalamo-pituitary-gonadal axes, impair the development of offspring 
[53], and possibly play a role in gene expression on the reproductive neuroendocrine axis in 
zebrafish [54]. The parallel associations observed between BPS and TSH, and BPS and FT4 
could be indicative of a change in the feedback regulatory circuits similar to the effects observed 
in zebrafish [53]. However, no previous human studies were identified that have investigated the 
effect of BPS on thyroid hormones. In the same LifeCodes cohort, BPA was associated with a 
decrease in TSH and an increase in FT4, particularly at later time points in pregnancy [33]. 
While BPS was also associated with TSH and FT4, the associations were in the opposite 
direction. BPA and BPS were not correlated in this study (Spearman correlation = 0.24), and 
structural variations among bisphenols may be sufficient to alter receptor-binding affinities [55]. 
This structural variation partly explains the differences observed in our results; however, the 
mechanism of action leading to the opposite directions in hormone associations is unclear. 
Furthermore, our detection level for BPS is very low (<25%), which may potentially introduce 
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some bias to our results. This makes the associations between BPS and BPA a little more 
difficult to interpret. 
The impact of TCS on thyroid hormones has been the most commonly researched in the 
literature, primarily in animal studies. TCS is structurally similar to thyroid hormones [56], and a 
study in pregnant rats showed that the greatest accumulation of TCS was in the placenta as 
compared to six other rat tissues, indicating pregnancy may be a sensitive time period for TCS 
exposure [57].  In this study, LMMs provided statistical power to observe a negative association 
between TCS and T3, and a positive association with TSH. This association with T3 is consistent 
with animal studies that also showed linear decreases in T3 with increased exposure to TCS [56], 
including in pregnant rats [58] and pregnant mice [59]. A study in pregnant mice observed an 
effect of TCS on signal pathways involved in placental growth through the activation of thyroid 
hormone receptors that trigger this signaling pathway [60]. On the other hand, no previous 
studies have reported an association between TCS and TSH during pregnancy in humans [32,61], 
or in animals [62,63]. However, if TCS was indeed responsible for the decrease in T3, it would 
make biological sense that TSH levels would increase given the negative feedback loop. A short-
term (n=12) and long-term (n=132) study of adult men and women found no effects on thyroid 
hormone levels following exposure to TCS-containing toothpaste [64,65]. Other studies point to 
a decrease in T4 levels in relation to TCS exposure, including animal dams [58,59,63,66–71]. In 
the present study we found a negative but not statistically significant association between TCS 
and T4 (%Δ = -1.04%; 95% CI = -2.55, 0.49; p value = 0.18).  
We found numerous associations between urinary paraben concentrations and hormone levels in 
the present study, and the associations differed by gestational age. MPB was positively 
associated with T3 and T4 at <15 weeks GA, PPB was associated with a decrease in FT4 at <15 
weeks GA, EPB was associated with a marginal decrease in the T3/T4 ratio at 15-21 weeks GA, 
and BPB was associated with a decrease in T3, T3/T4 ratio, and an increase in TSH during the 
second half of gestation. Few studies have looked into the effect of parabens on thyroid 
hormones in pregnant women.  In our previous cohort study of pregnant women in Puerto Rico, 
BPB was positively associated with FT4 during pregnancy, which we did not observe in the 
present study [32]. In the earlier study, MPB was positively associated with FT4 early in 
pregnancy, and negatively associated with FT4 later in pregnancy [32]. In the present study MPB 
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was negatively associated with FT4 earlier in pregnancy, and non-significant with FT4 later in 
pregnancy. This could indicate that impacts on thyroid signaling in relation to exposure to 
parabens is dependent on the timing of the exposure, although chance findings cannot be ruled 
out. In other research, a study on NHANES women over the age of 20 reported that all measured 
parabens were negatively associated with FT4, and BPB and EPB were negatively associated 
with T4 [10].  [72] found that MPB and PPB significantly decreased T4 levels in prepubertal 
female rats.  However, two small human studies in men found no effect on thyroid hormones 
[73,74]. It is unclear why the associations with hormones between parabens varied to this extent. 
This could be explained by the higher levels of MPB and PPB in our study, the differences in 
paraben concentrations by study visit, or true differences in the associations due to the structural 
differences between the parabens.  
Our study had a few limitations. Even though we applied sampling weights in our analyses to 
account for the case-control study design, there may still be constraints to the generalizability of 
our results to other populations given our sampling methods. Additionally, our study population 
had older maternal ages, and high educational attainment as compared to the general public, 
which could reduce the generalizability of our results. Loss to follow up may introduce selection 
bias, although the sample size at study visit 4 was still relatively high as compared to the study 
population at study visit 1. Although our study design greatly improved upon the standard cross-
sectional design by measuring urinary biomarkers at four separate time points, variation of 
phenols and parabens is relatively high, and the four time points may not be sufficient to 
eliminate potential bias stemming from random measurement error. Another limitation was the 
lack of data on iodine status of the women, given that deficiencies in these minerals could affect 
thyroid hormone function. However, controlling for iodine status could lead to bias, given that 
iodine may act as mechanistic intermediate between the exposure and thyroid hormone [75]. 
Further, iodine had no impact on the associations between phenols/parabens and thyroid 
hormones in our previous study of NHANES data [10]. We also did not measure thyroperoxidase 
antibodies and human chorionic gonadotropin (hCG). Thyroperoxidase antibodies may influence 
thyroid function in pregnancy [76], and hCG has similar homology to TSH, and may affect 
maternal thyroid function in pregnancy [22]. Finally, given the exploratory nature of the study, 
many comparisons were made, increasing the chance of Type I error.  
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Our study also had many strengths, including a robust sample size, sensitive and state-of-the-art 
biomarkers of exposure, and the collection of data at four time points during pregnancy to 
account for the chemicals’ short lifespan in the body, and the varying levels of thyroid hormones 
throughout pregnancy. The repeated measures allow us to control for intra-individual variability 
and increase statistical power, as well as explore potential windows of susceptibility for these 
associations.  
 Conclusion 
Our results provide suggestive human evidence for associations between phenols and parabens 
with thyroid hormones during pregnancy. The strength of our associations may vary across 
pregnancy. Further studies are required to confirm our findings, determine the biological 
mechanisms involved, and better understand if and how these hormone changes may affect 
downstream maternal and infant health outcomes. 
 
Table II.1: Summary demographics of the 439 pregnant women in the sample 
 
  
N % of cohort* 
Age 18–24 years 54 12 
 25–29 years 92 21 
 30–34 years 176 40 
 35+ years 117 27 
Race/ethnicity White 247 56 
 African-American 75 17 
 Other 117 27 
Education High school degree 67 16 
 Technical school 76 18 
 Junior college or some college 127 29 
 College graduate 159 37 
Health insurance provider Private/HMO/Self-pay 344 81 
 Medicaid/SSI/MassHealth 83 19 
BMI at initial visit < 25 kg/m
2 227 52 
 25–29.9 kg/m2 113 26 
 ≥ 30 kg/m2 99 22 
Tobacco use Smoking during pregnancy 31 7 
 No smoking during pregnancy 402 93 
Alcohol use Alcohol use during pregnancy 18 4 
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 No alcohol use during pregnancy 412 96 
 
*Weighted by case-control sampling probabilities to represent the general sampling population. 
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Table II.2: Weighted distributions of SG-corrected urinary phenols and parabens and thyroid hormones by study visit of sample collection in 
pregnancy (N = 439 subjects). Median gestational weeks: Visit 1: 10, Visit 2: 18, Visit 3: 26, Visit 4: 35.  
    All Visit 1 Visit 2 Visit 3 Visit 4 
  % LOD (LOD) GM (GSD) GM (GSD) GM (GSD) GM (GSD) GM (GSD) 
Urinary 
Biomarkers (μg/L) 
      
2,4-DCP 15.7 (0.2) 0.89 (3.51) 0.95 (3.85) 0.93 (3.50)* 0.81 (3.52)* 0.88 (3.14)* 
2,5-DCP  3.1 (0.2) 5.11 (6.42) 5.35 (7.08) 5.63 (6.63) 4.69 (6.46)* 4.77 (5.47)* 
BP-3 0.1 (0.4) 55.82 (8.48) 52.62 (8.16) 61.66 (8.11) 51.62 (8.76) 57.94 (9.02) 
BPB 29.3 (0.2) 1.19 (7.14) 1.21 (7.53) 1.29 (6.71) 1.18 (7.39) 1.09 (6.96) 
EPB 38.1 (1) 3.56 (5.82) 3.73 (6.20) 3.92 (6.05) 3.45 (5.67)* 3.15 (5.33)* 
MPB 0.1 (1) 169.64 (4.31) 152.43 (4.14) 208.05 (4.07) 161.80 (4.55) 161.49 (4.45) 
PPB 1 (0.2) 37.35 (5.71) 33.90 (5.67) 50.85 (5.04)* 34.36 (5.82) 32.63 (6.23) 
TCS 17.4 (2) 16.63 (6.65) 16.82 (6.98) 17.44 (6.20) 14.91 (6.49) 17.35 (6.95) 
TCC 85.9 (2) <LOD <LOD <LOD <LOD <LOD 
BPS 73.8 (0.4) <LOD <LOD <LOD <LOD <LOD 
 Thyroid Hormones 
      
FT4 (ng/dL) 98.2 (0.1) 1.10 (1.52) 1.37 (1.48) 1.08 (1.49)* 0.99 (1.50)* 0.96 (1.45)* 
TSH (μIU/mL) 99.5 (0.01) 1.13 (2.12) 0.77 (2.75) 1.29 (1.92)* 1.27 (1.68)* 1.31 (1.71)* 
T3 (ng/mL) 100 (0.1) 1.56 (1.30) 1.35 (1.31) 1.61 (1.27)* 1.65 (1.27)* 1.66 (1.29)* 
T4 (μg/dL) 100 (0.3) 10.22 (1.21) 9.98 (1.22) 10.61 (1.18)* 10.29 (1.20)* 10.01 (1.23) 
T3/T4 ratio - 0.15 (1.27) 0.14 (1.21) 0.15 (1.24)* 0.16 (1.27)* 0.17 (1.29)* 
 
GM: Geometric mean 
GSD: Geometric standard deviation 
* Significant difference (p<0.05) in urinary biomarker metabolite or thyroid hormone compared to reference (visit 1) using linear mixed models with a random intercept  
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Table II.3: Results of the linear mixed models regressing thyroid hormones versus phenols and parabens: % change in thyroid 
hormone per IQR change in urinary biomarker concentration  
 
    TSH (N=1069) FT4 (N=1240) T4  (N=1230) T3 (N=993) T3/T4 Ratio (N=985) 
2,4-DCP % Δ/IQR (95% CI) 0.24 (-5.71, 6.57) -0.30 (-3.46, 2.96) 0.31 (-0.96, 1.58) -1.33 (-3.15, 0.49) -1.44 (-3.11, 0.22) 
  p value 0.94 0.85 0.63 0.15 0.09* 
2,5-DCP % Δ/IQR (95% CI) -2.71 (-9.13, 4.16) -1.64 (-5.05, 1.90) -0.06 (-1.53, 1.40) -0.52 (-2.60, 1.56) -0.36 (-2.28, 1.55) 
  p value 0.43 0.36 0.93 0.63 0.71 
BP-3 % Δ/IQR (95% CI) 5.42 (-1.58, 12.9) -0.62 (-4.11, 3.00) -1.13 (-2.59, 0.34) -2.07 (-4.16, 0.01) -1.33 (-3.24, 0.59) 
  p value 0.13 0.73 0.13 0.05* 0.18 
BPS◊ % Δ (95% CI) 9.77 (-0.89, 21.6) -1.11 (-6.27, 4.34) -0.30 (-0.19, 0.20) -0.68 (-3.68, 2.33) -0.54 (-3.29, 2.21) 
 p value 0.07* 0.68 0.77 0.66 0.70 
TCS % Δ/IQR (95% CI) 7.72 (0.01, 16.02) 1.22 (-2.59, 5.18) -1.20 (-2.76, 0.35) -2.53 (-4.75, -0.30) -0.80 (-2.84, 1.25) 
  p value 0.05** 0.54 0.13 0.03** 0.45 
TCC◊ % Δ (95% CI) -12.86 (-25.6, 2.05) 1.14 (-6.98, 9.96) -0.95 (-0.35, 0.27) -5.71 (-10.45, -0.97) -3.99 (-8.30, 0.33) 
  p value 0.09 * 0.79 0.56 0.02** 0.07* 
EPB % Δ/IQR (95% CI) 2.84 (-3.92, 10.1) 0.50 (-3.06, 4.18) 0.67 (-0.77, 2.11) -0.86 (-2.92, 1.20) -1.87 (-3.76, 0.02) 
  p value 0.42 0.79 0.36 0.41 0.05* 
MPB % Δ/IQR (95% CI) 0.55 (-5.45, 6.93) -2.13 (-5.24, 1.09) 1.19 (-0.10, 2.47) 2.41 (0.58, 4.24) 0.79 (-0.90, 2.48) 
  p value 0.86 0.19 0.07* 0.01** 0.36 
BPB % Δ/IQR (95% CI) 6.85 (-1.67, 16.1) 0.43 (-3.86, 4.92) 0.76 (-0.98, 2.49) -2.76 (-5.25, -0.26) -3.70 (-5.98, -1.42) 
  p value 0.12 0.85 0.39 0.03** 0.002** 
PPB % Δ/IQR (95% CI) 0.87 (-5.02, 7.13) -3.14 (-6.12, -0.06) 0.99 (-0.25, 2.22) 1.41 (-0.36, 3.18) 0.26 (-1.36, 1.88) 
  p value 0.78 0.05** 0.12 0.12 0.76 
◊ Phenol metabolite was transformed into a dichotomous variable. * represents a p value below 0.10, and **represents a p value below 0.05. 
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Figure II.1: Multiple linear regressions of thyroid hormone versus urinary concentrations of phenol/paraben stratified by gestational age. BPS and 
TCC are categorical variables. Associations with BPS and TCC are transformed to % changes in the hormone comparing urinary biomarkers above 
and below the LOD. * represents at least one marginal association between the urinary concentration and the hormone across the four time points. ** 
represents at least one significant association between the urinary concentration and the hormone across the four time points. 
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Figure II.2: Heat map of Spearman correlations between urinary phenol and paraben biomarkers. 
Biomarkers were adjusted for urinary dilution. 
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Figure II.3: Heat map of Spearman correlations between serum thyroid hormones. 
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Table II.4: Results of the multiple linear models regressing thyroid hormones versus phenols/parabens by gestational age.  
  <15 GA weeks 15-21 GA weeks 21-30 GA weeks >30 GA weeks 
FT4 
N 334  323  288  295  
2,4-DCP -2.91 (-6.98, 1.35) 0.18 -0.15 (-4.66, 4.57) 0.95 -2.44 (-8.08, 3.55) 0.42 -0.40 (-5.18, 4.62) 0.87 
2,5-DCP -3.21 (-8.25, 2.1) 0.23 -2.00 (-7.6, 3.95) 0.50 -1.59 (-6.7, 3.8) 0.56 -0.83 (-6.13, 4.77) 0.77 
BP-3 -1.53 (-7.7, 5.06) 0.64 -3.98 (-10.08, 2.54) 0.23 -0.18 (-7, 7.14) 0.96 3.44 (-2.97, 10.28) 0.30 
BPS♦◊ -9.63 (-18.1, -0.33) 0.04** 6.17 (-4.53, 18.06) 0.27 4.69 (-7.82, 18.89) 0.48 -5.28 (-14.94, 5.48) 0.32 
TCS -4.73 (-10.67, 1.61) 0.14 5.07 (-1.06, 11.59) 0.11 1.75 (-6.18, 10.36) 0.67 1.54 (-4.69, 8.18) 0.64 
TCC◊ 6.84 (-8.56, 24.82) 0.41 -3.05 (-17.52, 13.94) 0.71 7.01 (-9.32, 26.28) 0.42 -3.69 (-18.83, 14.28) 0.67 
EPB -0.45 (-6.83, 6.36) 0.89 -5.42 (-12.26, 1.94) 0.15 2.88 (-4.81, 11.2) 0.47 2.88 (-4.35, 10.65) 0.45 
MPB* -4.19 (-8.84, 0.69) 0.09* -4.66 (-10.09, 1.09) 0.11 -0.43 (-6.48, 6.01) 0.89 1.77 (-3.71, 7.57) 0.53 
BPB 1.61 (-5.28, 8.99) 0.66 -3.42 (-10.34, 4.04) 0.36 0.53 (-7.92, 9.76) 0.91 0.58 (-6.18, 7.82) 0.87 
PPB* -4.60 (-8.88, -0.12) 0.05** -5.57 (-10.74, -0.10) 0.05** 0.57 (-5.93, 7.52) 0.87 1.40 (-4.09, 7.2) 0.62 
T3 
N 273  268  240  212  
2,4-DCP -0.88 (-4.43, 2.67) 0.63 1.20 (-1.83, 4.24) 0.44 -4.05 (-7.49, -0.61) 0.02** -1.20 (-5.18, 2.77) 0.55 
2,5-DCP -0.06 (-4.49, 4.38) 0.98 2.63 (-0.97, 6.24) 0.15 -2.44 (-5.52, 0.64) 0.12 -1.27 (-5.7, 3.16) 0.57 
BP-3 -5.39 (-10.6, -0.24) 0.04** -1.59 (-5.55, 8.77) 0.43 -5.14 (-9.29, -0.98) 0.02** -6.87 (-11.65, -2.09) 0.01** 
BPS♦◊ -6.15 (-14.3, 2.01) 0.14 0.35 (-8.07, 12.28) 0.93 3.67 (-5.84, 13.17) 0.45 -4.59 (-15.21, 6.03) 0.40 
TCS -2.73 (-7.86, 2.41) 0.30 -0.49 (-4.23, 3.24) 0.80 -3.04 (-7.64, 1.57) 0.20 1.54 (-3.76, 6.84) 0.57 
TCC◊ 0.38 (-13.09, 13.85) 0.96 -3.74 (-16.83, 9.35) 0.58 -7.35 (-20.24, 5.53) 0.26 -11.15 (-29.48, 7.18) 0.23 
EPB 2.52 (-2.87, 7.91) 0.36 -2.62 (-7.16, 1.92) 0.26 -3.73 (-8.43, 0.96) 0.12 -0.37 (-6.05, 5.32) 0.90 
MPB 3.67 (-0.33, 7.67) 0.07* -0.14 (-3.79, 3.51) 0.94 -0.23 (-4, 3.55) 0.91 0.95 (-3.61, 5.51) 0.68 
BPB -2.77 (-8.41, 2.87) 0.34 -3.12 (-7.72, 1.49) 0.19 -6.38 (-11.34, -1.43) 0.01** -6.80 (-12.34, -1.27) 0.02** 
PPB 2.32 (-1.56, 6.19) 0.24 -0.34 (-3.87, 3.19) 0.85 -0.80 (-4.78, 3.17) 0.69 1.12 (-3.44, 5.68) 0.63 
T3/T4 
N 270  266  238  211  
2,4-DCP -0.76 (-3.02, 1.51) 0.51 2.65 (-0.25, 5.55) 0.07* -1.90 (-5.58, 1.78) 0.31 -0.98 (-5.41, 3.45) 0.66 
2,5-DCP -1.40 (-4.23, 1.44) 0.34 2.82 (-0.64, 6.29) 0.11 -0.86 (-4.13, 2.40) 0.61 -1.61 (-6.51, 3.29) 0.52 
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BP-3♦ -1.35 (-4.71, 2.02) 0.43 2.73 (-1.05, 6.51) 0.16 -1.41 (-5.85, 3.03) 0.53 -7.37 (-12.7, -2.04) 0.01** 
BPS◊ 1.07 (-4.19, 6.32) 0.69 -2.01 (-9.52, 5.51) 0.60 2.94 (-6.68, 12.57) 0.55 -3.01 (-14.78, 8.76) 0.62 
TCS -1.30 (-4.6, 2.0) 0.44 -0.13 (-3.71, 3.44) 0.94 -3.62 (-8.48, 1.25) 0.15 2.98 (-2.87, 8.84) 0.32 
TCC◊ -0.94 (-9.55, 7.67) 0.83 -6.53 (-18.05, 4.99) 0.27 -5.38 (-18.43, 7.66) 0.42 -13.06 (-33.16, 7.03) 0.20 
EPB 1.03 (-2.45, 4.51) 0.56 -0.93 (-5.27, 3.42) 0.68 -4.29 (-9.24, 0.65) 0.09* -0.23 (-6.54, 6.08) 0.94 
MPB 2.65 (0.09, 5.21) 0.04** 1.55 (-1.95, 5.04) 0.39 -3.21 (-7.2, 0.78) 0.12 -1.65 (-6.69, 3.40) 0.52 
BPB -1.57 (-5.21, 2.06) 0.40 0.58 (-3.84, 5.0) 0.80 -5.74 (-10.98, -0.50) 0.03** -5.46 (-11.65, 0.73) 0.09* 
PPB 2.07 (-0.41, 4.54) 0.10 1.06 (-2.36, 4.48) 0.54 -3.20 (-7.41, 1.01) 0.14 -0.79 (-5.85, 4.26) 0.76 
T4 
N 328  317  304  301  
2,4-DCP 0.88 (-1.38, 3.14) 0.44 -0.35 (-2.25, 1.54) 0.71 -1.28 (-3.95, 1.39) 0.35 0.12 (-2.44, 2.68) 0.93 
2,5-DCP 0.62 (-2.21, 3.45) 0.67 -0.63 (-3.03, 1.78) 0.61 -1.50 (-3.85, 0.84) 0.21 1.33 (-1.51, 4.18) 0.36 
BP-3 -3.33 (-6.74, 0.08) 0.06* -3.82 (-6.42, -1.22) 0.004** -4.42 (-7.55, -1.30) 0.01** -1.71 (-5.11, 1.68) 0.32 
BPS◊ -1.03 (-6.26, 4.21) 0.70 0.61 (-4.05, 5.28) 0.80 4.79 (-1.0, 10.58) 0.11 -1.76 (-7.33, 3.81) 0.54 
TCS -1.97 (-5.36, 1.42) 0.26 0.04 (-2.42, 2.50) 0.97 0.32 (-3.21, 3.85) 0.86 -0.79 (-4.18, 2.61) 0.65 
TCC◊ 3.17 (-4.81, 11.15) 0.44 0.56 (-6.46, 7.57) 0.88 2.26 (-5.2, 9.73) 0.55 6.92 (-1.93, 15.77) 0.13 
EPB -0.15 (-3.66, 3.35) 0.93 -0.43 (-3.49, 2.62) 0.78 0.13 (-3.35, 3.61) 0.94 -0.68 (-4.47, 3.11) 0.73 
MPB* 0.42 (-2.21, 3.05) 0.75 -0.18 (-2.54, 2.18) 0.88 2.13 (-0.60, 4.87) 0.13 2.33 (-0.60, 5.25) 0.12 
BPB -1.23 (-4.92, 2.46) 0.51 -2.18 (-5.24, 0.88) 0.16 -1.71 (-5.50, 2.07) 0.38 -1.71 (-5.41, 1.99) 0.37 
PPB* -0.10 (-2.57, 2.37) 0.94 -0.24 (-2.56, 2.09) 0.84 1.70 (-1.24, 4.64) 0.26 1.63 (-1.32, 4.58) 0.28 
TSH 
N 286  283  258  242  
2,4-DCP♦ -4.37 (-14.90, 7.47) 0.45 -2.28 (-10.52, 6.71) 0.61 6.81 (-0.74, 14.94) 0.08* 5.94 (-2.11, 14.65) 0.15 
2,5-DCP♦ -0.69 (-14.3, 15.08) 0.93 -8.79 (-17.99, 1.44) 0.09* 0.74 (-5.61, 7.53) 0.82 10.03 (0.74, 20.19) 0.03** 
BP-3♦ 4.06 (-12.31, 23.48) 0.65 16.38 (3.63, 30.7) 0.01** 7.85 (-1.22, 17.75) 0.09* -0.68 (-10.35, 10.03) 0.90 
BPS♦◊ 26.02 (-3.53, 64.63) 0.09* -10.03 (-26.18, 9.65) 0.30 5.11 (-10.35, 23.23) 0.54 1.80 (-14.94, 21.83) 0.85 
TCS 9.59 (-7.48, 29.81) 0.29 7.01 (-4.12, 19.43) 0.23 7.13 (-2.89, 18.18) 0.17 -1.45 (-11.51, 9.74) 0.79 
TCC◊ -3.72 (-38.2, 49.90) 0.87 -0.65 (-26.52, 34.33) 0.97 4.02 (-15.65, 28.29) 0.71 -5.48 (-29.61, 26.91) 0.71 
EPB 0.71 (-15.49, 20.0) 0.94 -1.93 (-14.05, 11.91) 0.77 1.56 (-7.91, 12) 0.76 4.97 (-6.51, 17.85) 0.41 
MPB -9.98 (-21.09, 2.69) 0.12 -1.50 (-11.32, 9.41) 0.78 -6.98 (-13.91, 0.51) 0.07* 4.49 (-4.80, 14.68) 0.36 
BPB 11.66 (-7.36, 34.57) 0.25 8.18 (-5.51, 23.85) 0.26 2.51 (-7.79, 13.97) 0.65 14.64 (2.36, 28.39) 0.02** 
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PPB -6.81 (-18.06, 5.97) 0.28 -6.93 (-16.02, 3.15) 0.17 -5.19 (-12.72, 2.99) 0.21 6.72 (-2.74, 17.09) 0.17 
 
Beta coefficients are transformed into percent change of hormone in an IQR change in the biomarker. ◊ Phenol metabolite was transformed into a categorical variable. Beta 
coefficients and their 95% CI are displayed. ♦ represents a significant interaction term between the biomarker*visit in LMM models. ** p value <0.05; * 0.05< p value < 0.10. 
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Table II.5: Linear mixed models in term births only (defined by >37 weeks). 
    TSH FT4 T4 T3 T3/T4 
  N=816 N=949 N=933 N=754 N=746 
2,4-DCP % Δ/IQR (95% CI) 2.86 (-2.41, 8.41) -0.29 (-3.12, 2.63) 0.66 (-0.45, 1.76) -0.44 (-1.96, 1.07) -0.71 (-2.18, 0.76) 
  p value 0.29 0.85 0.24 0.57 0.34 
2,5-DCP % Δ/IQR (95% CI) 0.01 (-6.74, 7.25) -2.53 (-6.05, 1.13) 0.74 (-0.78, 2.26) 0.69 (-1.36, 2.74) 0.14 (-1.87, 2.15) 
  p value 1.00 0.17 0.34 0.51 0.89 
BP-3 % Δ/IQR (95% CI) 3.93 (-3.64, 12.1) -0.13 (-4.2, 4.11) -1.20 (-2.84, 0.44) -2.76 (-4.94, -0.57) -2.27 (-4.4, -0.13) 
  p value 0.32 0.95 0.15 0.01** 0.04** 
BPS◊ % Δ (95% CI) 11.77 (0.08, 24.8) -0.88 (-6.92, 5.55) -1.34 (-3.57, 0.88) -1.18 (-4.31, 1.95) -0.11 (-3.15, 2.94) 
  p value 0.05** 0.78 0.24 0.46 0.94 
TCS % Δ/IQR (95% CI) 11.57 (3.66, 20.1) -0.33 (-4.29, 3.79) -0.62 (-2.18, 0.95) -1.12 (-3.25, 1.01) 0.08 (-1.99, 2.15) 
  p value 0.004** 0.87 0.44 0.30 0.94 
TCC◊ % Δ (95% CI) -14.49 (-27.9, 1.46) 0.00 (-9.27, 10.2) 1.31 (-2.17, 4.78) -0.38 (-5.36, 4.61) -1.63 (-6.42, 3.16) 
  p value 0.07* 1.00 0.46 0.88 0.51 
EPB % Δ/IQR (95% CI) 2.99 (-4.51, 11.1) 2.24 (-2.06, 6.71) 1.15 (-0.47, 2.77) -1.03 (-3.22, 1.16) -2.02 (-4.14, 0.11) 
  p value 0.45 0.31 0.16 0.36 0.06* 
MPB % Δ/IQR (95% CI) 2.75 (-3.18, 9.04) -0.93 (-4.19, 2.44) 1.31 (0.06, 2.55) 2.17 (0.46, 3.87) 0.71 (-0.96, 2.37) 
  p value 0.37 0.58 0.04** 0.01** 0.41 
BPB % Δ/IQR (95% CI) 11.27 (2.51, 20.8) 0.69 (-3.86, 5.45) 0.72 (-1.02, 2.46) -3.09 (-5.47, -0.72) -3.38 (-5.69, -1.08) 
  p value 0.01 0.77 0.42 0.01** 0.004** 
PPB % Δ/IQR (95% CI) 2.98 (-3.24, 9.59) -1.66 (-5.0, 1.79) 1.28 (-0.01, 2.57) 1.05 (-0.71, 2.81) 0.05 (-1.66, 1.76) 
 p value 0.36 0.34 0.05* 0.24 0.95 
Beta coefficients are transformed into percent change of hormone in an IQR change in the biomarker. ◊ Phenol metabolite was transformed into a categorical variable.  
Beta coefficients and their 95% CI are displayed. ** p value <0.05; * 0.05< p value < 0.10. 
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 A Repeated Measures Study of Phenol, Paraben and 
Triclocarban Urinary Biomarkers and Circulating Maternal Hormones 
during Gestation (PROTECT) 
 
 
 
Abstract: 
Introduction: Prenatal exposure to some phenols and parabens has been associated with adverse 
birth outcomes. Hormones may play an intermediate role between phenols and adverse 
outcomes. We examined the associations of phenol and paraben exposures with maternal 
reproductive and thyroid hormones in 602 pregnant women in Puerto Rico. Urinary triclocarban, 
phenol and paraben biomarkers, and serum hormones (estriol, progesterone, testosterone, sex-
hormone-binding globulin (SHBG), corticotropin-releasing hormone (CRH), total 
triiodothyronine (T3), total thyroxine (T4), free thyroxine (FT4) and thyroid-stimulating 
hormone (TSH)) were measured at two visits during pregnancy. Methods:  Linear mixed models 
with a random intercept were constructed to examine the associations between hormones and 
urinary biomarkers. Results were additionally stratified by study visit. Results were transformed 
to hormone percent changes for an inter-quartile-range difference in exposure biomarker 
concentrations (%Δ). Results: Bisphenol-S was associated with a decrease in CRH [(%Δ -11.35; 
95% CI: -18.71, -3.33), and bisphenol-F was associated with an increase in FT4 (%Δ: 2.76; 95% 
CI: 0.29, 5.22).  Butyl-, methyl- and propylparaben were associated with decreases in SHBG 
[(%Δ: -5.27; 95% CI: -9.4, -1.14); (%Δ: -3.53; 95% CI: -7.37, 0.31); (%Δ: -3.74; 95% CI: -7.76, 
0.27)]. Triclocarban was positively associated with T3 (%Δ: 4.08; 95% CI: 1.18, 6.98) and 
T3/T4 ratio (%Δ: 4.67; 95% CI: -1.37, 6.65), and suggestively negatively associated with TSH 
(%Δ: -10.12; 95% CI: -19.47, 0.32). There was evidence of susceptible windows of vulnerability 
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for some associations. At 24-28 weeks gestation, there was a positive association between 2,4-
dichlorophenol and CRH (%Δ: 9.66; 95% CI: 0.67, 19.45) and between triclosan and estriol 
(%Δ: 13.17; 95% CI: 2.34, 25.2); and a negative association between triclocarban and SHBG 
(%Δ: -9.71; 95% CI:-19.1, -0.27) and between bisphenol A and testosterone (%Δ: -17.37; 95% 
CI: -26.7, -6.87). Conclusion: Phenols and parabens are associated with hormone levels during 
pregnancy. Further studies are required to substantiate these findings. 
 
 Introduction 
Exposure to phenols and parabens has been linked to various adverse health effects, including 
ovarian toxicity, cancer, and adverse neurodevelopmental outcomes [1–4]. Prenatal exposure to 
these chemicals, in particular, may have a long lasting effect on fetal health into adulthood. For 
example, prenatal exposure to phenols and parabens has been linked to adverse birth outcomes 
[5,6], respiratory health effects in  children [7], and cardiometabolic risk [8]. The exact 
mechanisms at play are still not fully understood; however, endocrine disruption is hypothesized 
to be one of the main toxicity pathways [3,9–11]. 
Reproductive and thyroid hormones play an essential role in the maintenance of pregnancy and 
the development of the fetus [12–16], therefore pregnancy is a vulnerable window for endocrine 
disruption due to the varying levels of hormones involved in the growing organism [17]. 
Endocrine disrupting chemicals could act through several pathways, including hormone 
synthesis, regulation, transport and metabolism, and/or interference with receptors. Phenols and 
parabens have estrogenic and androgenic properties [1,18–21], but few human studies have 
looked into the effect of these chemicals on maternal hormones during pregnancy. Most existing 
studies in this area use smaller study populations or only examined a single time point in 
pregnancy, which do not capture the changing hormone levels and high variability of phenols 
and paraben exposure during pregnancy. Furthermore, no or few studies explored the 
associations between these chemicals and maternal testosterone, corticotropin-releasing hormone 
(CRH), sex hormone-binding globulin (SHBG) and estriol, all of which play essential roles in 
maintaining healthy pregnancies.  
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Given the growing evidence of the endocrine disrupting effects of phenols and parabens [19,22–
26], our aim was to study the relationships between phenols and parabens on reproductive and 
thyroid hormones in our ongoing cohort of pregnant women in Puerto Rico. The study follows 
the women over multiple time points during pregnancy, providing more power than previous 
studies, and allows for the identification of potential windows of susceptibility. We previously 
reported early preliminary results on associations between select phenols and parabens with 
hormones in this Puerto Rican cohort [27]. This manuscript is an update of our previous results 
that utilizes a much larger sample size, includes additional hormones (estriol, testosterone, total 
triiodothyronine, and total thyroxine), as well as additional exposure biomarkers yet to be studied 
in detail (ethylparaben, BPS, BPF and triclocarban). Due to the lack of human health data, this 
study was exploratory in nature, with the exception of BPA, triclosan, methylparaben and 
propylparaben. We hypothesized a decrease in serum thyroid hormone levels in association with 
triclosan, methyl- and propyl-paraben, and an increase in serum thyroid hormones with BPA 
concentrations.  
 Methods  
Study Participants 
Participants for the present study were from an ongoing prospective cohort of pregnant women in 
Puerto Rico, named the Puerto Rico Testsite for Exploring Contamination Threats (PROTECT) 
cohort. Details on the recruitment and inclusion criteria have been described previously [28,29]. 
The study participants included in the present analysis were recruited from 2012-2017 at 14 ± 2 
weeks gestation from two hospitals and five affiliated prenatal clinics in Northern Puerto Rico. 
They were aged between 18-40 years. The exclusion criteria included women who lived outside 
the region, had multiple gestations, used oral contraceptives within three months prior to getting 
pregnant, got pregnant using in vitro fertilization, or had known medical health conditions 
(diabetes, hypertension, etc.). Three visits were conducted with the study participants to coincide 
with periods of rapid fetal growth and routine clinical visits (Visit 1: 16-20; Visit 2: 20-24; Visit 
3: 24-28 gestation weeks). Demographic information was collected via questionnaires at the 
initial study visit. Spot urine samples were collected at the three study visits, whereas blood 
samples were collected during the first and third visits. 
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The present analysis includes 602 women recruited into the study (of the total 1311 women 
enrolled in the cohort to date) for whom both total phenol and paraben concentrations and 
hormone measurements from at least one study visit were available. This study was approved by 
the research and ethics committees of the University Of Michigan School Of Public Health, 
University of Puerto Rico, Northeastern University, and the University of Georgia. All study 
participants provided full informed consent prior to participation. The involvement of the 
Centers for Disease Control and Prevention (CDC) laboratory did not constitute engagement in 
human subjects research.  
 Quantification of urinary biomarkers  
After collection, spot urine samples were divided into aliquots and frozen at -80oC until they 
were shipped overnight with dry ice to the CDC for analysis. Urine samples were analyzed for 
seven phenols (2,4-dichlorophenol, 2,5-dichlorophenol, BPA, BPS, BPF, benzophenone-3, 
triclosan), triclocarban,  and four parabens [ethylparaben, methylparaben, butylparaben, 
propylparaben] using online solid phase extraction-high-performance liquid chromatography-
isotope dilution tandem mass spectrometry [30–32]. Biomarker concentrations below the limit of 
detection (LOD) were assigned a value of the LOD divided by √2 [33]. The LODs were as 
follows: 0.1 µg/L (2,4-dichlorphenol, 2,5-dichlorophenol, BPS, triclocarban, butylparaben, 
propylparaben); 0.2 µg/L (BPA, BPF); 0.4 µg/L (benzophenone-3); 1 µg/L (methylparaben, 
ethylparaben); and 1.7 µg/L (triclosan). Urinary dilution was accounted for by using urinary 
specific gravity (SG), and was measured using a digital handheld refractometer (AtagoCo., Ltd., 
Tokyo, Japan). For preliminary data analysis, urinary biomarker concentrations were corrected 
for SG using the following formula: 
Pc = M [ (SGm – 1) / (SGi – 1) ] where Pc is the SG-corrected concentration (µg/L), M is the 
measured concentration, SGm is the study population median urinary specific gravity (1.0196), 
and SGi is the individual’s urinary specific gravity. The sample size for BPF, BPS, triclocarban 
and ethylparaben was smaller than the rest of the biomarkers because they were only quantified 
in a later sub-sample of the cohort.  
 Hormone measurement 
Serum samples were collected during visits 1 and 3. Volume limitations resulted in differences in 
the number of samples analyzed by hormone. All hormone analyses were conducted at the 
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Central Ligand Assay Satellite Services (CLASS) laboratory, Department of Epidemiology, 
School of Public Health, University of Michigan. Progesterone, SHBG, testosterone, total 
triiodothyronine (T3), total thyroxine (T4), free thyroxine (FT4), and thyroid-stimulating 
hormone (TSH) were measured in serum using a chemiluminescence immunoassay (ADVIA 
Centaur® CP Immunoassay System, Seimens Healthineers). Estriol and CRH were measured in 
serum using an enzyme immunoassay (Estriol ELISA Kit, ALPCO; CRH ELISA Kit, LifeSpan 
BioSciences). In addition to measured hormones, the ratio of progesterone to estriol (Prog/Estriol 
Ratio), and the ratio of T3 and T4 (T3/T4 ratio) were calculated for the purposes of this analysis. 
Hormone ratios may be a better indicator of adverse pregnancy outcomes (such as preterm birth) 
than the individual hormones alone [34–36]. Two samples had a TSH level below the LOD. 
Because this result was not biologically plausible, these two values were dropped from the 
analyses. 
 Statistical Analyses 
Distributions of key demographic characteristics were calculated. All urinary exposure 
biomarkers, and the serum hormones progesterone, estriol, CRH, TSH and progesterone/estriol 
ratio were positively-skewed, and were natural log-transformed. The distributions of SHBG, 
FT4, T3, T4 and T3/T4 ratio approximated normality and remained untransformed in all 
analyses. Geometric means and standard deviations were calculated for all SG-corrected 
exposure biomarkers, hormones, and the ratios of progesterone/estriol and T3/T4. We examined 
urinary exposure biomarkers concentrations and serum hormone levels by study visit, and 
calculated Spearman correlations between unlogged average SG-corrected exposure biomarkers. 
To assess differences in exposure biomarkers and hormones across study visits, we ran Linear 
Mixed Models (LMM) with a subject-specific random intercept regressing the biomarker or 
hormone against the study visit. Specific gravity was used as a covariate in the model instead of 
using the SG-corrected biomarker concentrations. The selection of a random intercept and slope 
was determined using BIC values. BPF and ethylparaben were detected in less than 50% of the 
samples. Therefore, we transformed BPF and ethylparaben into dichotomous variables, where 0 
represented concentrations below the LOD, and 1 represented detectable concentrations. These 
categorical BPF and ethylparaben variables were used in all of the following regression analyses. 
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In our repeated measures analysis, we regressed one hormone or hormone ratio on one urinary 
biomarker using LMM, with a subject-specific random intercept for each model to account for 
intra-individual correlation of serial hormone measurements collected over the two study visits. 
The urinary biomarker concentrations at the two visits were treated as time-varying variables in 
the LMM models. Crude models included specific gravity and study visit as covariates. Potential 
confounders were selected a priori from the existing literature, and included as covariates if they 
were found to change the main effect estimate by >10%. Final models were adjusted for specific 
gravity, study visit, body mass index (BMI) at the first study visit, maternal age, the number of 
hours of second-hand smoking exposure per day, and a socio-economic variable. All covariates, 
except for maternal age and specific gravity, were categorical. The socio-economic variable used 
in the model differed by the hormone regressed. Maternal education was a strong confounder for 
models regressing progesterone, estriol, and progesterone/estriol ratio against urinary biomarkers 
concentrations, and was used as the socio-economic index for those models. All other models 
used insurance type as the socio-economic status index. The selection of the socio-economic 
variable was based on the percent change in the main effect estimate, and the p value of the 
socio-economic variable in final models. In an effort to compare our exposure distributions to 
our previous study discussed in CHAPTER II, we plotted density plots of each exposure 
biomarker from the PROTECT and LifeCodes cohorts. 
To assess windows of vulnerability, we ran two more analyses. First, we ran the same LMMs 
regressing hormones and urinary biomarkers concentrations with an interaction term between the 
urinary biomarker and the study visit. Second, we ran multiple linear regressions (MLR) 
stratified by study visit of sample collection. The MLR models were adjusted for the same 
covariates as those in the LMMs.  
To increase interpretability of our results, we transformed regression coefficients to percent 
changes (and associated 95% confidence intervals, CIs) in hormone concentration in relation to 
the interquartile range (IQR) increase in urinary biomarker concentrations. Beta coefficients 
from models with categorical biomarkers (BPF and ethylparaben) were transformed to percent 
changes (and associated 95% confidence intervals) in hormone concentration at detectable vs 
non-detectable biomarker concentrations. The alpha level was set at 0.05.  All statistical analyses 
were conducted in R Version 3.4.2. 
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As a sensitivity analysis, all models were re-run using specific gravity as a covariate in 
combination with exposure biomarkers corrected for specific gravity as was described by 
O’Brien et al [37]. We observed no differences in our results, and therefore, retained our original 
models using un-corrected exposure biomarkers with specific gravity included as a covariate. We 
observed no differences in our results, and therefore, retained our original models using un-
corrected exposure biomarkers with SG included as a covariate. In an effort to compare our 
exposure distributions to our previous study discussed in CHAPTER II, we plotted density plots 
of each exposure biomarker from the PROTECT and LifeCodes cohorts. 
 Results 
The 602 study participants had a mean age of 26.4 and approximately 60% had BMI levels 
below 30 kg/m2 (Table III.1). Although the majority of women reported never smoking (75%), 
4% reported currently smoking, and 7% reported exposure to second-hand smoking for more 
than an hour per day. Six percent reported consuming alcohol in the last few months. A quarter 
of the study participants reported a household income of less than $10,000, and only 11% 
reported a household income >$50,000. A quarter of the participants did not report their 
incomes. As compared to the overall PROTECT cohort, the study participants included in the 
present analysis had higher rates of smoking, and had overall lower household income and 
education levels. 
The exposure biomarkers included in this analysis were highly detected in the study population, 
with the exception of ethylparaben and BPF (Table III.2). BPF was detected in between 50%-
60% of the study sample; ethylparaben was detected in between 42%-54% of the sample, 
depending on study visit. Concentrations of urinary biomarkers remained relatively consistent 
across the two study visits, with the exception of a decrease in BPA (p <0.001) and butylparaben 
(p = 0.04). There was an increase in most hormones across the two study visits, particularly 
progesterone, estriol, SHBG and CRH. T4 levels remained consistent from 16-20 and 24-28 
weeks gestation. 
Methylparaben and propylparaben were strongly correlated [Spearman correlation of 0.8 
(p<0.001)] (Figure III.1). Ethylparaben and butylparaben showed moderate correlation with 
methylparaben and propylparaben with Spearman correlations between 0.33-0.47 (p values < 
0.001). 2,4-Dichlorophenol and 2,5-dichlorophenol showed a fairly strong correlation (Spearman 
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r = 0.6, p<0.001). Triclosan was moderately correlated with 2,4-dichlorophenol (Spearman r = 
0.5, p<0.001), but not with 2,5-dichlorophenol (Spearman r = -0.03). BPA, BPS and BPF 
showed low correlation (Spearman r = 0.11-0.21, p<0.001).  
As compared to the exposure biomarkers in the LifeCodes nested case control, PROTECT 
women had higher concentrations of 2,4-dichlorophenol, 2,5-dichlorophenol, BPA, BPS and 
triclocarban Error! Reference source not found.Figure III.5 ). Women in the LifeCodes cohort 
had higher concentrations of butylparaben and propylparaben. However, the LOD’s from both 
cohorts differed. PROTECT had lower LOD’s for a number of exposure biomarkers, including 
2,4-dichlorophenol, 2,5-dichlorophenol, BPA, BPS, triclocarban, butylparaben and 
propylparaben. The lower LOD’s in PROTECT indicate that the differences between the two 
populations may be even larger than observed in the plots. 
Results from LMMs and MLRs are described in detail below by biomarker (Table III.3, Table 
III.4, and Table III.5). There were few differences between most adjusted and unadjusted 
models, with the exception of associations with CRH. MPB and PPB were associated with CRH 
in our unadjusted models, but in the adjusted models, these associations disappeared, and CRH 
was associated with BPS and TCS. A further analysis of CRH concentrations across the 
covariate levels did not reveal any large differences to report. 
There were no associations between 2,4-dichlorophenol and 2,5-dichlorophenol with hormones 
in LMMs. An IQR increase in 2,4-dichlorophenol was associated with a 10% increase in CRH at 
24-28 weeks [9.66 percent change in hormone per IQR change in the biomarker/ percent change 
in hormone at detectable biomarker concentrations (%Δ); 95% CI: 0.67, 19.45], and a suggestive 
2% decrease in T3 at 16-20 weeks (%Δ -2.22 95% CI -4.55, 0.10).  
Associations across the bisphenols differed, and BPS had the strongest associations in LMM 
models. BPS was associated with an 11% decrease in CRH (%Δ -11.35; 95% CI: -18.71, -3.33), 
and this association was stronger at 16-20 weeks gestation. At this time point, BPS was 
additionally associated with a 12% decrease in TSH (%Δ -11.93; 95% CI: -22.49, 0.07). BPF 
was associated with a 3% increase in FT4 (%Δ 2.76; 95% CI: 0.29, 5.22), and this association 
was also stronger at 16-20 weeks. BPA, on the other hand, had stronger associations at 24-28 
weeks gestation. BPA was associated with a 17% decrease in testosterone, and 2-4% increases in 
FT4 and T3 at 24-28 weeks [(%Δ -17.37; 95% CI: -26.7, -6.87); (%Δ 2.38; 95% CI: 0.04, 4.72); 
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(%Δ4.33, 95% CI: 0.11, 8.55), respectively]. The increase in FT4 and T3 in relation to BPA was 
in line with our a priori hypothesis 
Benzophenone-3 was not significantly associated with any hormones.  
Triclocarban was associated with a number of thyroid hormones and SHBG. An IQR increase in 
triclocarban is associated with a 4% increase in T3 (%Δ 4.08; 95% CI: 1.18, 6.98), a 5% increase 
in the T3/T4 ratio (%Δ 4.67; 95% CI: 1.24, 10.10), a suggestive 10% decrease in TSH (%Δ -
10.12; 95% CI: -19.47, 0.32), and a 10% decrease in SHBG at 24-28 weeks (%Δ -9.71; 95% CI: 
-19.1, -0.27). 
Triclosan was associated with an increase in a number of reproductive hormones, however most 
were only suggestive with p values between 0.05 and 0.10. This includes a 9% increase in CRH 
(%Δ 9.20; 95% CI: -0.97, 20.42), a 7% increase in testosterone (%Δ 7.13; 95% CI: -0.60, 15.5), 
and 10-13% increases in progesterone and estriol at 24-28 weeks [(%Δ 9.72, 95% CI: -1.27, 
21.9); (%Δ 13.2; 95% CI: 2.34, 25.2), respectively]. In addition, triclosan was associated with a 
5.8% decrease in T3 at 24-28 weeks; this finding was in line with our a priori hypothesis. 
IQR increases in butylparaben, methylparaben and propylparaben were associated with a 
decrease in SHBG [(%Δ -5.27; 95% CI:-9.40, -1.14); (%Δ -3.53; 95% CI: -7.37, 0.31); (%Δ -
3.74; 95% CI: -7.76, 0.27), respectively].  Methylparaben was also associated with decreases in 
reproductive hormones, including an 8% decrease in estriol, a suggestive 3% increase in the 
progesterone/estriol ratio, and a suggestive decrease in testosterone at 16-20 weeks [(%Δ -7.76; 
95% CI: -15.4, 0.61); (%Δ 3.14; 95% CI: -2.95, 9.61); (%Δ -6.77; 95% CI: -13.13, 0.29), 
respectively]. Conversely, an IQR increase in propylparaben was associated with a 9-10% 
increase in progesterone and estriol at 24-28 weeks [(%Δ 9.67; 95% CI: -1.30, 21.85); (%Δ 8.92; 
95% CI: -1.56, 20.52)]. Interaction terms between study visit*methylparaben and propylparaben 
had p values <0.05 in models regressed against estriol. We expected to see a decrease in thyroid 
hormones in relation to methyl- and propyl- paraben, but only observed a decrease in TSH in 
association with methylparaben, particularly at 16-20 weeks (%Δ -11.69; 95% CI: -21.97, -0.06). 
The decrease in TSH could indicate an increase in circulating thyroid hormones, in contrast to 
our hypothesis. 
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 Discussion 
Associations differed by exposure biomarker and hormone, and there was little consistency 
within chemical classes with the exception of some parabens. There was evidence of a decrease 
up to 6% in T3 in association with 2,4-dichlorophenol, BPA and triclosan, whereas triclocarban 
was associated with a 4% increase in T3. In the case of bisphenols, BPS was more strongly 
related to decreases in hormones at 16-20 weeks, and BPA had stronger negative relationships at 
24-28 weeks. Triclosan was associated with general increases in reproductive hormones of 
approximately 10%, and triclocarban was associated with 5-10% changes in thyroid hormones. 
Parabens were associated with a decreased level of SHBG.  
While there may be structural similarities between BPA, BPS and BPF, the structural variations 
may be sufficient to alter receptor-binding affinities across the bisphenols [38]; therefore, the 
biological effects may vary among the bisphenols. To this, we found that the earlier time point 
(16-20 weeks gestation) may be a more vulnerable time of exposure to BPS and BPF, in contrast 
to the stronger relationships observed at the 24-28 weeks with respect to BPA.  Our results were 
somewhat consistent with results from previous studies. BPA has been suspected to interfere 
with thyroid hormones, as evidenced by several epidemiological studies. We observed an 
increase in FT4 and T3, which was consistent with two previous studies our group conducted in 
a preliminary analysis in the PROTECT cohort, and a cohort of pregnant women in Boston, MA 
with four repeated measures during pregnancy [39,40]. Two cross-sectional studies in the United 
States (N=249 and 476 women) also looked at the association between maternal BPA and 
thyroid hormones during gestation [41,42]. The only significant association reported was 
between maternal urinary BPA and a decrease in T4 [41], which we did not observe in the 
present study. A decrease in T4 could be indicative of an increase in FT4, in the case of 
thyroxine becoming less bound to thyroxine-binding globulin, however, the associations between 
BPA and T4 in the current study had p values ranging from 0.51-0.93. Furthermore, we did not 
observe a relationship between BPA and TSH that was reported in the Boston cohort study [43], 
and among adults from the Korean National Environmental Health Survey [44].  
One of the strongest associations we observed was the 17% decrease in testosterone in relation to 
BPA. This is the first study that explores this association in pregnant women, and there is little 
correlation between maternal and fetal testosterone levels [45]. However, a decrease in 
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testosterone was identified in an in vitro study on TM3 murine Leydig with BPA exposure [46], 
in the F2 generation after in-utero BPA exposure in mice [47], and in-utero BPA concentrations 
in young boys aged 8-14 [48]. These associations provide further evidence in support of our 
finding.  Although the role of maternal testosterone in gestation is still unclear, evidence points 
to androgens playing an essential role in myometrial relaxation, cervical ripening and initiating 
parturition [49].  Therefore, BPA, via reduced testosterone, could increase gestational age, which 
we previously observed in this cohort [50]. Additionally, maternal testosterone has a role in 
gender role behaviors [51], indicating that maternal testosterone may impact fetal development. 
No human studies have previously investigated the associations between triclocarban, phenols 
and parabens on CRH during pregnancy; however, CRH plays an important role in gestation. 
Maternal CRH levels during pregnancy largely originate from gestational tissues [52]. Evidence 
suggests CRH inhibits immune rejection processes by killing activated T cells [53], plays an 
important role in determining time of parturition, and an increase in CRH has been associated 
with the onset of miscarriage and preeclampsia [54–58]. CRH receptor expression is regulated by 
estrogen, and CRH gene expression in the placenta is mediated by ER-α [59,60]. Given the 
endocrine disrupting potential of bisphenols via estrogen receptors [61], associations between 
CRH and bisphenols (and potentially other phenols and parabens) could be important to consider 
in pregnancy studies. Animal and in vitro studies showed an increase in CRH with exposure to 
BPA and BPS, contrary to our results of an inverse relationship between CRH and BPS. BPA 
increased plasma concentrations of CRH in pregnant mice [62] and CRH levels in human 
placenta primary trophoblast cells [63]. The differences in our results could be in part due to the 
unique role CRH plays in human pregnancies, as compared to animals [64].  
Triclosan was suggestively associated with select hormones, but none reached statistical 
significance, including an increase in testosterone, an increase in CRH at 16-20 weeks gestation, 
and a decrease in T3 at 24-28 weeks gestation. There was a similar decrease in T3 with increased 
urinary triclosan concentrations in the Boston cohort, albeit the associations were stronger earlier 
in pregnancy, in contrast to our stronger associations at the later visit in the current study [40]. 
While larger human studies with more statistical power may be needed, the decrease in T3 in 
association with triclosan is consistent with animal studies [65], including in pregnant rats [66] 
and pregnant mice [67,68], perhaps due to triclosan’s structural similarities to thyroid hormones 
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[65]. Animal studies also report a decrease in T4 with triclosan exposure, including rat and mice 
dams [66–76], but we did not find evidence of this in humans. Other population studies found no 
associations between triclosan and thyroid hormones [77–79], although there was evidence of 
vulnerable time points during gestation [77,78]. Interestingly, a study in pregnant rats showed 
that the greatest accumulation of triclosan was in the placenta, indicating that pregnancy may be 
a sensitive time period for triclosan exposure [80]. Alternatively, maternal serum TSH and FT4 
levels at >28 weeks gestation (obtained from medical records) were negatively associated with 
urinary triclosan at 38 weeks gestation [81]. The differences in our results could be explained by 
the differences in the study population, exposure biomarker concentrations, and differences in 
the pregnancy time points examined.  
No studies have looked at the effect of triclosan on maternal testosterone and CRH during 
pregnancy in humans. However, in contrast to our results, triclosan was found to reduce 
testosterone levels in male rats[82], and in pregnant rats [80]. An excess of maternal testosterone 
has been associated with restricted fetal growth [83], as well as an increased chance of 
developing Alzheimer disease [84] and anxiety like symptoms in the offspring. 
Triclocarban was associated with thyroid hormone changes. We observed an increase in T3 and a 
decrease in TSH in association with triclocarban, which is in line with the negative feedback 
loop in maintaining thyroid hormone homeostasis. We also observed a decrease in SHBG. 
SHBG levels tend to rise with thyroid hormones, so this observed pattern was unexpected. This 
could be due to factors influencing the relationship between thyroid hormone and SHBG levels 
that have not been accounted for in the present study. Our previous Boston study also reported a 
negative association between triclocarban and TSH, but a negative association with T3. 
Triclocarban concentrations in this cohort were much higher than the exposure levels found in 
the Boston cohort. In fact, the triclocarban concentrations observed in PROTECT are 37 times 
larger than the concentration observed in NHANES women of reproductive age [85]. This 
difference in exposure levels may explain the differences in the associations observed. 
All parabens were generally negatively associated with SHBG. In contrast to our current 
findings, our previous preliminary analysis in the PROTECT cohort showed that methylparaben 
was positively associated with SHBG [27]. However, the current study has a much larger sample 
size.  Associations between parabens and some hormones appeared to be dependent on the 
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timing of exposure. Associations between methylparaben and propylparaben and estriol changed 
direction from a negative association at 16-20 weeks to a positive association at 24-28 weeks 
gestation. We observed a similar change in direction in our preliminary analyses between 
methylparaben and propylparaben with estradiol [27]. Although not statistically significant, 
associations between methylparaben and propylparaben with progesterone followed a similar 
pattern to that of estriol. Given that the population urinary levels of methylparaben and 
propylparaben remained consistent between the two time points, the similar change of direction 
observed in associations with methylparaben and propylparaben in both of our previous analyses, 
and the significant interaction term between these parabens and visit in association with estriol, 
this lends confidence that these observations may not be occurring by chance and may be 
detected in future larger studies. The strong correlation between propyl- and methylparaben 
could indicate that their associations with estriol are being driven by only one of the parabens. 
However, given the differences in the associations between these two parabens and all hormones, 
there do seem to be unique relationships between the exposure and hormone levels. No previous 
studies have looked at the effect of parabens on estriol, SHBG or CRH; however, evidence 
suggests parabens have ER-β agonistic activity [86], and stimulate progesterone mRNA 
expression via ER-α signaling [87,88]. This could suggest a potential mechanism by which 
reproductive hormone levels could be directly or indirectly altered in response to paraben 
exposure.  
The present study also showed a general decrease in TSH in association with parabens, but only 
methylparaben reached a significant association with TSH. Additionally, methylparaben and 
propylparaben were associated with a decrease in the T3/T4 ratio, particularly at 24-28 weeks 
gestation. Results from our Boston cohort also showed a decrease in T3/T4 ratio, as well as T3, 
at median 26 weeks gestation [89]. In other research, human and animal studies reported a 
decrease in T4 and FT4 with paraben exposure in females [79,90], and two small studies in men 
found no associations between parabens and thyroid hormones [91,92]. The difference in the 
results is likely due to the different study populations; none of those studies looked specifically 
at prenatal exposure. 
Our study had several limitations. We did not have data on the iodine status of the women; 
deficiency in this element could affect thyroid hormone function. However, iodine may act as 
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mechanistic intermediate exposure between the exposure and thyroid hormone, and controlling 
for iodine status could lead to bias [93]. Furthermore, iodine had no effect on the associations 
between phenols and thyroid hormones in our previous study of NHANES data [79]. We also did 
not have data on thyroperoxidase antibodies nor human chorionic gonadotropin (hCG), which 
could potentially affect thyroid function as well [94,95]. While data at two time points is a great 
improvement from the more common cross-sectional study design, the two time points may not 
be sufficient to understand the potential influence of these biomarkers on maternal hormones. 
The relatively high variation in urinary concentrations of the target biomarkers (particularly 
BPA) over time may also introduce potential bias stemming from random measurement error. 
Given the multiple comparisons conducted, there is a chance of Type I error, and caution must be 
used when interpreting our findings. Finally, although one of the strengths of the present study is 
our ability to investigate the relationships between these chemicals and hormone levels in a 
vulnerable population, our study population was based in a population in Puerto Rico of lower 
income who also had higher urinary concentrations of some of the exposure biomarkers; 
therefore, the results may not be fully generalizable to other populations. 
Our study also had many strengths. Our robust sample size, and the collection of exposure 
biomarkers and hormone data at two time points during pregnancy helps account for the 
biomarkers’ short lifespan in the body, and the varying levels of hormones throughout 
pregnancy. The repeated measures allow for the control of intra-individual variability, and 
increases statistical power. We were also able to explore potential windows of susceptibility for 
these associations.  
Additionally, we were able to compare our results from this analysis to our own analyses that 
employed similar statistical methods in two other data sets, namely LMMs to capture biomarkers 
at various time points and allow subject-specific intercepts. While there were many similarities 
in the results across the three analyses, the differences in results may point to the importance of 
outside factors that may not be captured in our models that alter the associations between these 
chemicals and endocrine disruption through interaction with the chemicals. These outside factors 
could include other endocrine-altering variables, such as exposure to other unaccounted for 
chemicals, maternal stress, genetic, epigenetic, or other differences. It is imperative that future 
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studies look beyond the association between a single chemical and singe hormone, and explore 
potential interactions with chemical exposure. 
 Conclusion 
Our results provide suggestive human evidence for associations between select biomarkers with 
maternal thyroid and reproductive hormones during gestation. Of note, we report negative 
associations between parabens and SHBG, a negative association between BPS and CRH, and 
associations between triclocarban and triclosan with reproductive and thyroid hormones. Our 
stratified analyses show that some associations may be stronger at certain time points during 
pregnancy. Further studies in larger populations and with more repeated measures across 
pregnancy to will be useful to confirm our findings, and better understand if and how these 
hormone changes may affect downstream maternal and infant health outcomes. 
 
Table III.1: Summary demographics of the 602 pregnant women in the study population 
 Included Not Included p 
Total N 602 709  
Age (mean [SD]) 26.51 (5.66) 26.94 (5.34) 0.25 
BMI in kg/m2 (%)   0.99 
<25 245 (40.7) 192 (27.1)  
25-30 114 (18.9) 87 (12.3)  
>30 73 (12.1) 56 (7.9)  
Missing 170 (28.2) 374 (52.8)  
Current Smoker (%)     0.03 
Never 440 (73.1) 323 (45.6)  
Ever 63 (10.5) 57 (8.0)  
Current 23 (3.8) 6 (0.8)  
Missing 76 (12.6) 323 (45.6)  
Exposure to Second-Hand 
Smoking per Day (%) 
    
0.16 
Up to half an hour 443 (73.6) 338 (47.7)  
Up to an hour 25 (4.2) 19 (2.7)  
More than an hour 41 (6.8) 18 (2.5)  
Missing 93 (15.4) 334 (47.1)  
Alcohol Consumption (%)     0.61 
No 273 (45.3) 190 (26.8)  
Before pregnancy 215 (35.7) 170 (24.0)  
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Yes within the last few 
months 
36 (6.0) 24 (3.4) 
 
Missing 78 (13.0) 325 (45.8)  
Household Income in U.S. $ 
(%) 
    
0.03 
<10,000 152 (25.2) 82 (11.6)  
10,000 - 30,000 132 (21.9) 114 (16.1)  
30,000 - 50,000 101 (16.8) 83 (11.7)  
>50,000 64 (10.6) 59 (8.3)  
Missing 153 (25.4) 371 (52.3)  
Maternal Education (%)     0.02 
< High School 123 (20.4) 64 (9.0)  
Some college 194 (32.2) 137 (19.3)  
College graduate 210 (34.9) 182 (25.7)  
Missing 75 (12.5) 326 (46.0)  
Insurance Type (%)     0.001 
Public (Mi Salud) 318 (52.8) 340 (48.0)  
Private 222 (36.9) 153 (21.6)  
Missing 62 (10.3) 216 (30.5)  
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Table III.2: SG-corrected urinary biomarker concentrations and hormones by study visit of sample collection in pregnancy.  
 
16-20 weeks (N=389) 24-28 weeks (N=262)  
Biomarkersa GM (GSD) % <LOD 25% 50% 75% 95% GM (GSD) % <LOD 25% 50% 75% 95% p-value 
2,4-DCP 1.17 (3.24) 0.5 0.52 0.93 2.0 10.7 1.13 (9.8) 2.3 0.46 0.86 2.19 12.9 0.65 
2,5-DCP 14.03 (5.14) 0.3 4.57 10.4 30.2 432.6 13.63 (360.3) 0 4.63 9.61 26.53 429.6 0.70 
BPA 2.31 (2.25) 0.3 1.33 2.14 3.36 9.56 1.88 (2.4) 0.8 1.14 1.83 3.0 6.18 <0.001* 
BPSi 0.54 (3.15) 3.4 0.23 0.50 1.07 4.01 0.54 (5.2) 8.6 0.23 0.47 1.06 4.23 0.95 
BPFi 0.35 (3.18) 51.9 <LOD 0.25 0.56 2.88 0.31 (2.4) 59.9 <LOD 0.24 0.46 2.09 0.22 
BP-3 38.34 (6.49) 0.5 10.6 22.4 110.8 1547 
44.27 
(2500.4) 
0.8 11.9 25.3 160.7 1913.5 0.69 
TCS 21.78 (8.72) 11.1 3.70 13.1 146.8 877.4 25.03 (327.4) 6.1 4.73 17.9 118.6 960.2 0.64 
TCCi 4.34 (10.27) 5.8 0.70 3.36 33.6 157.7 4.86 (56.2) 5.6 0.78 4.78 32.76 168.6 0.46 
EPBi 3.42 (7.73) 42.4 <LOD 1.66 15.4 177.5 2.55 (62.1) 54 <LOD <LOD 7.6 76.1 0.12 
MPB 80.72 (5.06) 0.3 25.08 116.5 274.8 846.1 92.5 (359) 0.8 30.2 111 314.5 1054.9 0.18 
BPB 0.55 (8.12) 23.8 0.10 0.25 2.17 39.1 0.42 (12.2) 33.5 0.10 0.2 0.91 32.6 0.04* 
PPB 17.51 (7.19) 0 3.59 21.1 80.5 262.4 17.61 (111.4) 0.4 4.0 25.17 83.65 253.8 0.99 
 16-20 weeks (N=483) 24-28 weeks (N=389) 
 
Hormones GM (GSD) % <LOD 25% 50% 75% 95% GM (GSD) % <LOD 25% 50% 75% 95% p-value 
Progesterone
b 
49.63 (1.49) 0 37.2 48.5 61.6 98.2 95.94 (1.65) 0 70.9 90.9 129.2 222.7 <0.001* 
Estriolb 18.85 (1.76) 0 13.2 17.6 27.5 50.5 44.63 (1.59) 0 33.8 44.9 57.5 97.3 <0.001* 
SHBG c 575.22 (1.4) 0 482.4 588.6 703.8 907.9 670.19 (1.35) 0 536.3 672.9 832.6 1097.7 <0.001* 
Prog/Estriol 2.64 (1.69) - 1.97 2.66 3.70 5.83 2.15 (1.62) - 1.58 2.12 2.86 4.48 <0.001* 
CRHd 76.67 (1.70) 0 54.8 80.6 111.8 171.9 78.01 (1.76) 0 55.2 82.8 114.3 178.1 <0.001* 
Testosteronef 50.55 (1.81) 1.8 37.5 51.5 73.5 124.4 60.22 (1.75) 0.9 45.1 60.7 88.1 131.6 <0.001* 
TSHe 1.29 (2.14) 0 0.93 1.38 2.06 3.28 1.45 (1.79) 0 1.08 1.51 2.05 3.64 0.04* 
FT4f 1.10 (1.13) 0 1.02 1.10 1.19 1.35 1.06 (1.13) 0 0.98 1.06 1.15 1.29 <0.001* 
T3b 1.94 (1.22) 0 1.71 1.97 2.22 2.59 1.95 (1.21) 0 1.72 1.99 2.24 2.67 0.03* 
T4 g 11.90 (1.20) 0 10.7 11.95 13.3 15.7 11.71 (1.20) 0 10.5 11.7 13.2 15.5 0.27 
T3/T4 0.16 (1.21) - 0.14 0.16 0.19 0.23 0.17 (1.22) - 0.15 0.17 0.19 0.23 <0.001* 
GM: Geometric mean; GSD: Geometric standard deviation 
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2,4-DCP: 2,4-dichlorophenol; 2,5-DCP: 2,5-dichlorophenol; BP-3: Benzophenone; TCS: Triclosan; TCC: Triclocarban; EPB: ethylparaben; MPB: 
Methylparaben; BPB: Butylparaben; PPB: Propylparaben 
Range of gestational weeks: 16-20 weeks: 16-20 weeks gestation, 24-28 weeks: 24-28 weeks gestation. 
* Significant difference (p<0.05) in urinary biomarker or hormone compared to reference (16-20 weeks) using linear mixed models with a random intercept 
a Units: µg/L. b Units: ng/mL. c Units: nmol/L. d Units: pg/mL. e Units: uIU/mL. f Units: ng/dL. g Units: µg/dL.  
I BPS, BPF, TCC and EPB had the lowest sample sizes because they were added to the biomarker assay at mid-study. At 16-20 weeks, these four urinary 
biomarkers had N= 295. At 24-28 weeks, these four urinary biomarkers had N= 198. 
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Table III.3: Results of the LMMs regressing hormones versus exposure biomarkers.  
  
CRH SHBG Testosterone Progesterone Estriol 
Progesterone/ 
Estriol Ratio 
2,4-DCP % Δ/IQR 5.30 (-2.81, 14.08) 2.06 (-1.49, 5.61) 3.26 (-3.01, 9.94) 1.60 (-3.42, 6.87) -1.93 (-7.54, 4.01) 3.58 (-1.85, 10.16) 
 p 0.21 0.26 0.32 0.54 0.52 0.24 
2,5-DCP % Δ/IQR 3.89 (-3.29, 11.61) 0.96 (-2.25, 4.17) 1.75 (-3.85, 7.69)a -0.46 (-4.79, 4.07) -2.21 (-7.12, 2.96) 1.35 (-3.46, 6.82) 
 p 0.30 0.56 0.55 0.84 0.40 0.61 
BPA % Δ/IQR 3.68 (-4.21, 12.22) -0.22 (-3.60, 3.15) -4.19 (-9.64, 1.59)a -3.50 (-8.16, 1.39) -2.18 (-7.78, 3.78) -1.55 (-6.18, 5.01) 
 p 0.37 0.90 0.15 0.16 0.47 0.60 
BPFb % Δ/IQR 3.90 (-9.72, 19.57) -2.97 (-8.04, 2.11) 0.33 (-8.89, 10.49) -1.33 (-23.9, 13.78) 3.84 (-6.40, 15.21) -4.65 (-13.44, 5.05) 
 p 0.60 0.26 0.95 0.76 0.48 0.34 
BPS % Δ/IQR -11.35 (-18.71, -3.33) -0.56 (-4.37, 3.25) 2.54 (-3.5, 8.97) -4.38 (-9.49, 1.02) -2.05 (-8.16, 4.47) -2.96 (-7.85, 3.85) 
 p 0.008** 0.77 0.42 0.11 0.53 0.34 
BP-3 % Δ/IQR -0.04 (-7.96, 8.57) 1.10 (-2.61, 4.82) -0.51 (-6.8, 6.21) 0.46 (-4.62, 5.81) -0.91 (-6.66, 5.18) 1.81 (-3.60, 8.42) 
 p 0.99 0.56 0.88 0.86 0.76 0.56 
TCC % Δ/IQR -3.69 (-14.5, 8.50) -4.54 (-10.03, 0.94) 5.18 (-3.4, 14.51) -3.22 (-10.13, 4.21) 0.36 (-7.93, 9.39) -3.75 (-8.64, 7.7) 
 p 0.54 0.11 0.25 0.39 0.94 0.39 
TCS % Δ/IQR 9.20 (-0.97, 20.42) 2.81 (-1.46, 7.08) 7.13 (-0.60, 15.5) 2.84 (-3.2, 9.25)a 4.16 (-3.07, 11.93)a 0.31 (-5.8, 8.4) 
  p 0.08* 0.20 0.07* 0.37 0.27 0.93 
EPBb % Δ/IQR 1.52 (-11.55, 16.52) -1.93 (-8.14, 4.29) 5.11 (-4.64, 15.86) a -2.41 (-10.62, 6.56) -1.92 (-11.4, 8.58) -0.77 (-10.22, 9.67) 
 p 0.83 0.55 0.32 0.59 0.71 0.88 
BPB % Δ/IQR -1.86 (-10.64, 7.8) -5.27 (-9.4, -1.14) -6.77 (-13.3, 0.29) -3.65 (-9.11, 2.14) -5.18 (-11.45, 1.52) 1.96 (-4.9, 8.52) 
 p 0.70 0.01** 0.06* 0.21 0.13 0.58 
MPB % Δ/IQR 5.88 (-3.0, 15.59) -3.53 (-7.37, 0.31) -4.41 (-10.68, 2.3) 0.03 (-5.29, 5.64) -2.50 (-8.6, 4.01)a 2.64 (-3.06, 9.74) 
 p 0.20 0.07* 0.19 0.99 0.44 0.43 
PPB % Δ/IQR 4.82 (-4.48, 15.02) -3.74 (-7.76, 0.27) -3.54 (-10.14, 3.54) 2.35 (-3.55, 8.6) -0.63 (-7.36, 6.58)a 3.65 (-2.36, 11.66) 
 p 0.32 0.07* 0.32 0.44 0.86 0.31 
         
   TSH FT4 T3 T4 T3/T4 ratio  
2,4-DCP % Δ/IQR 4.80 (-2.58, 12.74) 0.21 (-1.19, 1.60) -1.58 (-3.58, 0.42) -0.79 (-2.71, 1.13) -1.16 (-4.86, 1.33)  
 p 0.21 0.77 0.12 0.42 0.31  
2,5-DCP % Δ/IQR 4.63 (-2.08, 11.79) 0.82 (-0.43, 2.07) -0.55 (-2.36, 1.26) 0.51 (-1.22, 2.24) -1.38 (-4.64, 1.06)  
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 p 0.18 0.2 0.56 0.57 0.18  
BPA % Δ/IQR -0.28 (-6.99, 6.91) 0.00 (-1.36, 1.36) 2.10 (0.22, 3.99) 0.69 (-1.13, 2.51) 1.46 (-2.23, 3.52)  
 p 0.94 1 0.03** 0.46 0.19  
BPFb % Δ/IQR 7.29 (-4.59, 20.64) 2.76 (0.29, 5.22) a -1.22 (-4.34, 1.90) 1.84 (-1.37, 5.04) -2.50 (-6.47, 1.47)  
 p 0.24 0.03** 0.45 0.26 0.22  
BPS % Δ/IQR -1.01 (-8.12, 6.66) -0.07 (-1.6, 1.46) 0.14 (-1.89, 2.18) 0.04 (-1.97, 2.05) 0.58 (-2.47, 2.9)  
 p 0.79 0.93 0.89 0.97 0.64  
BP-3 % Δ/IQR -5.89 (-12.87, 1.65) -0.40 (-1.85, 1.04) -1.47 (-3.56, 0.63) -1.37 (-3.35, 0.62) -0.21 (-5.33, 1.26)  
 p 0.13 0.59 0.17 0.18 0.86  
TCC % Δ/IQR -10.12 (-19.47, 0.32) -0.61 (-2.76, 1.55) 4.08 (1.18, 6.98) -0.65 (-3.53, 2.23) 4.67 (-1.37, 6.65)  
 p 0.06* 0.58 0.007** 0.66 0.01**  
TCS % Δ/IQR 0.57 (-7.74, 9.63) -0.74 (-2.45, 0.96) -1.97 (-4.36, 0.41) -1.60 (-3.9, 0.69) -0.15 (-2.69, 4.55)  
  p 0.9 0.39 0.11 0.17 0.91  
EPBb % Δ/IQR -6.78 (-17.6, 5.46) -0.45 (-2.9, 2.0) -0.76 (-4.10, 2.58) -0.03 (-3.29, 3.24) -1.68 (-5.66, 2.30)  
 p 0.27 0.72 0.66 0.99 0.41  
BPB % Δ/IQR -4.88 (-12.62, 3.54) 1.10 (-0.54, 2.74) 0.70 (-1.61, 3.02) 1.74 (-0.49, 3.96) -1.56 (-7.01, -0.26)  
 p 0.25 0.19 0.55 0.13 0.24  
MPB % Δ/IQR -6.92 (-13.91, 0.64)a 0.77 (-0.76, 2.29) -0.39 (-2.53, 1.76) 1.02 (-1.04, 3.09) -1.78 (-4.64, 1.53)  
 p 0.07* 0.33 0.73 0.33 0.15  
PPB % Δ/IQR -6.29 (-13.6, 1.64) 0.81 (-0.8, 2.42) 0.21 (-2.02, 2.45) 0.65 (-1.52, 2.81) -0.67 (-3.89, 2.63)  
 p 0.12 0.32 0.85 0.56 0.60  
 
2,4-DCP: 2,4-dichlorophenol; 2,5-DCP: 2,5-dichlorophenol; BP-3: Benzophenone; TCS: Triclosan; TCC: Triclocarban; EPB: ethylparaben; MPB: 
Methylparaben; BPB: Butylparaben; PPB: Propylparaben 
Results converted to % change in hormone per IQR change in biomarker concentration. 
* represents a p value below 0.10, and **represents a p value below 0.05; a Significant interaction (p<0.05) between urinary biomarker*visit; b Dichotomous 
variable  
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Table III.4: Results of the MLRs regressing reproductive hormones versus exposure biomarkers by visit. 
 16-20 weeks gestation 
 
  CRH SHBG Testosterone Progesterone Estriol 
Progesterone/ 
Estriol Ratio 
2,4-DCP 
% 
Δ/IQR 
2.93 (-6.84, 13.73) 0.18 (-3.39, 3.74) 3.66 (-3.47, 11.32) -0.33 (-4.75, 4.29) -3.54 (-9.78, 3.12) 3.70 (-2.35, 11.15) 
 p 0.57 0.92 0.32 0.92 0.29 0.89 
2,5-DCP 
% 
Δ/IQR 
5.20 (-4.94, 16.43) -0.16 (-3.79, 3.47) 2.11 (-5.04, 9.8)a 0.45 (-4.05, 5.17) -0.92 (-7.4, 6.01) 1.48 (-5.03, 8.31) 
 p 0.33 0.93 0.57 0.94 0.79 0.86 
BPA 
% 
Δ/IQR 
6.35 (-4.08, 17.92) 0.09 (-3.64, 3.81) 2.77 (-4.58, 10.69)a -2.11 (-6.36, 2.34) 0.17 (-6.4, 7.21) -2.55 (-8.2, 4.6) 
 p 0.24 0.96 0.47 0.45 0.96 0.38 
BPFb 
% 
Δ/IQR 
10.11 (-11.4, 36.8) -6.81 (-14.8, 1.16) 3.71 (-8.85, 18.01) -1.45 (-27.8, 36.5) 7.50 (-7.52, 24.96) -8.14 (-17.62, 2.43) 
 p 0.39 0.1 0.58 0.97 0.35 0.79 
BPS 
% 
Δ/IQR 
-16.15 (-26.6,-4.2) -2.37 (-7.36, 2.61) 3.08 (-5.01, 11.86) -4.51 (-9.77, 1.05) -3.16 (-11.46, 5.9) -1.48 (-8.62, 8.97) 
 p 0.01** 0.35 0.47 0.35 0.48 0.13 
BP-3 
% 
Δ/IQR 
-2.66 (-12.44, 8.2) 1.25 (-2.53, 5.04) 2.69 (-4.78, 10.75) -0.60 (-5.27, 4.29) -3.14 (-9.84, 4.06) 2.22 (-4.1, 9.93) 
 p 0.62 0.52 0.49 0.72 0.38 0.82 
TCC 
% 
Δ/IQR 
-6.95 (-21.9, 10.9) -3.95 (-10.4, 2.5) 5.18 (-5.5, 17.07) -3.93 (-10.9, 3.57) 1.68 (-9.36, 14.07) -5.60 (-13.01, 8.6) 
 p 0.42 0.23 0.36 0.62 0.78 0.32 
TCS 
% 
Δ/IQR 
13.79 (-1.82, 31.9) 1.44 (-3.89, 6.76) 7.81 (-3, 19.83) -0.65 (-6.78, 5.9)a 0.17 (-9.12, 10.4) a 0.12 (-6.88, 12.69) 
 p 0.09* 0.60 0.16 0.63 0.97 0.85 
EPBb 
% 
Δ/IQR 
3.40 (-15.66, 26.8) -2.28 (-9.73, 5.18) -0.25 (-11.9, 12.9)a -0.31 (-49.9, 98.2) 4.83 (-8.72, 20.39) -5.05 (-13.8, 4.58) 
 p 0.75 0.55 0.97 0.32 0.5 0.95 
BPB 
% 
Δ/IQR 
2.51 (-10.1, 16.9) -3.47 (-8.18, 1.23) -3.51 (-12.19, 6.04) -1.80 (-7.08, 3.79) -5.69 (-13.5, 2.78) 4.38 (-4.17, 12.69) 
 p 0.71 0.15 0.46 0.71 0.18 0.56 
MPB 
% 
Δ/IQR 
4.27 (-8.72, 19.1) -5.94 (-10.7, -1.2) -8.11 (-16.46, 1.09) -5.33 (-10.6, 0.19) -7.76 (-15.4, 0.6) a 3.14 (-2.95, 9.61) 
 p 0.54 0.01** 0.08* 0.10 0.07* 0.08* 
PPB 
% 
Δ/IQR 
3.55 (-10.07, 19.2) -6.32 (-11.4, -1.3) -7.02 (-15.95, 2.86) -1.95 (-8.11, 4.62) -6.35 (-14.9, 3.0) a 5.40 (-2.2, 17.62) 
 74 
 
 p 0.63 0.01** 0.16 0.54 0.18 0.57 
 24-28 weeks gestation 
 
  CRH SHBG Testosterone Progesterone Estriol 
Progesterone/ 
Estriol Ratio 
2,4-DCP 
% 
Δ/IQR 
9.66 (0.67, 19.45) 2.50 (-3.84, 8.83) 0.50 (-9.18, 11.22) 5.81 (-3, 15.42) 0.53 (-7.55, 9.31) 5.07 (-2.4, 14.89) 
 p 0.04** 0.44 0.92 0.20 0.90 0.24 
2,5-DCP 
% 
Δ/IQR 
3.92 (-3.66, 12.09) 0.22 (-5.35, 5.79) -0.27 (-8.76, 9.01)a -0.80 (-8.01, 6.97) -4.58 (-11.2, 2.56) 3.74 (-2.69, 11.87) 
 p 0.32 0.94 0.95 0.83 0.20 0.32 
BPA 
% 
Δ/IQR 
-3.53 (-13.3, 7.32) -0.48 (-8.26,7.31) -17.37 (-26.7, -6.9)a -3.65 (-13.4, 7.2) -5.27 (-14.4, 4.87) 1.86 (-6.16, 14.1) 
 p 0.51 0.90 0.002** 0.49 0.30 0.72 
BPFb 
% 
Δ/IQR 
-1.64 (-16.7, 16.1) -0.30 (-12.5,11.9) -10.98 (-24.8, 5.41) 4.68 (-10.1, 21.88) 4.57 (-9.89, 21.35) 0.04 (-13.0, 15.07) 
 p 0.84 0.96 0.18 0.56 0.56 1.00 
BPS 
% 
Δ/IQR 
-7.61 (-16.3, 2.01) -1.77 (-9.38, 5.8) -6.26 (-15.49, 3.98) -3.85 (-13.1, 6.4) -2.05 (-10.75, 7.5) -1.86 (-9.81, 7.49) 
 p 0.12 0.65 0.22 0.45 0.66 0.69 
BP-3 
% 
Δ/IQR 
1.71 (-7.23, 11.51) 1.80 (-5.09, 8.69) -2.59 (-12.66, 8.64) 1.29 (-7.62, 11.1) 3.41 (-5.31, 12.94) -2.09 (-9.89, 6.96) 
 p 0.72 0.61 0.64 0.79 0.46 0.63 
TCC 
% 
Δ/IQR 
-5.00 (-16.1, 7.57) -9.71 (-19.1,-0.27) 10.25 (-3.14, 25.5) -1.80 (-13.9, 12.0) -1.94 (-13.1, 10.7) 0.14 (-7.77, 15.3) 
 p 0.42 0.05** 0.14 0.79 0.75 0.98 
TCS 
% 
Δ/IQR 
8.46 (-2.31, 20.43) 4.27 (-3.44, 11.98) 12.46 (-0.47, 27.08) 9.72 (-1.27, 21.9)a 13.17 (2.34, 25.2) a -3.00 (-12.61, 6.43) 
  p 0.13 0.28 0.06* 0.09* 0.02** 0.56 
EPBb 
% 
Δ/IQR 
-3.51 (-17.06, 12.3) -2.36 (-13.99, 9.3) 13.05 (-3.38, 32.28)a -4.05 (-18.03, 12.3) -11.47 (-23.3, 2.16) 8.43 (-5.77, 24.76) 
 p 0.29 0.69 0.13 0.61 0.10 0.26 
BPB 
% 
Δ/IQR 
-6.35 (-13.8, 1.71) -3.77 (-9.86, 2.31) -8.88 (-17.24, 0.32) -2.20 (-10.1, 6.4) -3.30 (-10.8, 4.87) 1.05 (-7.26, 8.5) 
 p 0.12 0.23 0.06* 0.61 0.42 0.80 
MPB 
% 
Δ/IQR 
8.20 (-1.67, 19.06) 1.25 (-5.82, 8.32) -7.70 (-17.49, 3.25) 8.21 (-1.7, 19.11) 
6.54 (-2.86, 16.84) 
a 
1.05 (-7.83, 10.78) 
 p 0.11 0.73 0.16 0.11 0.18 0.82 
PPB 
% 
Δ/IQR 
8.87 (-1.95, 20.89) -0.39 (-8.13, 7.35) -2.21 (-13.55, 10.61) 9.67 (-1.3, 21.85) 
8.92 (-1.56, 20.52) 
a 
0.19 (-8.79, 10.8) 
 p 0.11 0.92 0.72 0.09* 0.10 0.97 
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2,4-DCP: 2,4-dichlorophenol; 2,5-DCP: 2,5-dichlorophenol; BP-3: Benzophenone; TCS: Triclosan; TCC: Triclocarban; EPB: ethylparaben; MPB: Methylparaben; BPB: 
Butylparaben; PPB: Propylparaben 
Beta coefficients are transformed into percent change of hormone in an IQR change in the exposure. Beta coefficients and their 95% CI are displayed. a represents a significant 
interaction term between the exposure*visit in LMM models (p<0.05). *p values < 0.1. ** p values < 0.05. b Dichotomous variable. 
 
Table III.5: Results of the MLRs regressing thyroid hormones versus exposure biomarkers by visit. 
 16-20 weeks gestation 
 
 TSH FT4 T3 T4 T3/T4 Ratio 
2,4-DCP % Δ/IQR 6.72 (-2.7, 17.06) 0.21 (-1.4, 1.82) -2.22 (-4.55, 0.1) -0.85 (-3.07, 1.37) -1.56 (-3.95, 0.84) 
 p 0.17 0.80 0.06* 0.45 0.20 
2,5-DCP % Δ/IQR 3.01 (-6.3, 13.25) 0.78 (-0.86, 2.41) -1.32 (-3.7, 1.06) 0.51 (-1.76, 2.77) -2.12 (-4.55, 0.32) 
 p 0.54 0.35 0.28 0.66 0.09* 
BPA % Δ/IQR -4.08 (-12.94, 5.68) -1.38 (-3.04, 0.29) 1.04 (-1.38, 3.47) 0.19 (-2.1, 2.48) 0.96 (-1.54, 3.46) 
 p 0.40 0.11 0.40 0.87 0.45 
BPFb % Δ/IQR 15.44 (-5.92, 41.66) 6.94 (3.26, 10.62)a 0.26 (-4.94, 5.45) 3.00 (-1.87, 7.87) -2.42 (-8.31, 3.47) 
 p 0.17 0.0002** 0.92 0.23 0.42 
BPS % Δ/IQR -11.93 (-22.49, 0.07) 0.32 (-1.99, 2.62) 2.50 (-0.56, 5.56) 0.38 (-2.57, 3.33) 2.69 (-0.74, 6.12) 
 p 0.05* 0.79 0.11 0.80 0.13 
BP-3 % Δ/IQR -5.90 (-14.75, 3.87) -1.37 (-3.07, 0.33) -1.10 (-3.57, 1.38) -1.74 (-4.06, 0.58) 0.90 (-4.88, 2.77) 
 p 0.23 0.12 0.39 0.14 0.49 
TCC % Δ/IQR -10.72 (-24.34, 5.34) 0.06 (-2.93, 3.04) 6.27 (2.38, 10.17) 1.00 (-2.85, 4.85) 5.67 (1.24, 10.10) 
 p 0.18 0.97 0.002** 0.61 0.01** 
TCS % Δ/IQR 5.49 (-8.15, 21.16) 0.29 (-2.11, 2.7) -0.81 (-4.32, 2.69) -0.25 (-3.55, 3.06) -0.28 (-3.86, 3.3) 
 p 0.45 0.81 0.65 0.88 0.88 
EPBb % Δ/IQR -2.50 (-19.56, 18.16) -0.75 (-4.18, 2.69) -1.47 (-6.11, 3.17) -1.02 (-5.45, 3.41) -1.12 (-6.34, 4.09) 
 p 0.80 0.67 0.54 0.65 0.67 
BPB % Δ/IQR -2.58 (-13.87, 10.2) 0.74 (-1.4, 2.88) 0.18 (-2.88, 3.25) 1.24 (-1.68, 4.17) -1.46 (-4.62, 1.70) 
 p 0.68 0.50 0.91 0.41 0.37 
MPB % Δ/IQR -11.69 (-21.97, -0.06) a 1.00 (-1.16, 3.16)  0.33 (-2.8, 3.45) 1.22 (-1.76, 4.2) -1.26 (-4.45, 1.94) 
 p 0.05** 0.36 0.84 0.42 0.44 
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PPB % Δ/IQR -9.74 (-20.79, 2.85) 0.82 (-1.47, 3.11) 1.51 (-1.78, 4.8) 1.32 (-1.83, 4.47) -0.06 (-3.44, 3.32) 
 p 0.12 0.48 0.37 0.41 0.97 
 
24-28 weeks gestation 
  TSH FT4 T3 T4 T3/T4 Ratio 
2,4-DCP % Δ/IQR 2.28 (-7.3, 12.84) 0.53 (-1.4, 2.46) 0.49 (-2.92, 3.89) 0.67 (-2.32, 3.66) -0.73 (-6.4, 4.94) 
 p 0.65 0.59 0.78 0.66 0.80 
2,5-DCP % Δ/IQR 0.50 (-7.81, 9.56) 1.01 (-0.68, 2.7) 2.12 (-0.86, 5.09) 0.83 (-1.8, 3.45) -0.45 (-5.55, 4.65) 
 p 0.91 0.24 0.16 0.54 0.86 
BPA % Δ/IQR 2.68 (-9.14, 16.03) 2.38 (0.04, 4.72) 4.33 (0.11, 8.55) 2.12 (-1.62, 5.85) 1.00 (-5.72, 7.72) 
 p 0.67 0.05** 0.05** 0.27 0.77 
BPFb % Δ/IQR 1.23 (-15.77, 21.66) -2.14 (-5.74, 1.45)a -1.17 (-7.46, 5.12) 1.19 (-4.33, 6.70) 8.39 (-10.62, 27.39) 
 p 0.90 0.24 0.72 0.67 0.39 
BPS % Δ/IQR 1.10 (-9.89, 13.43) -1.40 (-3.75, 0.96) -1.35 (-5.35, 2.66) -1.01 (-4.66, 2.63) -0.68 (-6.28, 4.92) 
 p 0.85 0.25 0.51 0.59 0.81 
BP-3 % Δ/IQR -5.48 (-15.04, 5.17) 0.99 (-1.1, 3.08) -3.11 (-6.78, 0.56) -1.08 (-4.32, 2.17) -3.46 (-9.22, 2.3) 
 p 0.30 0.35 0.10 0.52 0.24 
TCC % Δ/IQR -7.90 (-20.02, 6.06) -0.81 (-3.75, 2.13) 5.64 (0.81, 10.46) 0.71 (-3.8, 5.22) 0.41 (-6.79, 7.61) 
 p 0.25 0.59 0.02** 0.76 0.91 
TCS % Δ/IQR 5.46 (-6.44, 18.86) -1.20 (-3.54, 1.14) -5.81 (-9.9, -1.73) -1.82 (-5.47, 1.82) -1.33 (-8.32, 5.67) 
 p 0.39 0.32 0.01** 0.33 0.71 
EPBb % Δ/IQR -10.15 (-24.31, 6.66) 0.39 (-3.19, 3.97) -1.08 (-7.07, 4.91) 2.78 (-2.72, 8.27) 12.88 (-18.25, 44.01) 
 p 0.22 0.83 0.72 0.32 0.42 
BPB % Δ/IQR -7.03 (-15.34, 2.11) 0.65 (-1.2, 2.5) -0.74 (-4.01, 2.54) 1.32 (-1.56, 4.2) -3.45 (-8.78, 1.89) 
 p 0.13 0.49 0.66 0.37 0.21 
MPB % Δ/IQR -7.22 (-16.8, 3.47) a 0.84 (-1.31, 2.98) -2.96 (-6.74, 0.81) 0.95 (-2.4, 4.29) -4.70 (-10.15, 0.76) 
 p 0.18 0.45 0.13 0.58 0.09* 
PPB % Δ/IQR -8.89 (-19.14, 2.65) 1.10 (-1.25, 3.44) -1.72 (-5.87, 2.44) 0.76 (-2.9, 4.41) -6.08 (-12.38, 0.23) 
 p 0.13 0.36 0.42 0.69 0.06* 
2,4-DCP: 2,4-dichlorophenol; 2,5-DCP: 2,5-dichlorophenol; BP-3: Benzophenone; TCS: Triclosan; TCC: Triclocarban; EPB: ethylparaben; MPB: Methylparaben; BPB: 
Butylparaben; PPB: Propylparaben 
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Beta coefficients are transformed into percent change of hormone in an IQR change in the exposure. Beta coefficients and their 95% CI are displayed. a represents a significant 
interaction term between the exposure*visit in LMM models (p<0.05). *p values < 0.1. **p values < 0.05. b Dichotomous variable. 
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Figure III.1: Heat map of Spearman correlations between unlogged urinary triclocarban, phenols and 
parabens. Biomarkers concentrations were adjusted for urinary dilution.  
2,4-DCP: 2,4-dichlorophenol; 2,5-DCP: 2,5-dichlorophenol; BP-3: Benzophenone; TCS: Triclosan; TCC: 
Triclocarban; EPB: ethylparaben; MPB: Methylparaben; BPB: Butylparaben; PPB: Propylparaben 
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Figure III.2: Adjusted multiple linear regressions of hormones versus urinary concentrations of biomarkers stratified by study visit. Visit 1: 16-20 
weeks; Visit 3: 24-28 weeks. EPB and BPF are categorical variables. * represents at least one marginal association between the urinary 
concentration and the hormone across the four time points. ** represents at least one significant association between the urinary biomarker 
concentration and the hormone across the four time points. BPF and EPB were dichotomous variables. 2,4-DCP: 2,4-dichlorophenol; 2,5-DCP: 
** 
** 
* 
* 
* 
** 
* 
* 
* 
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2,5-dichlorophenol; BP-3: Benzophenone; TCS: Triclosan; TCC: Triclocarban; EPB: ethylparaben; MPB: Methylparaben; BPB: Butylparaben; 
PPB: Propylparaben 
 
 
Figure III.3: Spearman correlation heat map of average phenols, parabens, triclocarban and hormones. All biomarkers are arranged by first 
principle component order. Color and size of circle depicts strength of association, correlations with p values > 0.05 displayed with X. BPF and 
EPB were dichotomous variables. 2,4-DCP: 2,4-dichlorophenol; 2,5-DCP: 2,5-dichlorophenol; BP-3: Benzophenone; TCS: Triclosan; TCC: 
Triclocarban; EPB: ethylparaben; MPB: Methylparaben; BPB: Butylparaben; PPB: Propylparaben 
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Figure III.4: Spearman correlation heat map of phenols, parabens, triclocarban and hormones at 16-20 weeks and 24-28 weeks gestation. All 
biomarkers are arranged by first principle component order. Color and size of circle depicts strength of association, correlations with p values > 
0.05 displayed with X. BPF and EPB were dichotomous variables. 2,4-DCP: 2,4-dichlorophenol; 2,5-DCP: 2,5-dichlorophenol; BP-3: 
Benzophenone; TCS: Triclosan; TCC: Triclocarban; EPB: ethylparaben; MPB: Methylparaben; BPB: Butylparaben; PPB: Propylparaben 
 
 
 
16-20 weeks 24-28 weeks 
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Figure III.5:   Distribution of specific-gravity corrected logged exposure biomarkers comparing densities across PROTECT and LifeCodes cohorts. 
Note: The density plot for BPS in LifeCodes was not clear due to the large percentage of BPS concentrations below the LOD. 2,4-DCP: 2,4-
dichlorophenol; 2,5-DCP: 2,5-dichlorophenol; BP-3: Benzophenone; TCS: Triclosan; TCC: Triclocarban; EPB: ethylparaben; MPB: 
Methylparaben; BPB: Butylparaben; PPB: Propylparaben
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Figure III.6: Distribution of specific-gravity corrected logged BPS across PROTECT and LifeCodes 
cohorts. BPS: Bisphenol-S 
 
Table III.6: Result comparison between the common exposure biomarkers and hormones from the 
preliminary analyses previously published* and the current analysis. Blue box shows similar associations; 
red boxes shows opposite directions of associations. 
 Prog SHBG FT4 TSH 
  Prelim New Prelim New Prelim New Prelim New 
2,4-DCP                 
2,5-DCP    1↓  3↑        
BPA         ↑ 3↑     
BP-3    3↑        
TCS   (3↑)             
MPB    ↑ 1↓ ↑     1↓ 
BPB       ↓ ↑       
PPB   (3↑)   1↓         
2,4-DCP: 2,4-dichlorophenol; 2,5-DCP: 2,5-dichlorophenol; BP-3: Benzophenone; TCS: Triclosan; MPB: Methylparaben; BPB: 
Butylparaben; PPB: Propylparaben 
* Previous analysis:  Aker AM, Watkins DJ, Johns LE, Ferguson KK, Soldin OP, Anzalota Del Toro LV, et al. Phenols and parabens 
in relation to reproductive and thyroid hormones in pregnant women. Environ Res. 2016;151:30–7. 
Numbers in cell refer to a significant association observed in stated study visit only. Associations in brackets refer to suggestive 
associations with p values between 0.05 and 0.10. 
 
Table III.7: Result comparison between the common exposure biomarkers and hormones from the 
LifeCodes case-control analysis previously published* and the current analysis. Blue box shows similar 
associations; red boxes shows opposite directions of associations. 
  FT4 T4 T3 TSH 
  LifeCodes PROTECT LifeCodes PROTECT LifeCodes PROTECT LifeCodes PROTECT 
2,4-DCP         3↓ (1↓) (3↑)    
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2,5-DCP             4↑   
BPA ↑ 3↑       ↑ ↓   
BPS 1↓           (1↑)  1↓  
BP-3     1-3↓   ↓   2&3↑   
TCS         ↓ 3↓ ↑   
TCC         ↓ ↑ (↓)  ↓ 
EPB                 
MPB (1↓)    (↑)    ↑   (3↓)  1↓ 
BPB         3&4↓   4↑   
PPB 1&2↓               
2,4-DCP: 2,4-dichlorophenol; 2,5-DCP: 2,5-dichlorophenol; BP-3: Benzophenone; TCS: Triclosan; MPB: Methylparaben; BPB: 
Butylparaben; PPB: Propylparaben 
* Previous analysis:  Aker AM, Johns L, McElrath TF, Cantonwine DE, Mukherjee B, Meeker JD. Associations between maternal phenol 
and paraben urinary biomarkers and maternal hormones during pregnancy: A repeated measures study. Environ Int. 2018;113:341–9 
 Numbers in cell refer to a significant association observed in stated study visit only. Associations in brackets refer to suggestive associations 
with p values between 0.05 and 0.10. 
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 Associations between Prenatal Exposure to Triclocarban, 
Phenols and Parabens with Gestational Age and Birth Weight in Northern 
Puerto Rico  
 
 
Abstract 
Background: Prenatal exposure to certain xenobiotics has been associated with adverse birth 
outcomes. We examined the associations of triclocarban, phenols and parabens in a cohort of 922 
pregnant women in Puerto Rico, the Puerto Rico Testsite for Exploring Contamination Threats 
Program (PROTECT). Methods: Urinary triclocarban, phenols and parabens were measured at 
three time points in pregnancy (visit 1: 16-20 weeks, visit 2: 20-24 weeks, visit 3: 24-28 weeks 
gestation). Multiple linear regression (MLR) models were conducted to regress gestational length 
and birthweight z-scores against each woman’s log average concentrations of exposure 
biomarkers. Logistic regression models were conducted to calculate odds of preterm birth, small 
or large for gestational age (SGA and LGA) in association with each of the exposure biomarkers. 
An interaction term between the average urinary biomarker concentration and infant sex was 
included in models to identify effect modification. The results were additionally stratified by 
study visit to look for windows of vulnerability. Results were transformed into the change in the 
birth outcome for an inter-quartile-range difference in biomarker concentration (Δ). Results: 
Average benzophenone-3, methyl- and propyl-paraben concentrations were associated with an 
increase in gestational length [(Δ 1.90 days; 95% CI: 0.54, 3.26); (Δ 1.63; 95% CI: 0.37, 2.89); 
(Δ 2.06; 95% CI: 0.63, 3.48), respectively]. Triclocarban was associated with a suggestive 2-day 
decrease in gestational length (Δ -1.96; 95% CI: -4.11, 0.19). Bisphenol A measured at visit 1 
was associated with a suggestive increase in gestational length (Δ 1.37; 95% CI: -0.05, 2.79). 
Triclosan was positively associated with gestational length among males, and negatively 
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associated with gestational length among females. Methyl-, butyl- and propyl-paraben were 
associated with significant 0.50-0.66 decreased odds of SGA. BPS was associated with an 
increase in the odds of SGA at visit 3, and a suggestive increase in the odds of LGA at visit 1. 
Conclusion: Benzophenone-3, methyl-paraben and propyl-paraben were associated with an 
increase in gestational length. Concentrations of triclocarban, which were much higher than 
reported in other populations, were associated with a suggestive decrease in gestational length. 
The direction of the association between triclosan and gestational length differed by infant sex. 
Parabens were associated with a decrease in SGA, and BPS was associated with both SGA and 
LGA depending on the study visit. Further studies are required to substantiate these findings. 
Introduction 
Phenols and parabens are a group of chemicals commonly found in personal care products and 
household items, and have been associated with a number of growth parameters at birth, 
including birth weight, birth length and gestational length [1–5]. We previously reported on 
associations between bisphenols, parabens and triclocarban with various birth outcomes in a 
cohort of pregnant women in Puerto Rico [6].  
Maternal stress has also been associated with adverse birth outcomes. A population-based case 
control study reported a 60% increased odds of a very low birth weight among women who 
reported always feeling stressed as compared to women reporting no stress [7]. Likewise, other 
studies have reported a shortened gestational length with maternal stress or a larger number of 
negative life events [8–11]. The effects of maternal stress on the fetus could also extend beyond 
pregnancy, and potentially cause long-term adverse effects on the cognitive, behavioral and 
psychomotor development of the child [12,13]. 
There is a growing interest in looking at the combined effect of stressors in the environment on 
human health. In addition to looking at the effect of chemical mixtures on health, interactions 
between chemical and non-chemical stressors are important to consider in deepening our 
understanding on how the environment impacts humans. Although this area of research is 
relatively new and limited, evidence supports the notion of an increased risk of adverse effects 
with exposure to high concentrations of environmental chemicals and the modifying effect of 
high psychosocial stress levels. For example, a systematic review found the combined effect of 
chemical exposures such as smoking and traffic pollution in combination with high stress or 
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socio-economic stressors was associated with worse fetal growth parameters than with either 
chemical or socio-economic stressors on their own [14]. 
As a follow up to our previous study, we were interested in examining the potential modifying 
effect of maternal stress on our associations between some exposure biomarkers and gestational 
length. This study is part of the Puerto Rico Testsite for Exploring Contamination Threats 
(PROTECT) project, a multi-disciplinary center in Northern Puerto Rico that established a 
pregnancy cohort to investigate the role of environmental contamination in adverse birth 
outcomes. The analysis explores relationships between gestational length and the interaction 
between urinary concentrations of triclocarban, phenols (benzophenone-3, BPA and BPS) and 
parabens (methyl- and propyl-paraben) and psychosocial factors (depression, perceived stress, 
social support and life events).   
 Methods 
Study Population 
Participants for this study were from the PROTECT cohort, an ongoing prospective cohort of 
pregnant women based in Northern Puerto Rico. Details on the recruitment and inclusion criteria 
have been described previously [31,32]. The 922 study participants in the present analysis were 
recruited from 2011-2017 at 18 ± 2 weeks gestation from five affiliated health clinics whose 
patients deliver at two collaborating hospitals were older than 18 years old, and indicated that 
they were planning to deliver at one of the collaborating hospitals. The exclusion criteria 
included: 1) women who lived outside the region, 2) multiple gestations, 3) use of oral 
contraceptives within three months prior to getting pregnant, 4) pregnancy through in vitro 
fertilization, and 5) any known medical health complications (including diabetes, hypertension, 
etc.). Each woman participated in a total of up to three study visits which coincided with routine 
clinical visits and rapid fetal growth. Visit 1 was targeted at 16-20 weeks gestation; visit 2 was 
targeted at 20-24 weeks gestation; and, visit 3 was targeted at 24-28 weeks gestation.  
Demographic information was collected via questionnaire at visit 1. Spot urine samples were 
collected at each of the study visits, and blood samples were collected at the first and third visit. 
Study data were collected and managed using REDCap electronic data capture tools hosted at the 
University of Puerto. Rico [33]. 
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This study was approved by the research and ethics committees of the University Of Michigan 
School Of Public Health, University of Puerto Rico, Northeastern University, and the University 
of Georgia. All study participants provided full informed consent prior to participation. 
 Urinary biomarker measurement 
Spot urine samples collected during the three study visits were divided into aliquots and frozen at 
-80 oC until they were shipped overnight on dry ice to the Centers for Disease Control and 
Prevention for analysis. Samples were analyzed for triclocarban, seven phenols (2,4-
dichlorophenol, 2,5-dichlorophenol, BPA, BPS, BPF, benzophenone-3, triclosan), and four 
parabens (ethyl-paraben, methyl-paraben, butyl-paraben,  propyl-paraben) using online solid 
phase extraction-high-performance liquid chromatography-isotope dilution tandem mass 
spectrometry. Biomarker concentrations below the limit of detection (LOD) were assigned a 
value of the LOD divided by √2 [36]. Urinary dilution was accounted for using urinary specific 
gravity (SG), and was measured using a digital handheld refractometer (AtagoCo., Ltd., Tokyo, 
Japan) at the time of the urine collection. Urinary biomarkers were corrected for SG in 
preliminary analyses using the following formula: 
Pc = M [ (SGm – 1) / (SGi – 1) ] 
Equation 1: Specific gravity correction of exposure biomarkers 
where Pc is the SG-corrected biomarker concentration (ng/mL), M is the measured biomarker 
concentration, SGm is the study population median urinary specific gravity (1.0196), and SGi is 
the individual’s urinary specific gravity. The sample size for BPF, BPS, triclocarban and ethyl-
paraben was smaller than for the other urinary biomarkers because they were added to the 
analytical panel mid-way through the study, and thus, only available on a subset of the cohort. 
 Gestational Age Calculation 
The gestational length for complete pregnancies was calculated according to the American 
Congress of Gynecologists (ACOG) recommendations [37], and it is described as the best 
obstetrical estimate. In brief, gestational length determination utilizes both the last menstrual 
cycle date (LMP) as reported by the mother, and the gestational age from the first ultrasound 
obtained before 20 weeks gestation. The selection between the gestational age from the LMP or 
ultrasound depends on two criteria: 1) gestational age at which the ultrasound was conducted, 
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and 2) whether the difference in the estimated date of delivery (EDD) calculated from the LMP 
and from the ultrasound is less or more than seven days. Further details on this calculation can be 
found in the ACOG Committee Opinion document (Committee on Obstetric Practice, the 
American Institute of Ultrasound in Medicine, and the Society for Maternal-Fetal Medicine, 
2017). A PTB is defined as giving birth prior to 37 gestational weeks. 
 Birthweight Calculation 
Birthweight values extracted from medical records were converted to gestational length and sex 
specific z-scores, calculated according to the INTERGROWTH-21st standards [38].  
Infants were considered small for gestational age (SGA) if they fell below the 10th percentile of 
birthweight z-scores. Infants were considered large for gestational age (LGA) if they fell above 
the 90% percentile of birthweight z-scores.  
 Statistical Analyses 
Distributions of key demographic characteristics were calculated. Spearman correlations were 
calculated to examine correlations between specific gravity-corrected average biomarker 
concentrations. Distributions of subject-specific average biomarker concentrations were 
examined using select percentiles. Distributions were also examined by study visit. Ethyl-
paraben and BPF were detected in less than 50% of the samples. Therefore, we transformed BPF 
and ethyl-paraben into dichotomous variables, where 0 represents concentrations below the 
LOD, and 1 represents concentrations above the LOD (i.e. detected versus non-detected). These 
categorical BPF and ethyl-paraben variables were used for all regression analyses. The 
remaining urinary biomarkers were all positively-skewed, so they were log-transformed for the 
remainder of the analyses.  
Models were constructed to regress each of the four birth outcome variables against each of the 
exposure biomarker variables. Multiple linear regressions (MLR) were conducted to examine 
associations between gestational length and one average exposure biomarker, as well as 
birthweight z-scores and one average exposure biomarker. Logistic regression models were 
conducted to examine associations between PTB, SGA or LGA and one average exposure 
biomarker. Due to the similar complications SGA and LGA may incur, SGA models did not 
include LGA births, and LGA models did not include SGA births. The average urinary exposure 
biomarker variables are the average urinary exposure biomarker concentrations across the three 
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study visits. In the case of a missing value at one of the study visits, the average was taken of the 
two remaining concentrations. In the case of two missing concentrations, the “average” phenol or 
paraben concentration was equal to the single available concentration. Crude analyses included 
only the average urinary biomarker and the average specific gravity. Additional covariates were 
included in the model in a step-wise fashion. A covariate was maintained in the model if it 
changed the main effect estimate by >10%. Finals models were controlled for the following 
covariates: specific gravity, maternal age, insurance type, alcohol use, and exposure to second-
hand smoking. Other variables considered include parity, smoking, maternal education, marital 
status, number of children, and BMI. To increase interpretability of our results, we transformed 
regression coefficients from MLRs and odds ratios from logistic models to the change in the 
birth outcome in relation to the interquartile range (IQR) increase in urinary biomarker 
concentrations. The alpha level was set at 0.05. All statistical analyses were conducted in R 
Version 3.4.2. 
We performed two sensitivity analyses. First, we ran the same MLR and logistic regression 
models regressing the birth outcome measure against biomarkers concentrations stratified by 
study visit of sample collection. Second, we examined an interaction term between the average 
urinary biomarker concentration and infant sex in the models to examine any potential effect 
modification by infant sex, and then stratified the models by infant sex if the p value exceeded 
0.05.  
Given the right-skewed distribution of gestational length, we ran sensitivity analyses to test the 
robustness of our results. We created a new variable by subtracting the individual gestational 
length from the maximum gestational length, and then took the log of the result. The resulting 
variable had a normal distribution. We re-ran the MLR models using this new gestational length 
variable. There was no difference in the interpretation of the results; therefore, we maintained 
our original models. We also ran multinomial logistic regression models to examine associations 
between the chemicals and size at birth (SGA, LGA and 10-90% percentile at birth). There were 
no differences in the results between the multinomial logistic regression models and the original 
logistic regression modes; therefore, we maintained our original models. 
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 Results 
The mean age of the 922 study participants was 26.7 years (Table IV.1). Almost half of the 
participants had a body mass index (BMI) <25 kg/m2, and 14% had a BMI > 29.9 kg/m2, but 
17% of the BMI values were missing. Sixty percent of the study population was dependent on 
government health insurance, suggesting a low socio-economic status (SES), and 50% of the 
population had household incomes up to $30,000. This is representative of the general Puerto 
Rican population [39]. Only 13% had a household income of >$50,000, though 43% of the 
women attended college or technical school.  Three percent of the women smoked during 
pregnancy (the questionnaire was administered at 16-20 weeks gestation), and 6% reported over 
one hour of second-hand smoking exposure per day. Six and a half percent reported drinking 
alcohol within the last few months. Almost 80% of the women reported being married or living 
with their partner, while 20% reported being single. Nearly half of the women had no other 
children at home.  
Up to 867 women had available data on urinary exposure biomarker concentrations (Table IV.2). 
The target biomarkers were highly detected in the study population, with the exception of BPF 
and ethyl-paraben. Fifty-seven and 43 percent of BPF and ethyl-paraben concentrations were 
below the LOD. Biomarker concentrations remained relatively consistent across the three study 
visits, with the exception of 2,5-dichlorophenol (p value=0.02) and butyl-paraben (p 
value=0.004) that had higher concentrations during visit 1 versus visits 2 and 3. Average methyl- 
and propyl-paraben concentrations were strongly correlated (Spearman correlation=0.78, p 
value<0.001) (Figure IV.2). Propyl-paraben was also moderately correlated with butyl-paraben 
and ethyl-paraben (Spearman correlation=0.42, p value<0.001). 2,4-Dichlorophenol and 2,5-
dichlorophenol were strongly correlated (Spearman correlation=0.67, p value<0.001), and 2,4-
dichlorophenol was also moderately correlated with triclosan (Spearman correlation=0.51, p 
value<0.001).  
The sensitivity analysis showed no difference in the interpretation of results between the 
transformed and untransformed gestational length variables (Table IV.7); therefore, the 
remainder of the results are retrieved from MLR models using the untransformed gestational 
length variable. 
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Benzophenone-3, methyl-paraben and propyl-paraben were associated with an increase in 
gestational length [(1.90 change in gestational length days per IQR increase in biomarker 
concentration (Δ/IQR); 95% CI: 0.54, 3.26); (Δ/IQR 1.63; 95% CI: 0.37, 2.89); (Δ/IQR 2.06; 
95% CI: 0.63, 3.48), respectively] (Table IV.3). Conversely, triclocarban was associated with a 
suggestive decrease in gestational length (Δ/IQR -1.96; 95% CI: -4.11, 0.19).  
After stratification by study visit, visit 1 (16-20 weeks gestational length) showed stronger 
associations for a number of exposure biomarkers ( 
Table IV.4). At visit 1, BPA was suggestively associated with an increase in gestational length 
(Δ/IQR 1.37; 95% CI:-0.05, 2.79). Additionally, associations between gestational length and 
triclocarban, methyl-paraben and propyl-paraben were strongest (largest change in days and 
lowest p values) at visit 1. Propyl-paraben was also associated with a significant increase in 
gestational length at 24-28 weeks gestation (Δ/IQR 1.84; 95% CI: 0.02, 3.65), but not at 20-24 
weeks gestation. Benzophenone-3 was consistently associated with an approximate 1.5 day 
increase in gestational length at all three study visits.  
Sex differences were then explored by including an interaction term between the urinary 
biomarkers and infant sex (Table IV.9). The infant sex*biomarker interaction term was 
significant in the model for gestational length and triclosan (p value=0.006). Urinary triclosan 
concentration was associated with a suggestive decrease in gestational length among females 
(Δ/IQR -2.31; 95% CI:-4.86, 0.24; p value = 0.08), and associated with an increase in gestational 
length among males (Δ/IQR 2.96; 95% CI: 0.41, 5.51; p value = 0.02). Figure IV.1 is a graph of 
the interaction effect of infant sex on the association between the average triclosan concentration 
and gestational length. Figure IV.3 shows the conditional effect of the average triclosan 
concentration on gestational length stratified by infant sex to better view the difference in the 
direction of association between male and female infants. 
Results from these models regressing PTB resembled the results observed in models regressing 
gestational length against the exposure biomarkers. Average BP-3, MPB and PPB were 
associated with a decreased odds of PTB [(OR/IQR 0.54; 95% CI: 0.36, 0.83); (OR/IQR 0.70; 
95% CI: 0.49, 0.98); and (OR/IQR 0.64; 95% CI: 0.44, 0.94). The associations with BP-3 did not 
differ by study visit, but associations with MPB and PPB with PTB were stronger at study visit 1 
[(OR/IQR 0.58; 95% CI: 0.38, 0.89) and (OR/IQR 0.51; 95% CI: 0.32, 0.80)]. BPA and TCC 
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were also associated with PTB at visit 1 only. BPA was associated with a suggestive decreased 
odds of PTB at 16-20 weeks (OR/IQR 0.69; 95% CI: 0.45, 1.05), while TCC was associated with 
a suggestive increased odds of PTB at 16-20 weeks (OR/IQR 1.71; 95% CI: 0.94, 3.10). Lastly, 
BPF was associated with a decreased odds of PTB at 24-28 weeks (OR/IQR 0.36; 95% CI: 0.15, 
0.84). 
No averaged exposure biomarkers were associated with the birthweight z-score (Table IV.5). 
After stratification by study visit, butyl-paraben was associated with a suggestive increase of 
0.12 in the birthweight z-score at visit 2 (z-score Δ/IQR 0.12; 95% CI: -0.02, 0.26). Fetal sex did 
not modify any of the associations with birthweight z-scores; interaction terms between 
biomarkers and fetal sex were all above 0.10.  
Average triclosan was associated with a 70% increased odds of SGA (OR/IQR 1.70; 95% CI: 
1.06, 2.73); average 2,4-dichlorophenol was associated with a suggestive 32% increased odds of 
SGA (OR/IQR 1.32; 95% CI: 0.95, 1.84). Methyl-, butyl- and propyl-paraben were all associated 
with a 34-50% decrease in the odds of SGA [(OR/IQR 0.66; 95% CI: 0.47, 0.93); (OR/IQR 0.50; 
95% CI: 0.28, 0.88); (OR/IQR 0.61; 95% CI: 0.41, 0.91), respectively].  
After stratification of the results by study visit (Table IV.6), BPS was significantly associated 
with 82% increased odds of SGA at visit 3 (OR/IQR 1.82; 95% CI: 1.17, 2.84). Associations 
between parabens and SGA by study visit differed slightly by the type of paraben. There was no 
difference in association between SGA and methyl-paraben across the three time points. 
Associations between butyl-paraben and SGA was only significant at visit 2 and visit 3 
[(OR/IQR 0.47; 95% CI: 0.26, 0.84) and (OR/IQR 0.51; 95% CI: 0.28, 0.91), respectively], 
while propyl-paraben was associated with a decrease in the odds of SGA at visit 1 and visit 3 
[(OR/IQR 0.58; 95% CI: 0.38, 0.97); (OR/IQR 0.53; 95% CI: 0.32, 0.87), respectively]. 
Associations between triclosan and 2,4-dichlorophenol with SGA were significant at 20-24 
weeks [(OR/IQR 1.51; 95% CI: 0.95, 2.42) and (OR/IQR 1.34; 95% CI: 0.96, 1.85), 
respectively]. Fetal sex did not modify any of the associations with SGA; interaction terms 
between biomarkers and fetal sex were all above 0.05. 
Average BPS and BP-3 concentrations were associated with an increased odds of LGA 
[(OR/IQR 1.62; 95% CI: 1.06, 2.45) and (OR/IQR 1.38; 95% CI: 0.99, 1.93), respectively]. The 
association between BPS and SGA was strongest at study visit 1 (OR/IQR 1.49; 95% CI: 0.99, 
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2.25), whereas the association between BP-3 and LGA was strongest at study visit 2 (OR/IQR 
1.52; 95% CI: 1.09, 2.13). Fetal sex did not modify any of the associations with LGA; interaction 
terms between biomarkers and fetal sex were all above 0.10.  
 Discussion 
Urinary concentrations of benzophenone-3, methyl-paraben and propyl-paraben measured at up 
to 3 times during pregnancy were associated with an increase in gestational length. Urinary BPA 
concentrations at 16-20 weeks were also associated with a suggestive increase in gestational 
length. Triclocarban was associated with a suggestive decrease in gestational length, while the 
relationship between triclosan and gestational length differed by infant sex. PTB results mirrored 
gestational length results, with the addition of a decrease in the odds of PTB in association with 
BPF at 24-28 weeks gestation. No exposure biomarkers were associated with birth weight; 
however 2,4-dichlorophenol, triclosan and BPS were associated with an increase in the odds of 
SGA, while parabens were associated with a decrease in the odds of SGA. BP-3 and BPS were 
also associated with an increase in the odds of LGA.  
Benzophenone-3 was consistently associated with an increase in gestational length at all study 
visits and in both sexes in this study. However, in contrast to our results, a previous study 
reported a decrease in gestational length in association with urinary benzophenone-3 
concentrations at delivery in 567 infants [27]. We could not identify other studies that examined 
the effect of benzophenone-3 on gestational length, but did identify studies that reported 
associations between benzophenone-3 and other gestation growth parameters. Philippat et al. 
reported an increase in birth weight and head circumference in association with benzophenone-3 
among 520 male infants in France [26,40], whereas Wolff et al. found an increase in birth weight 
among boys and a decrease in birth weight among girls in a cohort of 404 pregnant women in 
New York City [28]. Benzophenone-3 was also associated with a decrease in the abdominal 
circumference among boys, and a suggestive increase in abdominal circumference among 
females in a cohort of 476 women in Boston [24]. The reported increases in gestational growth 
parameters in association with benzophenone-3 are consistent with our finding of an increased 
odds of LGA with benzophenone-3.  
The biological mechanisms involved in the observed associations between benzophenone-3 and 
birth outcomes are unclear. Benzophenone-3 exhibits estrogenic activity and can bind to estrogen 
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receptors α and β, as well as other estrogen-related receptors [41]. Therefore, an endocrine-
mediated mechanism could potentially be leading to the increase in gestational length. 
Alternatively, BP-3 was associated with lower concentrations of pro-inflammatory markers in a 
large pregnancy cohort [42] which may also impact duration of pregnancy.  
Methyl- and propyl-paraben were also associated with an increase in gestational length in this 
study, particularly at 16-20 weeks gestation, in addition to a decreased odds of SGA. One other 
study looked into the effect of parabens on gestational length. Geer et al. reported a decrease in 
gestational length in association with maternal urinary butyl-paraben at the third trimester, and a 
protective effect on PTB in association with cord blood propyl-paraben (but no effect on 
gestational length) in a small (N=185) immigrant population in New York  [43]. Although we 
did not identify any associations between butyl-paraben and gestational length, we did observe a 
decrease in the odds of PTB with urinary propyl-paraben concentrations, which was similar to 
the results observed in the New York study. With regards to other growth parameters, parabens, 
including methyl-paraben and propyl-paraben, were associated with an increase in birth weight 
among boys [26,44]. A large Chinese cohort (N=1006) also reported an increase in birth length 
in association with methyl-paraben in boys [44]. We observed a similar association between 
butyl-paraben and an increase in birthweight, as well as a protective effect of parabens on SGA; 
however, the associations were not specific to infant sex. Parabens have demonstrated endocrine 
disrupting effects [45–47], and have been associated with changes in estriol, progesterone, sex-
hormone binding globulin, and thyroid-stimulating hormone in this cohort (Aker el al., in press). 
These potential effects on hormone levels may play a role in the relationships between parabens 
and birth outcomes, though more research is needed to help clarify relevant biological 
mechanisms. Butyl-paraben has also been shown to activate PPARγ and increase adipogenesis, 
which could explain the decrease in the odds of SGA, although only butyl-paraben was included 
in this in vitro study [48].  
In the current study, BPA was associated with a suggestive increase in pregnancy duration, 
particularly for urinary measures at 16-20 weeks gestation. One study did observe an increase in 
gestational length with maternal plasma BPA levels, particularly among female infants [49]. The 
plasma was analyzed during early pregnancy, which is reflective of the timing of our study visit 
1; however it is difficult to compare BPA concentrations in plasma versus urine. In contrast, 
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other studies have found a decrease in gestational length in association with BPA. Urinary BPA 
at the third trimester was found to increase preterm birth in a nested case-control study 
conducted in Mexico [50]. Another nested case-control study found that maternal plasma BPA 
concentrations at time of delivery were associated with preterm birth, although interestingly, 
amniotic fluid BPA concentrations were not [51]. Three more cross-sectional studies looked at 
BPA levels at delivery, two of which reported a decrease in gestational length, particularly 
among male infants [27,52], and one that reported no association between BPA and gestation age 
among 496 mother-infant pairs [53]. It is important to note the difference in the timing of 
exposure assessment between past studies and our current study. Our study looked at earlier time 
points of BPA exposure, so it is possible that the differences in our results could be attributed to 
this difference in timing of the exposure measures, and possibly indicating a susceptible window 
of exposure. There are also noted differences in urine versus plasma BPA concentrations, with 
some possible bias in measuring plasma BPA concentrations as an exposure proxy given the high 
potential for contamination [54]. This difference in measurement could also explain the 
differences in our results.   
BPS was associated with an increased odds of both SGA and LGA, depending on the timing of 
exposure. While BPS concentrations at 16-20 weeks were associated with LGA, BPS 
concentrations at 24-28 weeks were associated with SGA. We did not identify any other studies 
that reported associations between BPS and SGA or LGA; however, similar to our results, two 
cohort studies found no association between BPS and overall birth weight [24,55]. This 
difference in the potential effect on the size of the fetus could be attributed to the transient 
hormonal levels present throughout the different stages of pregnancy. For example, in a previous 
study by our group, BPS was associated with changes to thyroid-stimulating hormone and 
corticotropin-releasing hormone at different time points in pregnancy (Aker et al., in press). 
Although the increase in both SGA and LGA in association with BPS differed by time point, 
these results are difficult to explain. Therefore, we caution over-interpretation of these results 
until these association are studied in other cohorts, and experimental studies help to better 
understand the biological mechanisms by which BPS may impact birth outcomes.  
We identified a relationship between triclosan and gestational length that differs by the sex of the 
infant, and an increase in the odds of SGA with urinary triclosan. There was an increase in 
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gestational length among boys, and a suggestive decrease in gestational length among females. 
In fact, four other studies observed associations between triclosan and birth outcomes among 
only boys [24–26,28]. The sex-specific effects observed could be attributed to sex hormone-
specific targets of triclosan in the developing fetus. For example, triclosan was associated with 
an increase in maternal testosterone in this cohort (Aker et al., in press), which may impact the 
developing male fetus differently than the female fetus. Another birth cohort of 376 mother-
infant pairs in Cincinnati collected urine at 16 and 26 weeks pregnancy [56]. Average triclosan 
concentrations were associated with a decrease in gestational length, but was not modified by 
infant sex.  A large cohort study in China including over 1000 pregnant women found no 
association between urinary triclosan concentrations and gestational length after confounder 
adjustment [57]. There were also no differences by infant sex. Differences in our results could be 
due to the difference in the timing of triclosan exposure as the Chinese study measured urinary 
triclosan just prior to delivery. Differences may also be due to the lower urinary triclosan 
concentrations in comparison to our cohort. Several other studies also reported no association 
between triclosan and birth outcomes, including gestational length [28,40,43,53]. However, our 
triclosan concentrations were 3-20 times higher than the concentrations reported in these studies. 
Similar to our results, no association was observed between triclosan and birth weight in two 
large prospective cohorts of pregnant Chinese women [53,57]. A study on a cohort of 378 
mother-infant pairs in Ohio did observe a decrease in birth weight, birth length and head 
circumference with a 10-fold increase in urinary triclosan [56]. While we did not observe any 
effects in birth weight, results in the Ohio cohort could be consistent with an increase in SGA, as 
we observed in our cohort. Conversely, another large (N=620) Chinese cohort identified an 
increase in the birth weight of newborns among females [58]. However, that study modeled birth 
weight, and included gestational length as a covariate in the model, as opposed to our gestational 
age-adjusted z-scores. This difference in statistical methods may partially explain some the 
differences in our results.  
A small study (N=185) reported no association between third trimester maternal urine triclosan 
concentrations and gestational length in an immigrant population in New York, but did find a 
significant decrease in gestational length with an increase in triclocarban neonatal cord blood 
plasma (N=34) [43]. This is similar to our finding of a suggestive decrease in gestational length 
 109 
 
in association with average urinary triclocarban, where we also found stronger associations with 
triclocarban measured earlier in pregnancy. To our knowledge, no other studies reported 
associations between triclocarban and gestational length. Triclocarban concentrations in 
PROTECT were exceptionally high compared to other studies [59]. The median urinary 
concentrations of triclocarban in the U.S. National Health and Nutrition Examination Survey 
(NHANES) in 2013-2014 was < LOD (0.1 μg/L), and 0.2 μg/L was the 75th percentile [60]. Our 
cohort, on the other hand, had a median of 2.3 μg/L and a 75th percentile of 26.8 μg/L. Similarly, 
a recent review reported a relatively low detection (4-25%) of urinary triclocarban in Canada, 
Greece and Denmark [61]. This points to the variability of exposure to triclocarban worldwide. 
Our findings and previous studies suggest an association between triclocarban and birth 
outcomes [61]. Therefore, additional studies will be useful to better understand these associations 
and potential mechanisms of action.  
While there was some consistency between our results and other studies, the differences with 
regards to observed associations, as well as the directions of association make the interpretations 
of results across studies difficult. However, this also may indicate the importance of 1) the 
timing of exposure on birth outcomes, 2) the methodological techniques used in analyzing 
exposure and outcome, and perhaps most importantly, 3) the undefined confounders and/or 
modifiers that may exist from one population to the other. Future studies should attempt to 
explore other factors that may interact with these chemicals that could explain the differences 
observed across cohorts. 
Our study had a few limitations. While data at three time points are a great improvement from 
the more common cross-sectional study design, it may not be sufficient to understand the effects 
of these biomarkers on gestational length. The variation of concentrations of these exposure 
biomarkers over time may also introduce potential bias, stemming from random measurement 
error, but most likely towards the null. We also had a smaller sample size for some of the 
emerging phenols of concern, such as BPA replacement chemicals, as these were added to the 
analytical panel part-way through the study. Finally, given the multiple comparisons conducted, 
there is a possibility of chance findings due to Type I error.  
Our study also had many strengths, including a robust sample size and the collection of exposure 
biomarkers data at three time points during pregnancy to help account for the chemicals’ short 
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lifespan in the body and likely episodic nature of the exposures, as previously reported [59] The 
repeated measures also allowed us to explore potential windows of susceptibility for these 
associations. Additionally, our urinary biomarker panel included triclocarban, BPS and BPF, all 
of which have not been well studied in the current literature. Finally, the relatively high 
biomarkers concentrations in our cohort, particularly triclocarban, triclosan and BPF, provides as 
opportunity to study the potential effects of these chemicals in a vulnerable human population. 
The results of this study add evidence to the possibility of an influence by exposure to phenols 
and parabens on birth outcomes. Further studies are needed to better understand how they impact 
birth outcomes, but in the meantime advising parents on simple ways to reduce exposure to these 
chemicals is warranted. 
 Conclusion 
Our study showed a significant association between triclocarban, and select phenols and 
parabens in association with gestational length and SGA. In particular, benzophenone-3, BPA, 
methyl- and propyl-paraben were associated with an increase in gestational length, while 
triclocarban was associated with a suggestive decrease in gestational length. Urinary biomarker 
concentrations at the earliest time point, 16-20 weeks gestation, may be a susceptible window of 
exposure for triclocarban and other chemicals. Triclosan, BPF and BPS were associated with an 
increase in SGA, whereas parabens were associated with a decrease in SGA. The association 
between triclosan and gestational length differed by infant sex, wherein triclosan was associated 
with an increase in gestational length among males, and a suggestive decrease in gestational 
length among females. These associations should be verified in further studies with repeated 
measures of exposure.  
Table IV.1: Summary demographics of the 922 pregnant women in the study population 
 Overall 
Total N 922 
Gestational Age 38.8 (2.0) 
Birthweight (Mean (SD)) 110.6oz (19.4) 
Preterm Birth 10.3% 
Small for Gestational Age 9.9% 
Large for Gestational Age 9.1% 
Maternal Age (Mean (SD)) 26.70 (5.5) 
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BMI (%)  
<25 kg/m2 437 (47.4) 
25-29.9 kg/m2 201 (21.8) 
>29.9 kg/m2 129 (14.0) 
Missing 155 (16.8) 
Insurance type (%)  
Public (Mi Salud) 555 (60.2) 
Private 322 (34.9) 
Missing 45 (4.9) 
Household Income (%)  
<$10,000 234 (25.4) 
$10,000-$30,000 246 (26.7) 
$30,000-$50,000 184 (20.0) 
>$50,000 123 (13.3) 
Missing 135 (14.6) 
Maternal Education (%)  
≤High School/GED 187 (20.3) 
Some College or technical school 331 (35.9) 
College graduate or technical school 392 (42.5) 
Missing 12 ( 1.3) 
Smoking (%)  
Never 763 (82.8) 
Ever 120 (13.0) 
Current 29 ( 3.1) 
Missing 10 ( 1.1) 
Exposure to second hand smoking (%)  
None 781 (84.7) 
Up to 1 hour 44 ( 4.8) 
More than 1 hour 59 ( 6.4) 
Missing 38 ( 4.1) 
Alcohol Consumption (%)  
None 463 (50.2) 
Before pregnancy 385 (41.8) 
Yes within the last few months 60 ( 6.5) 
Missing 14 ( 1.5) 
Marital Status (%)  
Single 180 (19.5) 
Married 517 (56.1) 
Divorced 11 ( 1.2) 
Living together 205 (22.2) 
Missing 9 ( 1.0) 
Number of previous children (%)  
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0 436 (47.3) 
1 364 (39.5) 
>1 111 (12.0) 
Missing 11 ( 1.2) 
Demographic variables collected during the second study visit 
(20-24 weeks). 
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Table IV.2: SG-corrected urinary biomarker average concentrations and by study visit of sample collection in pregnancy. Range of 
gestational weeks for sample collection: Visit 1: 16-20 weeks gestation, Visit 2: 20-24 weeks gestation Visit 3: 24-28 weeks gestation. 
 All Visit 1 
 % <LOD N GM (GSD) 25% 50% 75% % <LOD N GM (GSD) 25% 50% 75% 
2,4-Dichlorophenol 1.1 1871 1.09 (3.42) 0.50 0.99 2.17 0.7 674 1.16 (3.29) 0.50 1.01 2.10 
2,5-Dichlorophenola 0.1 1872 13.14 (5.40) 4.10 10.22 31.64 0.1 672 14.18 (5.42) 4.40 11.05 36.41 
BPA 0.6 1868 2.02 (2.54) 1.10 1.98 3.49 0.1 667 2.16 (2.49) 1.21 2.09 3.68 
BPS 6.1 1310 0.46 (3.16) 0.20 0.40 0.90 5.5 465 0.47 (3.32) 0.20 0.40 0.99 
BPF 56.8 1144 0.27 (2.97) 0.14 0.14 0.40 54 416 0.30 (3.22) 0.14 0.14 0.50 
Benzophenone-3 0.2 1869 39.45 (6.63) 10.36 26.50 124.85 0.4 671 42.06 (6.37) 11.35 29.27 126.61 
Triclosan 1.6 1874 22.75 (8.65) 3.61 15.79 139.27 2.1 669 23.76 (8.85) 3.71 15.75 149.51 
Triclocarban 6.4 1312 3.41 (10.90) 0.50 2.31 26.79 6.5 469 3.42 (10.79) 0.50 2.28 25.52 
Ethyl-paraben 42.9 1318 2.56 (6.48) 0.71 1.24 7.83 39.7 470 3.10 (7.11) 0.71 1.55 10.52 
Methyl-paraben 0.5 1876 74.74 (5.28) 23.56 88.54 249.93 0.4 670 77.67 (5.24) 25.50 97.51 262.15 
Butyl-parabena 26.3 1865 0.45 (7.61) 0.07 0.20 1.80 23.4 664 0.53 (8.43) 0.10 0.20 2.84 
Propyl-paraben 0.3 1875 14.78 (7.60) 3.19 17.17 76.76 0 670 15.96 (7.43) 3.39 20.06 78.86 
 
Visit 2 Visit 3 
 % <LOD N GM (GSD) 25% 50% 75% % <LOD N GM (GSD) 25% 50% 75% 
2,4-Dichlorophenol 0.9 674 1.08 (3.42) 0.50 0.91 2.11 1.9 523 1.04 (3.58) 0.40 0.90 2.19 
2,5-Dichlorophenola 0 675 12.22 (5.33) 3.83 9.58 27.29 0.2 525 13.08 (5.47) 4.01 9.84 29.67 
BPA 1.2 678 2.07 (2.69) 1.10 2.01 3.71 0.6 523 1.78 (2.40) 1.00 1.71 3.09 
BPS 6.9 476 0.45 (3.02) 0.20 0.40 0.90 5.7 369 0.45 (3.16) 0.20 0.40 0.90 
BPF 56.6 410 0.28 (3.05) 0.14 0.14 0.40 60.5 318 0.24 (2.52) 0.14 0.14 0.37 
Benzophenone-3 0 675 39.83 (6.49) 10.35 26.62 128.77 0.2 523 35.88 (7.17) 8.87 23.67 112.91 
Triclosan 1.2 676 22.56 (8.77) 3.57 16.18 147.99 1.5 529 21.76 (8.28) 3.61 15.72 121.40 
Triclocarban 6.9 476 3.27 (11.06) 0.50 2.31 28.94 5.5 367 3.58 (10.88) 0.51 3.30 27.45 
Ethyl-paraben 42 478 2.36 (5.98) 0.71 1.30 5.96 47.9 370 2.23 (6.25) 0.71 0.85 6.70 
Methyl-paraben 0.6 678 69.43 (5.37) 21.48 78.36 236.91 0.6 528 78.24 (5.23) 23.99 94.39 251.31 
Butyl-parabena 26.8 675 0.41 (6.81) 0.07 0.20 1.39 29.4 526 0.43 (7.59) 0.07 0.20 1.49 
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Propyl-paraben 0.4 677 13.48 (7.50) 3.04 14.16 69.40 0.4 528 15.08 (7.92) 3.08 18.87 78.10 
GM: Geometric mean 
GSD: Geometric standard deviation 
a Significant difference (p<0.05) in urinary exposure metabolite or hormone compared to reference (visit 1) using linear mixed models with a random 
intercept. 
All biomarker units: µg/mL.  
LODs for biomarkers: 2,4-dichlorphenol and 2,5-dichlorophenol, BPS, triclocarban, butylparaben, propylparaben: 0.1 µg/L. BPA and BPF: 0.2 µg/L. BPF: 0.4 
µg/L. Methyl-paraben and ethyl-paraben: 1 µg/L. Triclosan: 1.7 µg/L. 
  
 
Table IV.3: Adjusteda change in gestational length or odds ratios in relation to average exposure biomarker concentration across three time points 
during pregnancy. Beta coefficients were transformed to change or odds ratio for an IQR increase in exposure biomarker concentration. 
  Gestational Age Preterm Birth 
  N Change in days/IQR (95% CI) p OR/IQR change (95% CI) p 
2,4-Dichlorophenol 748 0.07 (-1.20, 1.33) 0.92 1.04 (0.75, 1.43) 0.81 
2,5-Dichlorophenol 749 -0.46 (-1.68, 0.76) 0.46 1.18 (0.87, 1.61) 0.29 
BPA 748 0.98 (-0.41, 2.37) 0.17 0.72 (0.48, 1.07) 0.10 
BPFb 500 0.06 (-0.28, 0.41) 0.72 0.60 (0.31, 1.17) 0.14 
BPS 540 -0.52 (-2.14, 1.09) 0.53 1.08 (0.70, 1.66) 0.72 
Benzophenone-3 749 1.90 (0.54, 3.26) 0.006** 0.54 (0.36, 0.83) 0.01** 
Triclosan 749 0.12 (-1.64, 1.87) 0.90 0.94 (0.58, 1.51) 0.79 
Triclocarban 544 -1.96 (-4.11, 0.19) 0.08* 1.50 (0.84, 2.67) 0.17 
Ethyl-parabenb 550 -0.11 (-0.44, 0.23) 0.53 0.89 (0.47, 1.68) 0.71 
Methyl-paraben 751 1.63 (0.37, 2.89) 0.01** 0.70 (0.49, 0.98) 0.04** 
Butyl-paraben 746 0.60 (-1.23, 2.42) 0.52 0.90 (0.54, 1.49) 0.67 
Propyl-paraben 752 2.06 (0.63, 3.48) 0.005** 0.64 (0.44, 0.94) 0.02** 
a Models adjusted for specific gravity, maternal age, insurance type, alcohol use, and exposure to second-hand smoking. 
b Categorical variable.  
* 0.05 < p value < 0.10; ** p value < 0.05 
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Table IV.4: Adjusteda change or odds ratio in relation to exposure biomarker concentration, stratified by visit during pregnancy. Beta coefficients 
were transformed to the change in the number of gestational days or odds ratio per IQR change in exposure biomarker concentration. 
 Gestational Age 
  Visit 1 (16-20 weeks ) Visit 2 (20-24 weeks) Visit 3 (24-28 weeks) 
  N Change in days (95% CI) p  N Change in days (95% CI) p N Change in days (95% CI) p 
2,4-DCP 613 0.05 (-1.21, 1.31) 0.94 624 0.65 (-0.59, 1.89) 0.30 470 -0.28 (-1.87, 1.31) 0.73 
2,5-DCP 612 -0.50 (-1.78, 0.78) 0.45 624 0.29 (-0.95, 1.52) 0.65 472 -0.92 (-2.30, 0.45) 0.19 
BPA 607 1.37 (-0.05, 2.79) 0.06* 626 1.13 (-0.26, 2.53) 0.11 470 0.90 (-0.81, 2.62) 0.30 
BPFb 381 0.12 (-0.27, 0.51) 0.55 381 -0.22 (-0.62, 0.18) 0.28 291 0.24 (-0.19, 0.68) 0.27 
BPS 422 -0.58 (-2.27, 1.11) 0.5 438 -0.27 (-2.02, 1.47) 0.76 329 0.44 (-1.34, 2.23) 0.63 
BP-3 611 1.56 (0.18, 2.93) 0.03** 623 1.44 (0.05, 2.83) 0.04** 470 1.63 (0.15, 3.12) 0.03** 
TCS 609 0.21 (-1.49, 1.91) 0.81 625 0.41 (-1.28, 2.09) 0.63 476 0.85 (-1.07, 2.76) 0.39 
TCC 426 -2.21 (-4.43, 0.01) 0.05* 437 -2.10 (-4.33, 0.14) 0.07* 328 -1.33 (-3.62, 0.96) 0.26 
EPBb 428 -0.20 (-0.55, 0.16) 0.28 440 0.06 (-0.30, 0.41) 0.75 330 -0.12 (-0.51, 0.26) 0.53 
MPB 610 2.24 (0.75, 3.73) 0.003** 625 0.56 (-0.91, 2.03) 0.45 475 1.03 (-0.59, 2.65) 0.21 
BPB 604 1.17 (-0.44, 2.79) 0.15 622 0.15 (-1.41, 1.72) 0.85 474 -0.13 (-1.91, 1.65) 0.89 
PPB 610 2.59 (0.97, 4.21) 0.002** 625 0.90 (-0.67, 2.46) 0.26 475 1.84 (0.02, 3.65) 0.05** 
 
Preterm Birth 
 Visit 1 (16-20 weeks) Visit 2 (20-24 weeks) Visit 3 (24-28 weeks) 
 N OR/IQR change (95% CI) p N OR/IQR change (95% CI) p N OR/IQR change (95% CI) p 
2,4-DCP 613 1.16 (0.83, 1.61) 0.38 624 0.85 (0.60, 1.21) 0.37 470 1.12 (0.74, 1.72) 0.59 
2,5-DCP 612 1.29 (0.92, 1.80) 0.14 624 0.99 (0.70, 1.39) 0.95 472 1.34 (0.93, 1.93) 0.11 
BPA 607 0.69 (0.45, 1.05) 0.09* 626 0.77 (0.51, 1.15) 0.20 470 0.98 (0.60, 1.60) 0.94 
BPFa 381 0.83 (0.41, 1.70) 0.62 381 1.30 (0.63, 2.67) 0.48 291 0.36 (0.15, 0.84) 0.02** 
BPS 422 1.07 (0.69, 1.66) 0.77 438 1.11 (0.71, 1.75) 0.64 329 0.98 (0.57, 1.69) 0.95 
BP-3 611 0.64 (0.42, 0.98) 0.04** 623 0.66 (0.43, 1.02) 0.06* 470 0.67 (0.41, 1.07) 0.10* 
TCS 609 0.98 (0.60, 1.58) 0.92 625 0.76 (0.46, 1.26) 0.29 476 0.77 (0.44, 1.36) 0.37 
TCC 426 1.71 (0.94, 3.10) 0.08* 437 1.61 (0.88, 2.94) 0.12 328 1.04 (0.51, 2.10) 0.92 
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EPBa 428 1.35 (0.69, 2.62) 0.38 440 0.79 (0.40, 1.54) 0.49 330 1.04 (0.46, 2.34) 0.93 
MPB 610 0.58 (0.38, 0.89) 0.01** 625 0.81 (0.53, 1.24) 0.34 475 0.75 (0.47, 1.19) 0.22 
BPB 604 0.75 (0.46, 1.21) 0.24 622 1.02 (0.65, 1.60) 0.92 474 0.95 (0.57, 1.59) 0.85 
PPB 610 0.51 (0.32, 0.80) 0.004** 625 0.76 (0.49, 1.18) 0.22 475 0.69 (0.42, 1.14) 0.15 
2,4-DCP: 2,4-dichlorophenol; 2,5-DCP: 2,5-dichlorophenol; BP-3: Benzophenone; TCS: Triclosan; TCC: Triclocarban; EPB: Ethyl-paraben; MPB: Methyl-
paraben; 
BPB: Butyl-paraben; PPB: Propyl-paraben 
a Models adjusted for specific gravity, maternal age, insurance type, alcohol use, and exposure to second-hand smoking. 
b Categorical variable.  
* 0.05 < p value < 0.10; ** p value < 0.05 
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Figure IV.1: Interaction effect of infant sex on the association between the average triclosan urinary 
concentration and gestational length. Female p value = 0.06. Male p value = 0.03. 
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Table IV.5: Adjusteda change in birth weight z-scores or odds ratios associated with average exposure biomarker concentration across three time 
points during pregnancy. Effect estimates presented as change or odds ratio for IQR increase in exposure biomarker concentration. 
  Birthweight z-scores 
 SGA  LGA 
 N Change in z-score (95% CI) p N OR/IQR change (95% CI) p N OR/IQR change (95% CI) p 
2,4-DCP 736 -0.02 (-0.13, 0.09) 0.70 662 1.32 (0.95, 1.84) 0.10 667 1.04 (0.74, 1.47) 0.82 
2,5-DCP 737 0.00 (-0.11, 0.10) 0.97 663 1.16 (0.84, 1.60) 0.36 668 1.11 (0.81, 1.54) 0.51 
BPA 736 -0.01 (-0.13, 0.11) 0.90 662 1.09 (0.75, 1.58) 0.66 667 0.94 (0.65, 1.36) 0.74 
BPFb 496 -0.09 (-0.30, 0.12) 0.39 444 1.00 (0.53, 1.89) 0.99 446 0.69 (0.36, 1.32) 0.26 
BPS 535 0.05 (-0.09, 0.20) 0.46 479 1.49 (0.97, 2.29) 0.07* 482 1.62 (1.06, 2.45) 0.02** 
BP-3 737 0.08 (-0.04, 0.20) 0.17 664 0.91 (0.62, 1.33) 0.63 668 1.38 (0.99, 1.93) 0.06* 
TCS 737 -0.09 (-0.24, 0.06) 0.26 663 1.70 (1.06, 2.73) 0.03** 668 0.91 (0.57, 1.46) 0.70 
TCC 539 -0.10 (-0.29, 0.09) 0.31 483 0.91 (0.50, 1.67) 0.77 486 1.04 (0.60, 1.81) 0.89 
EPBb 545 -0.06 (-0.26, 0.15) 0.58 489 1.57 (0.86, 2.89) 0.15 492 1.25 (0.68, 2.30) 0.47 
MPB 739 -0.01 (-0.12, 0.10) 0.88 665 0.66 (0.47, 0.93) 0.02** 670 0.92 (0.66, 1.30) 0.65 
BPB 734 0.11 (-0.05, 0.27) 0.16 660 0.50 (0.28, 0.88) 0.02** 666 1.02 (0.63, 1.65) 0.93 
PPB 740 0.01 (-0.11, 0.14) 0.85 666 0.61 (0.41, 0.91) 0.01** 671 0.96 (0.65, 1.41) 0.82 
2,4-DCP: 2,4-dichlorophenol; 2,5-DCP: 2,5-dichlorophenol; BP-3: Benzophenone; TCS: Triclosan; TCC: Triclocarban; EPB: Ethyl-paraben; MPB: Methyl-paraben; 
BPB: Butyl-paraben; PPB: Propyl-paraben 
a Models adjusted for specific gravity, maternal age, insurance type, alcohol use, and exposure to second-hand smoking. 
b Categorical variable. 
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Table IV.6: Adjusteda change in birth weight z-scores or odds in relation to exposure biomarker concentration, stratified by visit during pregnancy. 
Effect estimates presented as change or odds ratio for IQR increase in exposure biomarker concentration. 
 Birthweight 
  Visit 1 (16-20 weeks) Visit 2 (20-24 weeks) Visit 3 (24-28 weeks) 
  N Z-score change (95% CI) p N Z-score change (95% CI) p N Z-score change (95% CI) p 
2,4-DCP 603 -0.04 (-0.15, 0.08) 0.52 613 -0.01 (-0.12, 0.10) 0.88 462 -0.04 (-0.18, 0.10) 0.59 
2,5-DCP 602 -0.04 (-0.15, 0.08) 0.53 613 0.02 (-0.09, 0.13) 0.73 464 0.00 (-0.12, 0.13) 0.94 
BPA 597 0.01 (-0.12, 0.13) 0.92 615 0.05 (-0.07, 0.18) 0.41 462 -0.05 (-0.20, 0.10) 0.51 
BPFa 379 0.04 (-0.20, 0.28) 0.73 379 -0.20 (-0.43, 0.04) 0.10 289 -0.14 (-0.42, 0.14) 0.33 
BPS 418 0.08 (-0.07, 0.24) 0.28 433 0.03 (-0.13, 0.18) 0.73 325 0.02 (-0.15, 0.19) 0.80 
BP-3 601 0.06 (-0.06, 0.18) 0.31 612 0.10 (-0.02, 0.22) 0.12 462 0.06 (-0.07, 0.20) 0.35 
TCS 599 -0.02 (-0.17, 0.13) 0.79 614 -0.11 (-0.26, 0.04) 0.15 468 -0.03 (-0.20, 0.14) 0.76 
TCC 422 -0.11 (-0.31, 0.09) 0.28 432 -0.07 (-0.26, 0.13) 0.49 324 -0.02 (-0.23, 0.20) 0.88 
EPBa 424 -0.05 (-0.28, 0.17) 0.64 435 -0.08 (-0.30, 0.14) 0.46 326 -0.20 (-0.45, 0.05) 0.12 
MPB 600 0.03 (-0.10, 0.16) 0.67 614 -0.01 (-0.13, 0.12) 0.93 467 0.03 (-0.11, 0.18) 0.65 
BPB 594 -0.04 (-0.18, 0.11) 0.62 611 0.12 (-0.02, 0.26) 0.08* 466 0.11 (-0.04, 0.27) 0.15 
PPB 600 0.04 (-0.11, 0.18) 0.60 614 0.00 (-0.13, 0.14) 0.96 467 0.04 (-0.12, 0.20) 0.63 
  SGA 
  Visit 1 (16-20 weeks) Visit 2 (20-24 weeks) Visit 3 (24-28 weeks) 
 N OR/IQR change (95% CI) p N OR/IQR change (95% CI) p N OR/IQR change (95% CI) p 
2,4-DCP 530 1.15 (0.82, 1.60) 0.41 547 1.34 (0.96, 1.85) 0.08* 431 1.36 (0.90, 2.05) 0.14 
2,5-DCP 529 1.03 (0.73, 1.46) 0.87 547 1.24 (0.89, 1.72) 0.20 433 1.23 (0.86, 1.75) 0.25 
BPA 524 1.02 (0.71, 1.47) 0.90 549 1.07 (0.73, 1.55) 0.74 431 1.12 (0.74, 1.69) 0.59 
BPFa 444 1.00 (0.53, 1.89) 0.99 444 1.00 (0.53, 1.89) 0.99 444 1.00 (0.53, 1.89) 0.99 
BPS 369 0.91 (0.57, 1.46) 0.70 389 1.40 (0.89, 2.22) 0.14 304 1.82 (1.17, 2.84) 0.01** 
BP-3 528 1.07 (0.74, 1.55) 0.70 547 0.99 (0.67, 1.49) 0.98 431 0.69 (0.44, 1.08) 0.11 
TCS 526 1.44 (0.92, 2.26) 0.11 548 1.51 (0.95, 2.42) 0.08* 435 1.15 (0.69, 1.91) 0.60 
TCC 373 0.85 (0.46, 1.56) 0.59 389 1.06 (0.58, 1.94) 0.85 304 0.81 (0.43, 1.52) 0.51 
EPBa 489 1.57 (0.86, 2.89) 0.15 489 1.57 (0.86, 2.89) 0.15 489 1.57 (0.86, 2.89) 0.15 
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MPB 527 0.61 (0.42, 0.90) 0.01** 549 0.68 (0.45, 1.02) 0.06* 435 0.66 (0.43, 1.01) 0.06* 
BPB 522 0.76 (0.48, 1.20) 0.24 547 0.47 (0.26, 0.84) 0.01** 433 0.51 (0.28, 0.91) 0.02** 
PPB 527 0.58 (0.38, 0.91) 0.02** 548 0.81 (0.52, 1.27) 0.37 435 0.53 (0.32, 0.87) 0.01** 
  LGA 
 Visit 1 (16-20 weeks) Visit 2 (20-24 weeks) Visit 3 (24-28 weeks) 
 N OR/IQR change (95% CI) p N OR/IQR change (95% CI) p N OR/IQR change (95% CI) p 
2,4-DCP 535 1.06 (0.75, 1.50) 0.73 556 1.05 (0.76, 1.47) 0.76 425 1.07 (0.68, 1.68) 0.76 
2,5-DCP 534 1.02 (0.72, 1.45) 0.90 556 1.15 (0.83, 1.60) 0.39 427 1.06 (0.72, 1.56) 0.78 
BPA 529 0.85 (0.59, 1.24) 0.40 558 1.22 (0.86, 1.72) 0.26 425 0.88 (0.56, 1.40) 0.60 
BPFa 446 0.69 (0.36, 1.32) 0.26 446 0.69 (0.36, 1.32) 0.26 446 0.69 (0.36, 1.32) 0.26 
BPS 370 1.49 (0.99, 2.25) 0.06* 396 1.33 (0.88, 2.01) 0.18 299 1.46 (0.86, 2.49) 0.16 
BP-3 533 1.34 (0.96, 1.89) 0.09* 555 1.52 (1.09, 2.13) 0.01** 425 1.00 (0.67, 1.51) 0.98 
TCS 531 1.26 (0.81, 1.96) 0.31 557 0.77 (0.49, 1.22) 0.27 430 1.05 (0.61, 1.82) 0.85 
TCC 374 0.99 (0.55, 1.76) 0.97 395 1.10 (0.63, 1.91) 0.73 299 0.73 (0.37, 1.43) 0.36 
EPBa 492 1.25 (0.68, 2.30) 0.47 492 1.25 (0.68, 2.30) 0.47 492 1.25 (0.68, 2.30) 0.47 
MPB 532 1.02 (0.69, 1.50) 0.94 557 1.03 (0.69, 1.54) 0.88 430 0.99 (0.62, 1.56) 0.95 
BPB 527 0.88 (0.58, 1.35) 0.56 557 1.08 (0.72, 1.61) 0.72 428 1.21 (0.75, 1.95) 0.43 
PPB 532 1.09 (0.70, 1.70) 0.69 557 1.22 (0.81, 1.86) 0.34 430 0.91 (0.53, 1.55) 0.73 
2,4-DCP: 2,4-dichlorophenol; 2,5-DCP: 2,5-dichlorophenol; BP-3: Benzophenone; TCS: Triclosan; TCC: Triclocarban; EPB: Ethyl-paraben; MPB: Methyl-paraben; BPB: Butyl-paraben; PPB: 
Propyl-paraben 
a Models adjusted for specific gravity, maternal age, insurance type, alcohol use, and exposure to second-hand smoking. 
b Categorical variable. 
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Figure IV.2: Heat map of Spearman correlation coefficients of specific gravity corrected average triclocarban, phenol and paraben urinary 
biomarkers 
 
Table IV.7: Comparison of main effect estimates and p values of the two gestational length variables calculated as a sensitivity analysis. 
  Untransformed GA Transformed GA 
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 N β p-value β p-value 
2,4-dichlorophenol 748 0.01 0.92 -0.004 0.71 
2,5-dichlorophenol 749 -0.03 0.46 0.001 0.87 
BPA 748 0.14 0.17 -0.021 0.23 
BPS 540 -0.06 0.53 0.008 0.62 
BPF 500 -0.14 0.15 0.021 0.20 
BP-3 749 0.11 0.01** -0.018 0.01** 
Triclosan 749 0.0005 0.90 0.001 0.85 
Triclocarban 544 -0.07 0.08* 0.011 0.09* 
Ethyl-paraben 550 -0.01 0.82 0.003 0.70 
Methyl-paraben 751 0.12 0.01** -0.015 0.06* 
Butyl-paraben 746 0.02 0.52 -0.002 0.77 
Propyl-paraben 752 0.11 0.01** -0.015 0.03** 
 
Table IV.8: Comparing MLR results using continuous BPF and ethyl-paraben variables versus categorical BPF and ethyl-paraben variables 
  Continuous Variable Categorical Variable 
BPF Average -1.19 (-2.80, 0.42) 0.15 0.06 (-0.28, 0.41) 0.72 
 Visit 1 -1.20 (-2.61, 0.20) 0.09 0.12 (-0.27, 0.51) 0.55 
 Visit 2 0.42 (-0.84, 1.69) 0.51 -0.22 (-0.62, 0.18) 0.28 
 Visit 3 -1.18 (-2.75, 0.40) 0.14 0.24 (-0.19, 0.68) 0.27 
      
Ethyl-paraben Average -0.23 (-2.15, 1.69) 0.82 -0.11 (-0.44, 0.23) 0.53 
 Visit 1 0.61 (-1.20, 2.42) 0.51 -0.20 (-0.55, 0.16) 0.28 
 Visit 2 -0.86 (-2.40, 0.68) 0.28 0.06 (-0.3, 0.41) 0.75 
 Visit 3 0.32 (-1.31, 1.95) 0.70 -0.12 (-0.51, 0.26) 0.53 
 
Table IV.9: Beta coefficients of MLR and logistic regression models regressing birth outcomes against urinary exposure biomarkers with the 
addition of an interaction term between fetal sex and the urinary exposure biomarker 
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Gestational Age 
 N Main effect estimate p Fetal sex effect estimate p Interaction effect estimate p 
2,4-DCP 687 -0.058 0.54 -0.09 0.51 0.172 0.18 
2,5-DCP 688 -0.019 0.78 -0.104 0.70 0.012 0.90 
BPA 687 0.21 0.15 -0.026 0.89 -0.045 0.80 
BPFa 451 -0.112 0.44 -0.047 0.88 0.05 0.80 
BPS 488 0.059 0.68 -0.255 0.26 -0.133 0.49 
BP-3 688 0.075 0.19 -0.141 0.66 0.025 0.75 
TCS 688 -0.079 0.12 -0.669 0.01 0.194 0.006
** 
TCC 492 -0.034 0.57 -0.116 0.54 -0.044 0.56 
EPBa 498 -0.072 0.34 -0.267 0.16 0.102 0.30 
MPB 690 0.126 0.07 -0.04 0.93 -0.006 0.95 
BPB 685 0.048 0.41 -0.091 0.55 -0.038 0.63 
PPB 691 0.124 0.03 -0.058 0.82 -0.006 0.94 
  
Birth Weight 
 N Main effect estimate p Fetal sex effect estimate p Interaction effect estimate p 
2,4-DCP 683 0.032 0.57 0.016 0.85 -0.080 0.29 
2,5-DCP 684 0.051 0.21 0.193 0.24 -0.073 0.18 
BPA 683 0.018 0.84 -0.004 0.97 0.007 0.95 
BPFa 449 -0.140 0.39 -0.030 0.82 0.104 0.63 
BPS 486 0.069 0.43 0.044 0.75 0.012 0.92 
BP-3 684 0.053 0.13 0.122 0.53 -0.033 0.48 
TCS 684 -0.055 0.07 -0.138 0.38 0.048 0.26 
TCC 490 0.007 0.85 0.034 0.77 0.000 1.00 
EPBa 496 -0.219 0.18 -0.070 0.55 0.302 0.16 
MPB 686 -0.009 0.84 0.060 0.82 -0.014 0.80 
BPB 681 0.014 0.69 0.018 0.84 0.016 0.74 
PPB 687 -0.006 0.87 -0.017 0.91 0.006 0.90 
 
Small for Gestational Age 
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 N Main effect estimate p Fetal sex effect estimate p Interaction effect estimate p 
2,4-DCP 683 0.052 0.78 0.037 0.89 0.235 0.33 
2,5-DCP 684 -0.118 0.42 -0.631 0.23 0.285 0.11 
BPA 683 0.045 0.87 0.205 0.57 -0.106 0.76 
BPFa 449 0.345 0.50 0.243 0.57 -0.388 0.56 
BPS 486 0.124 0.65 0.060 0.89 0.100 0.78 
BP-3 684 -0.097 0.42 -0.239 0.70 0.107 0.50 
TCS 684 0.243 0.01 0.636 0.27 -0.141 0.30 
TCC 490 -0.117 0.32 -0.099 0.77 0.069 0.64 
EPBa 496 1.069 0.03 0.409 0.32 -1.092 0.10 
MPB 686 -0.108 0.44 0.643 0.41 -0.125 0.49 
BPB 681 -0.341 0.02 0.401 0.27 0.224 0.22 
PPB 687 -0.114 0.33 0.290 0.52 -0.062 0.68 
  
Large for Gestational Age 
 N Main effect estimate p Fetal sex effect estimate p Interaction effect estimate p 
2,4-DCP 683 0.032 0.85 -0.193 0.46 -0.067 0.78 
2,5-DCP 684 0.108 0.36 0.093 0.86 -0.111 0.50 
BPA 683 -0.292 0.28 -0.449 0.19 0.412 0.23 
BPFa 449 0.100 0.83 0.050 0.90 -0.622 0.35 
BPS 486 0.389 0.12 -0.175 0.64 -0.092 0.79 
BP-3 684 0.159 0.10 -0.190 0.76 -0.006 0.96 
TCS 684 -0.082 0.38 -0.320 0.51 0.049 0.72 
TCC 490 0.085 0.41 -0.036 0.92 -0.089 0.51 
EPBa 496 0.315 0.49 -0.004 0.99 -0.342 0.59 
MPB 686 -0.038 0.77 -0.449 0.59 0.061 0.74 
BPB 681 -0.107 0.34 -0.039 0.89 0.182 0.21 
PPB 687 -0.033 0.76 -0.525 0.29 0.121 0.42 
2,4-DCP: 2,4-dichlorophenol; 2,5-DCP: 2,5-dichlorophenol; BP-3: Benzophenone; TCS: Triclosan; TCC: Triclocarban; EPB: ethyl-paraben; MPB: Methyl-paraben; BPB: 
Butyl-paraben; PPB: Propyl-paraben 
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Figure IV.3: Conditional effect of the average triclosan concentration across the three study visits on gestational length, stratified by fetal sex. 
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Figure IV.4: Summary results of models regressing birth outcomes against average phenol, paraben and triclocarban.  
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 Interactions between Chemicals and Non-Chemical Stressors: 
The Modifying Effect of Life Events on the Association between 
Triclocarban, Phenols and Parabens with Gestational Length 
 
 
Abstract 
Background: Phenols, parabens and triclocarban are common additives to consumer products. 
There is evidence of adverse birth outcomes in association with prenatal exposure to phenols, 
parabens and triclocarban, as well as with psychosocial factors. Therefore, we examined the 
modifying effect of psychosocial stress on the association between chemicals and gestational 
length in 922 women among a cohort of pregnant women in Puerto Rico. Methods: Urinary 
triclocarban, phenols and parabens were measured at up to three time points in pregnancy (visit 
1: 16-20 weeks, visit 2: 20-24 weeks and visit 3: 24-28 weeks gestation). Four measures of 
psychosocial stress were collected to score depression, perceived stress, social support and life 
events. Only the life events score (LES) was a significant modifier. Multiple linear regression 
(MLR) models were conducted to investigate the association between gestational length and the 
interaction between each woman’s centered log average concentrations of exposure biomarkers 
and LES scores. MLR models regressing the exposure biomarkers in relation to gestational 
length were also stratified by Life Experiences Survey (LES), Negative LES and Positive LES 
scores, as well as by fetal sex. Results were transformed into the change in gestational length for 
an inter-quartile-range difference in the exposure. Results: Bisphenol-A, methylparaben and 
propyl paraben were associated with increase in gestational length, and triclocarban was 
associated with a decrease in gestational age. Associations between triclocarban, bisphenol S, 
methyl- and propyl-paraben in relation to gestational length were stronger among women with 
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negative Total LES scores. Among women with negative Total LES scores, bisphenol S and 
triclocarban were associated with a 3-5 day decrease in gestational length [(-3.15; 95% CI:-6.06, 
-0.24); (-4.68; 95% CI: -8.47, -0.89)], whereas methylparaben and propylparaben were 
associated with a 2-3 day increase in gestational length [(2.21; 95% CI: 0.02, 4.40); (2.92; 95% 
CI: 0.58, 5.26)]. Most interactions were driven by negative life events, but the association with 
triclocarban was driven by a lack of positive life events. Conclusions: Associations between 
exposure biomarkers and gestational length were stronger in the presence of negative life events. 
This provides evidence to the theory that stress makes the body more vulnerable to chemical 
exposure. Further research is required to substantiate these results.  
 Introduction 
Phenols and parabens are a group of chemicals commonly found in personal care products and 
household items, and exposure to these chemicals has been associated with a number of growth 
parameters at birth, including birth weight, birth length and gestational length [1–5]. We 
previously reported on associations between bisphenols, parabens and triclocarban with various 
birth outcomes in this cohort of pregnant women in Puerto Rico [6]. We found an increase in 
gestational length in association with benzophenone-3, bisphenol-A (BPA), and methyl- and 
propyl-paraben, and a decrease in gestational length in association with triclocarban. Bisphenol-
S (BPS) was associated with changes in birth size, depending on the timing of exposure.  
Maternal stress has also been associated with adverse birth outcomes. A population-based case 
control study reported a 60% increased odds of a very low birth weight infant among women 
who reported always feeling stressed as compared to women reporting no stress [7]. Likewise, 
other studies have reported a shortened gestational length with maternal stress or a larger number 
of negative life events [8–11]. The effects of maternal stress on the fetus also extend beyond 
pregnancy, and potentially cause long-term adverse effects on the cognitive, behavioral and 
psychomotor development of the child [12,13]. 
There is a growing interest in looking at the combined effect of stressors in the environment on 
human health. In addition to exploring the effect of chemical mixtures on health, interactions 
between chemical and non-chemical stressors are important to consider in deepening our 
understanding of how the environment impacts humans. Although this area of research is 
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relatively new and limited, evidence supports the notion of an increased risk of adverse effects 
with exposure to high concentrations of environmental chemicals and the modifying effect of 
high psychosocial stress levels. For example, a systematic review found the effect of chemical 
exposures, such as smoking and traffic pollution, in combination with high stress or socio-
economic stressors was associated with worse fetal growth parameters than with any of the 
chemical or socio-economic stressors on their own [14]. 
As a follow-up to our previous study, we examined the potential modifying effect of maternal 
stress on our associations between biomarkers of several common chemical exposures and 
gestational age. We tested this question using the Puerto Rico Testsite for Exploring 
Contamination Threats (PROTECT) project, a multi-disciplinary research center in Northern 
Puerto Rico that established a pregnancy cohort to investigate the role of environmental 
contamination in adverse birth outcomes. The analysis explored relationships between 
gestational length and the interaction between urinary concentrations of phenols, parabens and 
triclocarban, and psychosocial factors (depression, perceived stress, social support and life 
events). This Chapter focused on the exposure metabolites of interest based on our results from 
our previous analysis (benzophenone-3, BPA and BPS, triclocarban, methyl- and propyl-
paraben). 
 Methods 
Study Population 
The details of the study population were previously described. Briefly, participants for this study 
were from the PROTECT cohort, an ongoing prospective cohort of pregnant women recruited 
from two hospitals and five affiliated health clinics in Puerto Rico. The present analysis includes 
922 study participants recruited from 2011-2017 at 14 ± 2 weeks gestation. There were up to 
three study visits performed on each of the participants: visit 1 at 16-20 weeks gestation; visit 2 
at 20-24 weeks gestation; and, visit at 24-28 weeks gestation. These study visits coincided with 
routine clinical visits and rapid fetal growth. All demographic data was collected at visit 1, and 
questionnaires on psychosocial status were administered at study visits 2 and 3 (further details 
found below). Spot urine samples for urinary exposure biomarker measurement were collected at 
each of the three study visits. Women were excluded from the study if they: lived outside the 
region, had multiple gestations, used oral contraceptives within three months of getting pregnant, 
 135 
 
became pregnant through in vitro fertilization, or had any known medical health complications at 
time of recruitment (including diabetes, hypertension, etc.). This study was approved by the 
research and ethics committees of the University of Michigan School of Public Health, 
University of Puerto Rico, Northeastern University, and participating hospitals and clinics. All 
study participants provided full informed consent prior to participation. 
Urinary Biomarker Measurement 
Spot urine samples collected during the three study visits were divided into aliquots and frozen at 
-80oC. They were shipped overnight in dry ice to the Centers for Disease C for analysis. Samples 
were analyzed for seven phenols (2,4-dichlorophenol, and 2,5-dichlorophenol, BPA, BPS, BPF, 
benzophenone-3, triclosan), four parabens (ethyl-paraben, methyl-paraben, butyl-paraben and 
propyl-paraben) and triclocarban using online solid phase extraction-high-performance liquid 
chromatography-isotope dilution tandem mass spectrometry [15–17]. The sample size for BPS 
and triclocarban was smaller than for the other urinary biomarkers because they were added to 
the analytical panel mid-way through the study, and thus, only available on a subset of the 
cohort. Urinary specific gravity (SG) was measured using a digital handheld refractometer 
(AtagoCo., Ltd., Tokyo, Japan), and was used to account for urinary dilution. Samples below the 
limit of detection (LOD) were assigned a value of the LOD divided by √2 [18]. Urinary 
biomarkers were corrected for SG in preliminary analyses. For the purpose of clarity, this 
manuscript focuses on the exposure biomarkers associated with changes in birth outcomes from 
our previous analysis (Aker et al., 2018), which are benzophenone-3, BPA, BPS, triclocarban, 
methyl- and propyl-paraben.  
Psychosocial Scores 
The psychosocial status of study participants was determined via questionnaires. The 
questionnaire included questions from four instruments: 1) Center for Epidemiological Studies-
Depression (CES-D) [19]; 2) Perceived Stress Scale (PSS) [20]; 3) ENRICHD Social Support 
Instrument (ESSI) [21]; and, 4) Life Experiences Survey (LES) [22]. The CES-D, PSS and ESSI 
instruments were administered at 28 weeks gestation in the clinic, whereas the LES questionnaire 
was administered during the in-home study visit (20-24 weeks gestation). All questions were 
translated and administered in Spanish. As described below, new categorical psychosocial scores 
were created for statistical analyses. 
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The CES-D is a 20-item score that asks participants how they felt in the past week to determine 
their depression status. A score of ≥16 for CES-D is typically used to determine depression [23]; 
therefore CES-D was categorized into scores greater than or equal to 16 or below 16. 
The PSS is a 10-item score that aims to determine the participants’ perceived stress levels during 
the previous month. There is no established cut-off for PSS. Therefore, we set the cut-off for PSS 
at the 75% percentile (score of 28, maximum=49). A cut-off of 28 was also used previously used 
in the literature [24]. 
ESSI is a 7-item score that asks respondents how they currently feel with regards to the social 
support that they have. There is no established cut-off for ESSI; however, two recent studies 
used a cut-off of 18 for the ESSI score to define low social support [25,26]; therefore we used 
the same cut-off for our analyses. This population reported very high scores of social support, so 
a cut off of 18 also allowed us to establish a mathematically meaningful lower social support 
group. 
LES is a 38-item score that asks participants whether they experienced a list of events since 
becoming pregnant, and allows participants to rate how positive or negative they perceived the 
event to be on a scale of -3 to 3. The LES was categorized into three groups to take into account 
the negative and positive scores. The cut-off points were below -1, between -1 and 1, and above 
1 (labelled “negative”, “neutral” and “positive”). Two more scores were calculated from the LES 
score. A Positive LES score was calculated to include only life events scored > 0, and a Negative 
LES score was calculated to include only life events scored < 0. The categories for Positive and 
Negative LES scores were created to have a sufficient number of participants per group. The cut-
offs were scores below 2, between 2 and 5, and above 5 (labelled “low”, “medium”, and “high”).  
Gestational Age Calculation 
The American College of Gynecologists (ACOG) recommendations were used for the 
gestational length calculation of complete pregnancies [27]. In brief, ACOG recommends 
determining gestational length using either information from the first ultrasound or the last 
menstrual cycle date (LMP), depending on two cutoffs: 1) how far along the pregnancy the 
ultrasound was conducted, and 2) the difference in the estimated date of delivery (EDD) 
calculated from the LMP and from the ultrasound. Further details on this calculation can be 
found in the ACOG Committee Opinion document [27].  
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Statistical Analyses 
A detailed description of the preliminary analyses conducted for exposure biomarkers, 
gestational length, and important covariates can be found in CHAPTER IV. Briefly, after 
distributions of key demographic characteristics were calculated, multiple linear regressions 
(MLR) were conducted to examine associations between gestational length and each average 
exposure biomarker. We re-ran the bivariate analyses on the potential covariates and urinary 
exposure biomarkers, stratified by Total LES scores. To compare the differences in frequencies 
of categorical variables across the LES categories, we used the Chi square test. The continuous 
variables (age and urinary exposure biomarkers) were not normally distributed; therefore, to 
compare the continuous variables in the groups, we calculated the Mann–Whitney U test. 
Following this, we conducted univariate analysis on the four psychosocial scores we had 
available. The mean, median and select percentiles were calculated for each of the scores. In 
addition, the frequency of each life event was calculated in the case of LES. 
We constructed multiple linear regression (MLR) models to investigate associations between 
each categorical psychosocial score and gestational length. There was no evidence of non-
linearity after the addition of penalized and smoothing splines, so we constructed MLR models 
to regress the interaction between each mean-centered log average urinary exposure biomarker 
concentration and each categorical psychosocial score in relation to gestational length. The 
average urinary exposure biomarker concentration was calculated using the urinary exposure 
biomarker concentrations across the three study visits. In the case of a missing value at one of the 
study visits, the average was taken of the two remaining concentrations. In the case of two 
missing concentrations, the “average” phenol or paraben concentration was equal to the available 
concentration. Crude analyses included only the average specific gravity as a covariate in 
addition to the urinary biomarker and psychosocial score. We maintained a covariate if it 
changed the main effect estimate by >10%. Final models were controlled for the following 
confounders: specific gravity, maternal age, insurance type, alcohol use, and self-reported 
exposure to second-hand smoking.  
An interaction between a biomarker and a psychosocial parameter was considered of interest if 
the p value was less than 0.10. Only interactions with LES variables resulted in p values below 
0.10; therefore, the remainder of the analyses focused on interactions between biomarkers of 
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exposure and the Total LES, Positive LES and Negative LES scores. To better interpret the 
interaction results, the MLR models were stratified by LES categories. To study the effect of 
infant sex, we further stratified the MLR models by infant sex. All effect estimates from MLR 
models were transformed to the change in gestational length in relation to the interquartile range 
(IQR) increase in urinary biomarker concentrations. The alpha level was set at 0.05 for stratified 
analysis. All statistical analyses were conducted in R Version 3.4.2. 
As a sensitivity analysis, we included Positive LES scores as a covariate in models for Negative 
LES scores, and included Negative LES scores as a covariate in models for Positive LES scores. 
There were no differences in the results with the addition of these covariates. Second, we 
restricted our analysis to women with data from only one study visit, only two study visits, and 
all three study visits. The sample sizes in each group were too small to detect significant 
interactions, but the directions of the associations remained the same. Based on this, and the high 
intra-class correlation values, we proceeded with our calculation of the average exposure 
biomarker as described above.  
 Results 
Our study population included a total of 908 pregnant women with gestational length data. Table 
V.1 presents demographic characteristics of the study population stratified by Total LES scores.  
The study population was on average 26 years of age; over half had BMI levels <25; 3% were 
current smokers; 11% were exposed to second-hand smoking for at least 1 hour a day; and, 
approximately 20% were single. Women with overall positive Total LES scores were generally 
younger (25 years versus 27 years) and less likely to have more than one more child, whereas 
women with overall negative Total LES scores were more likely to be current smokers (4.9% 
versus 2%).  
Of the 38 life events included in the LES questionnaire, 14 life events were experienced by at 
least 10% of the study participants (Table V.2). Half of the participants experienced changes in 
eating and sleeping habits. Approximately 25% experienced mean negative changes in social and 
recreational activities, a mean negative change in financial status, and a mean positive change in 
personal achievements. Ten percent experienced an illness and/or death of a close family 
member. No psychosocial variables were associated with gestational length, and all p-values 
exceeded 0.50 (Table V.6). None of the interaction terms between any of the urinary biomarkers 
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and CES-D, PSS and ESSI were statistically significant (Table V.7). Therefore, the remainder of 
this manuscript focuses on the results of the interaction between phenol, paraben and triclocarban 
concentrations with Total LES, Positive LES and Negative LES on gestational length.  
In a previous study, we observed 1-2 day increases in gestational length in relation to urinary 
benzophenone-3, BPA, methyl-paraben and propyl-paraben, as well as a 2 day decrease in 
gestational length in relation to urinary triclocarban (Table V.3). Error! Reference source not 
found. shows the results of the MLR models regressing these urinary exposure biomarkers 
against gestational length when stratified by Total LES categories. There was a general linear 
trend across the Total LES categories such that the strongest associations between the urinary 
biomarker and gestational length were among women with negative Total LES scores, which the 
exception of BPA where no trends emerged. Among women with overall positive Total LES 
scores, associations between the urinary biomarkers and gestational length were largely not 
statistically significant (Table V.8). When treated as an ordinal variable, the interaction between 
Total LES and BPS, triclocarban and propylparaben was statistically significant (Table V.7).  
BPS and triclocarban were associated with a 3-5 day decrease in gestational length among 
women with negative Total LES scores [(-3.15 change in gestational length days per IQR 
increase in phenol or paraben (Δ); 95% CI:-6.06, -0.24); (Δ -4.68; 95% CI: -8.47, -0.89), 
respectively], whereas methylparaben and propylparaben were associated with a 2-3 day increase 
in gestational length among women with negative Total LES scores [(Δ 2.21; 95% CI: 0.02, 
4.40); (Δ 2.92; 95% CI: 0.58, 5.26), respectively]. As compared to the neutral Total LES scores, 
the association between BPS and gestational length was suggestively different among women 
with negative LES scores (p value = 0.06). Although BPS was not independently associated with 
gestational length, the strength of the interaction between LES and BPS, as well as the linear 
trend observed across the Total LES categories lend confidence to these results. Nevertheless, 
these associations should be interpreted with caution. Associations between benzophenone-3 and 
gestational length remained unchanged across any of the LES categories (not shown). 
Figure V.2 shows the MLR results stratified by Negative LES scores. No clear patterns emerged, 
although associations between BPA, methylparaben and propylparaben and gestational length 
were strongest among women with Negative LES scores in the medium category. The 
association between BPS and gestational length was not statistically significant in any of the 
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Negative LES categories; however, the 2 day decrease in gestational length among women with 
medium Negative LES was statistically different compared to the change in gestational length 
among women in the low Negative LES category (p value = 0.08).  
Figure V.3 shows the MLR results stratified by Positive LES scores. There was a strong 
association between triclocarban and reduced gestational length among women with low Positive 
LES scores (Δ -4.58; 95% CI: -7.70, -1.46). Given the lack of significant associations between 
triclocarban and gestational length when the results were stratified by Negative LES scores, this 
association could indicate that the relationship between triclocarban and gestational length 
among women with negative Total LES scores is driven by the lack of positive life events, rather 
than the presence of negative life events. Methylparaben and propylparaben (Spearman 
correlation = 0.78; Aker et al, 2018) were significantly associated with gestational length among 
women with low Positive LES scores; however, these associations were also observed among 
women with high Positive LES scores. 
After stratification by fetal sex, the associations with parabens discussed above were only 
observed in girls, and had larger magnitudes (Table V.9). For example, propylparaben was 
associated with a 4.7 day increase in gestational length among women with negative Total LES 
scores and female pregnancies (Δ 4.66; 95% CI: 1.53, 7.80). On the other hand, associations with 
BPA and BPS were only observed among males. For example, BPS was associated with a 5-day 
decrease in gestational length among women with negative Total LES scores and male 
pregnancies (Δ-5.06; 95% CI: -9.4, -0.72), and BPA was associated with a 3 day increase in 
gestational length among women with medium Negative LES scores carrying males (Δ 3.43; 
95% CI: 0.29, 6.57). However, the sample sizes for each group in this analysis were relatively 
small (60-90 women), so caution must be taken when interpreting these results.  
 Discussion 
Women with negative Total LES scores had strong associations between some exposure 
biomarkers and gestational length, especially in the case of BPS, triclocarban, methylparaben 
and propylparaben. The inverse association between triclocarban and gestational length was 
strongest among women with low Positive LES scores, suggesting a protective effect of positive 
life events against the impact of triclocarban on pregnancy duration. Fetal sex may also add 
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another layer of complexity, given that associations with parabens were stronger among female 
pregnancies, and associations with bisphenols were stronger in male pregnancies.    
Life events, a proxy for measuring maternal stress, have been linked to adverse birth outcomes 
[8–10,28–30]. However, in our population, LES scores were not associated with gestational 
length in adjusted models. This indicates that experiencing negative life events, and thus 
experiencing stress, may not be sufficient to illicit an adverse effect. It was only the combination 
of overall negative LES scores and higher concentrations of exposure biomarkers that we 
observe changes in gestational length of up to five days.  
An allostatic load framework could help describe the potential biological mechanisms at play. 
The allostatic load refers to the wear and tear of stress on the body, wherein the allostatic load 
increases as the body copes with stressors [31,32]. Olson et al. [33] use this framework to predict 
preterm birth risk. In their study, they prescribe to a “two-hit” theory whereby each “hit” or 
stressor cumulatively leads to changes in the complex mechanisms involved in parturition, 
potentially leading to a tertiary outcome with an increased number of “hits”. Rat dams were 
exposed to both stress and the pro-inflammatory cytokine, IL-1β. Even though neither stressor 
elicited a response on their own, the combined effect led to preterm birth in the rats. Thus, our 
results could be described under this framework, where the first “hit” may be maternal stress, 
and the second “hit” is the chemical exposure. When only one of our stressors was present in the 
model (LES or exposure biomarker), a small or no effect was observed on gestational length, but 
the interaction of the two led to changes in parturition and gestational length, consistent with a 
“two-hit” mechanism.  
Allostatic load assessments use a variety of physiological biomarkers, including inflammation 
and hormonal markers. The prevailing theory on the mechanism between maternal stress and 
gestational length is hypothesized to occur via the maternal-placental-fetal hypothalamic-
pituitary-adrenal (HPA) axis or inflammatory responses [11,12,34,35]. Maternal stress’ influence 
on the maternal HPA axis stimulates cortisol production via corticotropin-releasing hormone 
(CRH) [34]. Cortisol concentration is an important physiological marker because higher levels of 
maternal cortisol are linked to increased intrauterine constriction and preterm birth [36–38].  
CRH also stimulates the release of prostaglandins and inflammatory responses in the maternal-
placental-fetal systems, thereby preparing women for labor and stimulating myometrial 
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contractions [39–41]. In fact, women in preterm labor have higher levels of CRH compared to 
gestational age-matched women, as well as accelerated rates of CRH over the course of their 
gestation [41,42]. So it is possible that through this mechanism, an increase in CRH levels from 
maternal stress could lead to an earlier parturition. Elevated levels of circulating CRH in the 
early third trimester were reported among women with high perceived stress levels [43,44]. In 
addition, our team previously reported an increase in CRH in association with methyparaben and 
propylparaben, and a decrease in CRH in association with BPS in the PROTECT cohort (Aker et 
al., in press). However, the direction of these associations are in the opposite direction of what 
one would expect to cause an increase or decrease in gestational length, respectively. While our 
previous analyses on exposure-hormone associations provide valuable insight on the potential 
mechanisms leading to adverse outcomes, our models did not adjust for diurnal hormone changes 
within women. Hormone levels vary greatly throughout the day, and we not controlling for these 
changes in our models may describe some of the unexpected directions of associations observed 
in this study.  
In addition to the effects CRH has on prostaglandins and inflammatory mediators, chronic stress 
leads to inhibition of the hypothalamic-pituitary-adrenal axis. During chronic stress, prolonged 
periods of elevated levels of circulating cortisol inhibit hypothalamic production of thyroid 
stimulating hormone (TSH), leading to a decreased release of TSH from the pituitary gland, and 
subsequent decreased release of thyroxine (T4) from the thyroid. Furthermore, CRH inhibits 
conversion of thyroxine (T4) to the bioactive triiodothyronine (T3) [45,46]. However, these 
effects depend on the duration and intensity of the stressor [45]. In one study, decreased levels of 
FT4 was associated with higher rates of perinatal syndromal depression [47], which may be a 
result of decreased release of T4. There is evidence that circulating levels of thyroid hormones, 
particularly decreased FT4 and increased T3, are associated with preterm birth [48]. Our 
previous analysis found associations between urinary concentrations of BPA and triclocarban 
and an increase in T3 (Aker et al., in press). Thus, decreased FT4 levels from depression or high 
stress may be the first hit, and the increase in T3 from TCC could be the second hit, leading to a 
shortened gestational length. BPA was also associated with an increase in FT4, which may 
explain why we do not observe a shortened gestational length in this case.   
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Besides the neuroendocrine pathway, a potential mechanism of action could be via inflammatory 
responses. Some stressful life events during pregnancy were suggestively associated with 
elevated levels of 8‐iso‐PGF2α (an oxidative stress marker) measured at a median of 32 weeks 
[49]. Additionally, chronic stress is related to immunosuppression and changes in the response to 
antigens [50], which is related to a decreased gestational age at birth. Exposure to some phenol 
and parabens have also been associated with oxidative stress and inflammatory biomarkers, 
including BPA and propylparaben [17,51]. In summary, we suggest several pathways that could 
lead to an increase in allostatic load with the combined effect of chemical exposure and maternal 
stress, including: 1) a direct effect on cortisol; 2) a direct effect on CRH; 3) an indirect effect on 
thyroid hormones via CRH and cortisol; and 4) a direct effect on inflammatory responses.  
Our results also showed a difference in the associations by fetal sex. Although our sample sizes 
were too small to interpret these findings confidently, a difference in the effects by sex is 
plausible. Because both estrogens and androgens play a role in the regulation of the HPA axis via 
modulation of the adrenal, anterior pituitary and hypothalamic functions [52], it is possible that 
fetal reproductive hormones could impact the levels of placental CRH, thereby leading to 
adverse effects on gestational length that differ by fetal sex. Furthermore, placental CRH 
production can be suppressed by estrogen [53]. This further demonstrates the complexity of the 
effects of stress and chemicals on gestational length, given the additional importance of fetal sex.  
The association between triclocarban and gestational length appeared to be influenced by a lack 
of positive life events more so than an excess of negative life events. This is consistent with the 
literature that suggests positive life events and perceived social support may act as a buffer to 
stress and negative events [54]. For example, positive life events were correlated with lower 
salivary cortisol levels among a group of 60 pregnant women, while negative life events were not 
[55].  
We did not observe any interactions between exposure biomarkers and other psychosocial 
scores. One reason may be due to the different timing the scores attempt to capture. The ESSI 
score asks participants how they currently feel; the CES-D score asks participants how they felt 
in the past week, the PSS score focuses on the previous month, and LES pertains to events since 
becoming pregnant. While the scores are dependent on each other given they include similar 
questions, it is interesting to note that the only significant interactions we observed included the 
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psychosocial score that has the widest time frame and would presumably include the least 
subjective questions, LES.   
We did not identify other studies that have investigated the same associations as this study. We 
did, however, identify a study that looked at the combined effect of phthalate exposure and 
stressful life events on the anogenital distance (AGD) among over 700 women in a well-educated 
cohort based in four medical centers across the U.S. [56]. The study found that among boys, 
prenatal exposure to stressful life events modified the association between first trimester di(2- 
ethylhexyl) phthalate (DEHP) metabolite concentrations and altered genital measurements, such 
that the association between DEHP and altered genital measurements was only significant among 
mothers with low stress (and not high stress). While our results are not directly comparable, both 
studies support further exploration of the effect of chemical and non-chemical stressors on 
perinatal health. 
While our study is among the first to explore the effects of endocrine disruptors in addition to 
psychosocial variables, there were a few limitations. The timing of maternal stress could 
influence the effect on the fetus [44]; however, we do not have precise data on when the life 
event took place apart from happening sometime between the beginning of pregnancy and the 
second study visit (20-24 weeks gestation). Similarly, we have no data on the participants’ 
psychosocial profiles past the second study visit. Evidence also suggests that the type of life 
event is an important factor to consider (i.e. a family death versus changes in diet), rather than 
combining all life events as equal in magnitude and/or importance [30,49]. However, because 
our LES scores allowed the participant to rate how positive or negative the event was, this 
limitation is unlikely to have greatly affected our results. While our analysis used urinary 
exposure biomarker data from three time points, our analyses still resembles a cross-sectional 
study in this context. In addition, we constructed multiple models in this exploratory study, 
which increases the risk of Type 1 error.  
Our study also had many strengths. Our large sample size allowed us to explore the modifying 
effects of both psychosocial variables and fetal sex. We also had data on a total of four 
psychosocial scores, which allowed us to capture different methods of exploring stress during 
pregnancy. Most studies that examine the effect of life events focus solely on negative life 
events. However, our study shows the importance of both negative and positive life events, and 
 145 
 
our most consistent results were based on the Total LES scores rather than the Negative and 
Positive LES scores separately. Furthermore, our urinary exposure biomarker panel included 
BPS and triclocarban which have not been studied in detail to date. Our cohort also has higher 
levels of triclocarban as compared to other populations [57], allowing us to study the association 
between this biomarker, maternal stress, and gestational length in a vulnerable population. 
  Conclusion 
This study is one of the first to examine the effect of chemical exposure in the presence of 
maternal stress. Associations were stronger in the presence of negative life events, and positive 
events had some protective effect on the association between exposure biomarkers and 
gestational length. This indicates that stress makes the body more vulnerable to the effects of 
chemical exposure. Pregnancy is a stressful period in a woman’s life, and the increased 
vulnerability to chemical exposure could have adverse effects on her and the fetus. More 
research is required to verify these associations. 
 
 
Table V.1: Summary demographics of the 908 pregnant women in the study population stratified by Total 
LES Scores 
 
Total 
Negative Neutral Positive 
p Total LES 
Score 
Total LES 
Score 
Total LES 
Score 
N 908 330 272 306  
Maternal Age (median [IQR]) 
26 [22.00, 
31.00] 
27 [23.00, 
31.00] 
27 [22.00, 
31.00] 
25 [21.00, 
29.00] 
<0.001 
BMI (%)                0.16 
0-25 419 (56.5) 151 (54.9) 118 (53.6) 150 (61)  
25-29.9 200 (27.0) 84 (30.5) 57 (25.9) 59 (24)  
>29.9 122 (16.5) 40 (14.5) 45 (20.5) 37 (15)  
Insurance type (%) 
    0.71 
Mi Salud 586 (63.3) 216 (65.5) 180 (66.2) 190 (62.1)  
Private 322 (36.7) 114 (35.5) 92 (36.1) 116 (38.5)  
Household Income (%) 
    0.91 
<10,000 229 (29.5) 89 (31) 69 (29.4) 71 (28)  
10,000-30,000 244 (31.4) 87 (30.3) 70 (29.8) 87 (34.3)  
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30,000-50,000 182 (23.5) 68 (23.7) 55 (23.4) 59 (23.2)  
>50,000 121 (15.6) 43 (15) 41 (17.4) 37 (14.6)  
Maternal Education (%) 
    0.78 
<High School/GED 185 (20.6) 68 (20.7) 57 (21.4) 60 (19.9)  
Some College 324 (36.2) 124 (37.8) 88 (33.1) 112 (37.1)  
College graduate 387 (43.2) 136 (41.5) 121 (45.5) 130 (43)  
Smoking (%) 
    0.02 
Never 752 (83.7) 269 (82) 237 (88.4) 246 (81.5)  
Ever 118 (13.1) 43 (13.1) 25 (9.3) 50 (16.6)  
Current 28 ( 3.1) 16 (4.9) 6 (2.2) 6 (2)  
Exposure to second hand smoking (%)    0.86 
None 769 (88.4) 278 (87.1) 232 (89.9) 259 (88.4)  
Up to 1 hour 44 ( 5.1) 19 (6) 11 (4.3) 14 (4.8)  
More than 1 hour 57 ( 6.6) 22 (6.9) 15 (5.8) 20 (6.8)  
Alcohol Consumption (%) 
    0.15 
None 454 (50.8) 165 (50.6) 148 (55.4) 141 (46.8)  
Before pregnancy 380 (42.5) 136 (41.7) 108 (40.4) 136 (45.2)  
Yes within the last few months 60 ( 6.7) 25 (7.7) 11 (4.1) 24 (8)  
Marital Status (%)         0.09 
Single 178 (19.8) 63 (19.2) 48 (17.9) 67 (22.1)  
Married 510 (56.7) 186 (56.7) 168 (62.7) 156 (51.5)  
Divorced 11 ( 1.2) 7 (2.1) 1 (0.4) 3 (1)  
Living together 200 (22.2) 72 (22) 51 (19) 77 (25.4)  
Number of previous children (%)       0.002 
0 430 (47.9) 142 (43.3) 118 (44) 170 (56.5)  
1 358 (39.9) 143 (43.6) 108 (40.3) 107 (35.5)  
>1 109 (12.2) 43 (13.1) 42 (15.7) 24 (8)  
P values calculated from Chi squared test for categorical variables and Kruskal test for continuous variables. 
Totals may not add up to 100% due to missing values. 
 
 
Table V.2: Life events that occurred in at least 10% of the study population and their mean scores 
Life Event N (%) Mean score 
Drastic change in eating habits  463 (51.9) 0.21 
Drastic change in sleeping habits  462 (51.7) -0.52 
Major change in social activities  246 (27.6) -0.29 
Change in amount/type recreation  231 (25.9) -0.35 
Change in financial status  215 (24.1) -0.39 
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Successful personal achievement  211 (23.7) 1.16 
Change in number of discussions with spouse  192 (21.5) -0.70 
Change in church activities  150 (16.8) 0.37 
Change in proximity to family member  149 (16.7) 0.65 
Moved to a new location  163 (15.6) 1.55 
Changes in the workplace  127 (14.2) -0.14 
Changes in spouse's workplace  127 (14.2) 0.22 
Death of a close family member  95 (10.7) -1.70 
Illness in a close family member  91 (10.2) -1.56 
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Figure V.1: Adjusted change in gestational length in relation to average mean-centered exposure biomarker concentration across three time points 
during pregnancy, stratified by Total LES. Beta coefficients were transformed to change in gestational days for an IQR increase in exposure 
biomarker concentration. The star represents a statistically significant interaction as compared to the Neutral category. 
 149 
 
 
Figure V.2: Adjusted change in gestational length in relation to average mean-centered exposure biomarker concentration across three time points 
during pregnancy, stratified by Negative LES. Beta coefficients were transformed to change in gestational days for an IQR increase in exposure 
biomarker concentration. The star represents a statistically significant interaction as compared to the Low category. 
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Figure V.3: Adjusted change in gestational length in relation to average mean-centered exposure biomarker concentration across three time points 
during pregnancy, stratified by Positive LES. Beta coefficients were transformed to change in gestational days for an IQR increase in exposure 
biomarker concentration.  The star represents a statistically significant interaction as compared to the Low category. 
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Table V.3: Adjusteda change in gestational age in relation to average exposure biomarker concentration 
across three time points during pregnancy. Beta coefficients were transformed to change in gestational 
days for an IQR increase in exposure biomarker concentration. 
  N Change in days/IQR (95% CI) p 
BPA 748 0.98 (-0.41, 2.37) 0.17 
BPS 540 -0.52 (-2.14, 1.09) 0.53 
Benzophenone-3 749 1.90 (0.54, 3.26) 0.006** 
Triclocarban 544 -1.96 (-4.11, 0.19) 0.08* 
Methyl-paraben 751 1.63 (0.37, 2.89) 0.01** 
Propyl-paraben 752 2.06 (0.63, 3.48) 0.005** 
a Models adjusted for specific gravity, maternal age, insurance type, alcohol use, and exposure to second-hand smoking.  
* 0.05 < p value < 0.10; ** p value < 0.05 
 
Table V.4: SG-corrected urinary bisphenol, paraben and triclocarban biomarker concentrations (µg/mL) 
from all three study visits stratified by Total LES Scores 
 
Negative  
Total LES Score 
Neutral  
Total LES Score 
Positive  
Total LES Score 
p 
N 330 272 306  
 Median [IQR] Median [IQR] Median [IQR]  
BP-3 40.92 [14.64, 148.37] 30.05 [11.97, 159.75] 30.81 [12.25, 125.58] 0.25 
BPA 2.39 [1.42, 4.05] 2.23 [1.49, 3.52] 2.02 [1.31, 3.65] 0.33 
BPS 0.55 [0.30, 1.10] 0.45 [0.27, 0.99] 0.54 [0.25, 0.94] 0.43 
TCC 5.75 [0.60, 41.01] 3.27 [0.60, 31.31] 3.38 [0.63, 27.33] 0.62 
MPB 119.18 [38.93, 261.22] 108.46 [35.33, 257.22] 119.26 [43.58, 287.11] 0.63 
PPB 30.64 [5.95, 76.28] 24.15 [5.13, 81.62] 27.38 [7.89, 81.07] 0.74 
 
BP-3: Benzophenone; TCC: Triclocarban; MPB: Methylparaben; PPB: Propylparaben 
 
 
Table V.5: Specific gravity corrected ICC values across the three study visits for PROTECT phenol, 
paraben and triclocarban concentrations 
 SG-corrected ICC 95% CI 
BPA 0.26 (0.20, 0.32) 
BPS 0.17 (0.10, 0.24) 
Benzophenone-3 0.65 (0.61, 0.69) 
Triclocarban 0.74 (0.70, 0.77) 
Methyl-paraben 0.51 (0.46, 0.56) 
Propyl-paraben 0.48 (0.44, 0.53) 
 
Table V.6: Adjusted change in gestational length in relation to categorical psychosocial variables. Beta 
coefficients are untransformed.  
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N β 95% CI () p 
LES 835 -0.09 (-0.41, 0.23) 0.58 
Negative LES 835 -0.028 (-0.34, 0.29) 0.86 
Positive LES 835 -0.098 (-0.48, 0.28) 0.62 
CES-D 835 0.19 (-0.25, 0.63) 0.39 
SS 753 -0.103 (-0.83, 0.62) 0.78 
PSS 758 0.043 (-0.24, 0.33) 0.77 
Models were adjusted for maternal age, insurance type, smoking status and alcohol consumption. 
 
 
 
Figure V.4: Heat map of Spearman correlation coefficients of specific gravity corrected average 
triclocarban, phenol and paraben urinary biomarkers 
 
Table V.7: Adjusteda change in gestational length in relation to mean-centered average exposure 
biomarker concentration across three time points during pregnancy, and the interaction between exposure 
biomarkers and categorical psychosocial scores. 
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Biomark
er 
N Exp β p Int β p N Exp β p Int β p 
 CES-D PSS 
BP-3 670 0.10 0.04 -0.01 0.93 693 0.08 0.08 0.06 0.46 
BPA 668 0.11 0.33 0.06 0.75 692 0.06 0.56 0.30 0.14 
BPS 484 -0.12 0.27 0.33 0.08* 503 0.01 0.95 -0.06 0.77 
TCC 487 -0.07 0.11 0.00 0.97 506 -0.04 0.31 -0.09 0.30 
MPB 671 0.06 0.30 0.07 0.48 694 0.05 0.35 0.15 0.14 
PPB 672 0.05 0.27 0.05 0.54 695 0.06 0.21 0.09 0.28 
 SS LES 
BP-3 689 0.00 0.98 0.11 0.64 749 0.09 0.35 0.01 0.84 
BPA 687 -0.17 0.76 0.31 0.57 748 0.31 0.17 -0.09 0.41 
BPS 498 -0.43 0.53 0.42 0.54 540 -0.54 0.02 0.23 0.03** 
TCC 502 -0.20 0.49 0.15 0.61 544 -0.25 0.01 0.09 0.03** 
MPB 689 -0.05 0.85 0.14 0.60 751 0.27 0.03 -0.07 0.19 
PPB 690 -0.08 0.73 0.16 0.47 752 0.30 0.00 -0.09 0.05** 
 Negative LES Positive LES 
BP-3 749 0.11 0.35 0.00 0.96 749 0.10 0.26 0.01 0.88 
BPA 748 0.20 0.42 -0.03 0.79 748 0.07 0.74 0.04 0.69 
BPS 540 -0.42 0.13 0.16 0.17 540 -0.30 0.14 0.15 0.18 
TCC 544 -0.02 0.85 -0.02 0.65 544 -0.28 0.00 0.14 0.003** 
MPB 751 0.20 0.14 -0.03 0.54 751 0.21 0.05 -0.05 0.37 
PPB 752 0.18 0.09 -0.03 0.46 752 0.16 0.07 -0.03 0.57 
Exp β: effect estimate of the urinary biomarker; Int β: effect estimate of the interaction term between the urinary biomarker 
and psychosocial variable 
BP-3: Benzophenone; TCC: Triclocarban; MPB: Methylparaben; PPB: Propylparaben 
Cutoff points for psychosocial scores are as follows: 16 for CES-D; 28 for PSS; 25 for SS; -1 & 1 for LES;  
-5,-2 for Negative LES; 2,5 for Positive LES.  
Interaction β and p values assume linearity between psychosocial categories. 
** p value <0.05; * 0.05<p value<0.10. 
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Table V.8: Adjusteda change in gestational length in relation to average exposure biomarker concentration across three time points during 
pregnancy, stratified by LES variables. Beta coefficients were transformed to the change in the number of gestational days per IQR change in 
exposure biomarker concentration. 
 LES 
 Score: < -1 Score: (-1, 1] Score: > 1 
 N GA Change 95% CI () p N GA Change 95% CI () p N GA Change 95% CI () p 
2,4-DCP 277 0.45 (-1.23, 2.13) 0.60 219 0.19 (-1.96, 2.34) 0.86 252 -0.97 (-3.31, 1.36) 0.41 
      0.99     -     0.23 
2,5-DCP 276 -0.68 (-2.61, 1.25) 0.49 220 0.02 (-2.31, 2.34) 0.99 253 -0.74 (-2.88, 1.39) 0.50 
      0.52     -     0.40 
BP-3 279 0.85 (-1.29, 2.99) 0.44 219 2.50 (-0.24, 5.24) 0.08 251 1.92 (-0.36, 4.20) 0.10 
      0.39     -     0.51 
BPA 279 1.09 (-1.11, 3.29) 0.33 220 2.08 (-0.41, 4.57) 0.10 249 -0.30 (-2.55, 1.96) 0.80 
      0.25     -     0.05* 
BPS 194 -3.15 (-6.06, -0.24) 0.04 161 -0.54 (-3.82, 2.74) 0.75 185 1.62 (-0.96, 4.20) 0.22 
      0.06*     -     0.86 
BPF 178 -0.58 (-1.19, 0.03) 0.06 144 0.19 (-0.48, 0.85) 0.58 178 0.36 (-0.20, 0.92) 0.21 
      0.17     -     0.56 
TCS 277 1.47 (-1.47, 4.40) 0.33 221 -0.46 (-3.88, 2.95) 0.79 251 -1.32 (-4.23, 1.58) 0.37 
      0.33     -     0.66 
TCC 194 -4.68 (-8.47, -0.89) 0.02 161 -1.81 (-5.99, 2.37) 0.40 189 0.78 (-2.40, 43.96) 0.63 
      0.18     -     0.48 
EPB 198 -0.55 (-1.12, 0.02) 0.06 161 0.19 (-0.46, 0.84) 0.56 191 0.21 (-0.33, 0.76) 0.44 
      0.25     -     0.44 
MPB 280 2.21 (0.02, 4.40) 0.05 220 2.09 (-0.35, 4.53) 0.09 251 0.61 (-1.31, 2.53) 0.53 
      0.99     -     0.19 
BPB 277 0.88 (-1.86, 3.62) 0.53 219 1.61 (-2.19, 5.41) 0.41 250 -0.60 (-3.85, 2.65) 0.72 
      0.70     -     0.31 
PPB 280 2.92 (0.58, 5.26) 0.01 219 2.40 (-0.43, 5.23) 0.01 253 0.51 (-1.63, 2.65) 0.64 
   0.73   -   0.10* 
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LES Positive 
 Low  
Score: [0, 2] 
Medium 
Score: (2, 5] 
High 
Score: (5, 27] 
 N GA Change 95% CI () p N GA Change 95% CI () p N GA Change 95% CI () p 
2,4-DCP 407 0.27 (-1.21, 1.75) 0.72 157 0.16 (-2.02, 2.35) 0.88 184 -0.63 (-3.15, 1.90) 0.63 
      -     0.80     0.52 
2,5-DCP 407 -0.63 (-2.38, 1.12) 0.48 158 0.12 (-2.06, 2.29) 0.92 184 -0.75 (-3.13, 1.63) 0.54 
      -     0.62     0.95 
BP-3 409 1.67 (-0.17, 3.52) 0.08 156 2.07 (-0.59, 4.74) 0.13 184 2.48 (-0.34, 5.29 0.09 
      -     0.46     0.68 
BPA 408 0.46 (-1.56, 2.48) 0.66 159 1.58 (-0.78, 3.94) 0.19 181 1.11 (-1.44, 3.66) 0.39 
      -     0.49     0.77 
BPS 313 -1.65 (-4.05, 0.74) 0.18 105 -0.09 (-3.28, 3.10) 0.95 122 1.12 (-1.92, 4.12) 0.47 
      -     0.19     0.25 
BPF 288 -0.23 (-0.76, 0.29) 0.38 97 0.58 (-0.06, 1.22) 0.08 115 0.34 (-0.30, 0.98) 0.30 
      -     0.23     0.19 
TCS 409 0.67 (-1.93, 3.26) 0.61 156 -0.86 (-4.29, 2.58) 0.63 184 -0.79 (-3.95, 2.37) 0.63 
      -     0.42     0.46 
TCC 314 -4.58 (-7.70, -1.46) 0.004 106 1.77 (-2.12, 5.67) 0.38 124 2.03 (-1.91, 5.97) 0.31 
      -     0.01**     0.01** 
EPB 319 -0.19 (-0.67, 0.28) 0.43 107 0.35 (-0.31, 1.01) 0.30 124 -0.14 (-0.76, 0.48) 0.66 
      -     0.26     0.64 
MPB 409 2.39 (0.50, 4.28) 0.01 157 -0.29 (-2.79, 2.22) 0.82 185 1.68 (-0.36, 3.72) 0.11 
      -     0.05*     0.56 
BPB 406 1.42 (-1.19, 4.03) 0.29 156 -0.41 (-3.76, 2.93) 0.81 184 -0.53 (-4.10, 3.05) 0.77 
      -     0.22     0.38 
PPB 409 2.54 (0.58, 4.49) 0.01 158 -1.35 (-4.68, 1.98) 0.43 185 2.51 (0.33, 4.96) 0.03 
   -   0.02**   0.85 
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LES Negative 
 Low 
Score: [0, -2) 
Medium 
Score: [-2, -5) 
High 
Score: [-5, -30] 
 N GA Change 95% CI () p N GA Change 95% CI () p N GA Change 95% CI () p 
2,4-DCP 359 -0.46 (-2.58, 1.67) 0.67 186 -0.20 (-2.91, 2.51) 0.88 203 1.07 (-0.44, 2.58) 0.17 
      -     0.52     0.21 
2,5-DCP 360 -1.10 (-3.08, 0.89) 0.28 186 -0.42 (-3.14, 2.30) 0.76 203 0.57 (-1.20, 2.34) 0.53 
      -     0.70     0.21 
BP-3 360 1.92 (-0.01, 3.85) 0.05 184 0.72 (-2.39, 3.84) 0.65 205 2.20 (-0.06, 4.45) 0.06 
      -     0.94     1.00 
BPA 359 0.50 (-1.53, 2.53) 0.63 184 2.74 (-0.06, 5.53) 0.06 205 0.24 (-1.97, 2.44) 0.83 
      -     0.86     0.85 
BPS 274 0.65 (-1.81, 3.11) 0.61 136 -2.29 (-5.80, 1.23) 0.21 130 -1.61 (-4.45, 1.23) 0.27 
      -     0.08*     0.23 
BPF 258 0.34 (-0.15, 0.84) 0.18 124 -0.61 (-1.42, 0.20) 0.14 118 -0.04 (-0.61, 0.54) 0.90 
      -     0.09*     0.47 
TCS 361 0.37 (-2.19, 2.94) 0.78 184 -1.35 (-5.18, 2.48) 0.49 204 1.67 (-1.27, 4.60) 0.27 
      -     0.40     0.65 
TCC 276 -2.21 (-4.88, 0.47) 0.11 139 -1.41 (-6.50, 3.68) 0.59 129 0.27 (-3.59, 4.13) 0.89 
      -     0.60     0.53 
EPB 279 0.18 (-0.31, 0.66) 0.47 140 -1.02 (-1.76, -0.28) 0.008 131 0.22 (-0.32, 0.77) 0.42 
      -     0.01**     0.85 
MPB 361 0.70 (-1.06, 2.46) 0.44 184 3.27 (0.60, 5.94) 0.02 206 1.18 (-0.90, 3.27) 0.27 
      -     0.20     0.70 
BPB 357 0.42 (-2.77, 3.62) 0.80 184 2.14 (-1.86, 6.14) 0.30 205 -0.43 (-3.02, 2.15) 0.74 
      -     0.39     0.68 
PPB 362 0.77 (-1.13, 2.67) 0.43 184 4.34 (1.04, 7.63) 0.01 206 1.49 (-0.65, 3.62) 0.17 
   -    0.07*   0.63 
2,4-DCP: 2,4-dichlorophenol; 2,5-DCP: 2,5-dichlorophenol; BP-3: Benzophenone; TCS: Triclosan; TCC: Triclocarban; EPB: Ethyl-paraben; MPB: Methylparaben; BPB: 
Butylparaben; PPB: Propylparaben 
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a Models adjusted for specific gravity, maternal age, insurance type, alcohol use, and exposure to second-hand smoking. ** interaction p value <0.05; * 0.05< interaction p 
value<0.10. 
 
Table V.9: Adjusteda change in gestational length in relation to average exposure biomarker concentration across three time points during 
pregnancy, stratified by LES variables and infant sex. Beta coefficients were transformed to the change in the number of gestational days per IQR 
change in exposure biomarker concentration. 
 Total LES 
 Females Males 
 Negative Neutral Positive Negative Neutral Positive 
Urinary 
Biomarker 
GA Change  
95% CI () 
p 
GA Change 
 95% CI () 
p 
GA Change  
95% CI () 
p 
GA Change  
95% CI () 
p 
GA Change  
95% CI () 
p 
GA Change  
95% CI () 
p 
BPA 2.93 (-0.6, 6.46) 
0.1
1 
0.71 (-2.42, 
3.85) 
0.6
6 
1.48 (-2.75, 5.7) 
0.5
0 
1.7 (-1.78, 5.19) 
0.3
4 
2.97 (-1.02, 
6.97) 
0.1
5 
-0.51 (-3.5, 
2.45) 
0.7
4 
BPS 
-0.79 (-6.14, 
4.55) 
0.7
7 
-1.47 (-6.2, 
3.28) 
0.5
5 
1.38 (-2.98, 
5.74) 
0.5
4 
-5.06 (-9.4, -
0.72) 
0.0
3 
-0.77 (-5.66, 
4.1) 
0.7
6 
1.15 (-2.06, 
4.36) 
0.4
8 
TCS 
0.74 (-3.88, 
5.35) 
0.7
6 
-2.36 (-6.4, 
1.69) 
0.2
6 
-4.50 (-9.04, 
0.04) 
0.0
6 
2.40 (-1.54, 
6.34) 
0.2
4 
3.36 (-2.49, 9.2) 
0.2
6 
2.00 (-1.83, 
5.82) 
0.3
1 
TCC -6.41 (-13, 0.19) 
0.0
6 
1.29 (-4.3, 
6.88) 
0.6
5 
3.59 (-1.84, 
9.02) 
0.2
0 
-4.08 (-9.02, 
0.85) 
0.1
1 
-6.95 (-13.2, -
0.7) 
0.0
3 
1.43 (-2.69, 
5.56) 
0.5
0 
MPB 2.83 (0.17, 5.48) 
0.0
4 
1.22 (-1.69, 
4.12) 
0.4
2 
1.19 (-2.33, 4.7) 
0.5
1 
-0.93 (-4.47, 
2.62) 
0.6
1 
3.31 (-0.75, 
7.37) 
0.1
1 
0.56 (-1.67, 
2.79) 
0.6
2 
PPB 4.66 (1.53, 7.8) 
0.0
0 
0.23 (-2.74, 
3.21) 
0.8
8 
1.56 (-2.08, 
5.21) 
0.4
0 
0.75 (-2.75, 
4.25) 
0.6
8 
4.05 (-0.67, 
8.78) 
0.1
0 
0.37 (-2.32, 
3.05) 
0.7
9 
 
Negative LES 
 Females Males 
 Low Medium High Low Medium High 
Urinary 
Biomarker 
GA Change  
95% CI () 
p 
GA Change 
 95% CI () 
p 
GA Change  
95% CI () 
p 
GA Change  
95% CI () 
p 
GA Change  
95% CI () 
p 
GA Change  
95% CI () 
p 
BPA 
0.97 (-1.74, 
3.69) 
0.4
8 
3.15 (-2.99, 
9.29) 
0.3
2 
2.52 (-0.53, 
5.57) 
0.1
1 
-0.18 (-3.37, 
3.02) 
0.9
1 
3.43 (0.29, 
6.57) 
0.0
4 
0.25 (-2.92, 
3.43) 
0.8
8 
BPS 
0.83 (-2.54, 
4.19) 
0.6
3 
0.94 (-5.17, 
7.06) 
0.7
6 
1.25 (-4.71, 
7.22) 
0.6
8 
-0.53 (-4.51, 
3.45) 
0.7
9 
-3.44 (-7.35, 
0.5) 
0.0
9 
-1.26 (-4.8, 
2.27) 
0.4
9 
TCC 
0.23 (-4.01, 
4.47) 
0.9
2 
-5.90 (-15.8, 
4.0) 
0.2
5 
2.25 (-4.33, 
8.83) 
0.5
1 
-4.09 (-8.65, 
0.47) 
0.0
8 
0.47 (-3.89, 
4.83) 
0.8
3 
-1.96 (-6.01, 
2.1) 
0.3
5 
MPB -0.35 (-2.71, 2) 
0.7
7 
2.16 (-1.21, 
5.53) 
0.2
1 
4.52 (1.11, 7.93) 
0.0
1 
1.53 (-1.29, 
4.35) 
0.2
9 
1.98 (-0.79, 
4.75) 
0.1
6 
-1.29 (-4.8, 
2.22) 
0.4
7 
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PPB 
-0.51 (-2.9, 
1.88) 
0.6
7 
4.66 (0.34, 
8.98) 
0.0
4 
2.88 (-0.35, 
6.12) 
0.0
8 
1.05 (-1.69, 
3.79) 
0.4
5 
2.11 (-1.99, 
6.22) 
0.3
2 
2.21 (-1.35, 
5.76) 
0.2
3 
 
Positive LES 
 Females Males 
 Low Medium High Low Medium High 
Urinary 
Biomarker 
GA Change  
95% CI () 
p 
GA Change 
 95% CI () 
p 
GA Change  
95% CI () 
p 
GA Change  
95% CI () 
p 
GA Change  
95% CI () 
p 
GA Change  
95% CI () 
p 
BPA 
0.89 (-1.85, 
3.62) 
0.5
3 
2.27 (-1.61, 
6.15) 
0.2
6 
4.39 (-0.46, 
9.24) 
0.0
8 
0.77 (-2.58, 
4.11) 
0.6
5 
1.74 (-1.84, 
5.32) 
0.3
5 
0.82 (-1.99, 
3.63) 
0.5
7 
BPS 0 (-3.53, 3.53) 
1.0
0 
0.43 (-4.3, 
5.17) 
0.8
6 
1.37 (-4.58, 
7.32) 
0.6
6 
-2.15 (-6.35, 
2.04) 
0.3
2 
0.83 (-4.06, 
5.73) 
0.7
4 
0.39 (-2.54, 
3.32) 
0.8
0 
TCC 
-3.28 (-8.05, 
1.48) 
0.1
8 
-0.1 (-6.24, 
6.04) 
0.9
8 
7.94 (-1.86, 
17.75) 
0.1
2 
-6.53 (-11.3, -
1.8) 
0.0
1 
5.65 (-0.25, 
11.5) 
0.0
7 
1.86 (-1.85, 
5.58) 
0.3
3 
MPB 
1.77 (-0.44, 
3.97) 
0.1
2 
-0.71 (-4.36, 
2.9) 
0.7
0 
4.07 (0.31, 7.83) 
0.0
4 
2.08 (-1.03, 
5.19) 
0.1
9 
0.25 (-2.57, 
3.08) 
0.8
6 
0.55 (-2.42, 
3.53) 
0.7
2 
PPB 
2.16 (-0.23, 
4.55) 
0.0
8 
-0.53 (-3.55, 
2.5) 
0.7
3 
5.18 (1.08, 9.28) 
0.0
2 
2.42 (-1.08, 
5.93) 
0.1
8 
-0.95 (-4.14, 
2.2) 
0.5
6 
1.76 (-1.45, 
4.97) 
0.2
9 
TCC: Triclocarban; MPB: Methylparaben; PPB: Propylparaben 
a Models adjusted for specific gravity, maternal age, insurance type, alcohol use, and exposure to second-hand smoking. 
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  Conclusions and Integration of Findings 
 
 
This dissertation presents findings from four studies on the relationships between phenol, 
paraben and triclocarban exposure during pregnancy, maternal hormone levels, and birth 
outcomes. These results provide strong evidence for a role these chemicals have in impacting 
gestational length and birth size, suggesting a possible mediating effect of maternal hormones, as 
well as a possible modifying effect of maternal stress. Previous studies in this area have been 
limited, were cross-sectional in nature, and did not include the same breadth of exposure 
biomarkers and hormones. This is also the first study to report interactions between maternal 
stress and these exposure biomarkers on birth outcomes. Figure VI.1 summarizes the interaction 
between the hormone pathways explored in this dissertation that could be disrupted via chemical 
exposure and maternal stress, leading to changes in gestational length. While additional 
investigations are required, this dissertation provides implications for future health policies 
aimed to reduce adverse birth outcomes in the population.  
Exposure biomarkers and hormones. Aim 1 of this dissertation examined the effect of phenols, 
parabens and triclocarban on maternal thyroid and reproductive hormones. The first study was 
conducted on the LifeCodes cohort of pregnant women in Boston, MA, and only included 
thyroid hormones.  The associations differed by exposure biomarker, but the majority of the 
significant associations were with T3 and TSH, and few exposure biomarkers were associated 
with changes in FT4 and T4. BP-3, triclosan, triclocarban, and BPB were associated with a 
decrease in T3, while MPB was associated with an increase in T3. BPS and TCS were associated 
with an increase in TSH, whereas triclocarban was associated with a decrease in TSH. There 
appeared to be windows of vulnerability: BPS, MPB and PPB were associated with thyroid 
hormone at earlier time points in pregnancy, whereas BPB was associated with thyroid hormone 
later in pregnancy.   
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A second study was conducted on a cohort of pregnant women in Northern Puerto Rico. This 
study included reproductive hormones as well thyroid hormones, and included more exposure 
biomarkers than the first study. However, the women in this cohort had serum hormone analyses 
conducted at two time points during pregnancy, rather than the four time points the LifeCodes 
cohort included. There were differences in the associations observed. Triclosan was also 
associated with a decrease in T3; however, triclocarban was associated with an increase in T3 in 
this study. BPS was associated with a decrease in TSH at study visit 1, in contrast to the increase 
in TSH at study visit 1 in LifeCodes. There were no strong associations between MPB and 
thyroid hormones in the PROTECT cohort, as opposed to the increase in T4 and T3 with MPB in 
LifeCodes. However, MPB was associated with a decrease in TSH at the third study visit, similar 
to the LifeCodes cohort. Associations with BPS and MPB were stronger at the earlier time point 
in pregnancy, whereas associations with triclosan and triclocarban were stronger at the later time 
point. 
Differences in the results may be explained by differences in the study populations. The largest 
differences observed between the two cohorts included associations with triclocarban and BPS. 
Concentrations of triclocarban in the PROTECT cohort were much higher than the levels 
detected in LifeCodes, partly due to the differences in the LODs across both studies. The 
geometric mean of triclocarban was 4.3 µg/L in PROTECT with less than 6% below the LOD 
(0.1 µg/L), and geometric mean in LifeCodes was below the LOD (2 μg/L). Similarly, the 
geometric mean of BPS in PROTECT was 0.5 µg/L with less than 10% of samples below the 
LOD (0.1 μg/L), whereas the geometric mean of BPS concentrations in LifeCodes was below the 
LOD (0.4 μg/L). The differences in the LODs and higher concentrations observed in PROTECT 
may, at least partly, explain the differences observed between the two cohorts. Other exposure 
biomarkers in the PROTECT cohort also had lower LODs than the corresponding biomarkers in 
LifeCodes (including 2,4-DCP, 2,5-DCP, BPB and PPB) providing an advantage in exploring the 
dose-response curves of the exposure biomarkers at lower levels of exposure. No evidence of 
non-linearity was observed in the PROTECT cohort in exposure-hormone models. 
 In addition, the two study populations differed in their timing and characteristics. LifeCodes 
includes mostly White women of high income, whereas the PROTECT cohort is predominantly 
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Hispanic and dependent on public health insurance. Thus, there may be other residual 
confounders unaccounted for that explain the differences observed. 
With regards to reproductive hormones, parabens were associated with a decreased level of 
SHBG, particularly at the earlier time point. In conference with the decrease in SHBG, MPB was 
also associated with a decrease in testosterone, estriol, and progesterone at the earlier time point. 
The testosterone, estriol and progesterone concentrations measured are all total hormone 
concentrations; therefore, these concentrations include the SHBG-bound hormones. This could 
indicate a direct effect of MPB on the levels of SHBG, which subsequently decreased the total 
concentrations of SHBG-bound hormones. An in vitro study showed that parabens effectively 
bind to SHBG [1], which supports the hypothesis that parabens can directly impact the binding 
affinity of SHBG. This is further evidenced by the strength of associations observed in our study. 
SHBG binds strongly to testosterone, followed by estriol, and weakly to progesterone [2]. My 
analysis showed the strongest association at the earlier time point was between MPB and 
testosterone, followed by estriol, and finally progesterone, mimicking SHBG’s order of affinity. 
A decrease in SHBG may allow the mother to be more vulnerable to fetal sex hormones that pass 
through the placenta [3]. A decrease in SHBG has also been associated with hypothyroidism [4]; 
however, MPB in this study was also associated with a decrease in TSH. A decrease in TSH is 
evidence of hyperthyroidism, rather than hypothyroidism. Alternatively, this decrease in SHBG 
could indicate liver toxicity given that SHBG is produced in the liver. 
Other associations between exposure biomarkers and hormones varied. BPS was strongly 
associated with a decrease in CRH, whereas triclosan was strongly associated with an increase in 
CRH. Triclosan was also associated with an increase in testosterone and progesterone. BPA, on 
the other hand, was associated with a decrease in testosterone.  
There were limitations across both studies. While both studies improved upon the cross-sectional 
design, the included time points may not be sufficient in understanding the complexities of these 
associations due to the changing hormone levels, and the high variation in exposure biomarkers 
throughout the day and throughout pregnancy. Furthermore, we did not take into account the 
iodine status, nor did we measure thyroperoxidase antibodies and human chorionic gonadotropin 
(hCG), any of which could impact thyroid function and confound our results. There were many 
models run, and there may be associations observed simply due to chance. However, I did not 
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apply any adjustments to correct for the multiple comparisons (such as the Bonferroni 
adjustment) because the methods are too conservative, risking Type II error, and potentially 
missing important relationships in this exploratory analysis. Despite the limitations, there were 
many strengths to the studies. The collection of exposure biomarkers and hormone data at 
multiple time points during pregnancy helps account for the biomarkers’ short lifespan in the 
body, and the varying levels of hormones throughout pregnancy. Our robust sample size also 
allowed us to be able to explore potential windows of susceptibility for these associations. 
In conclusion, my findings from Aim 1 provide evidence of endocrine disruption properties of 
phenols, parabens and triclocarban. This endocrine disruption could potentially lead to adverse 
health outcomes, particularly in the context of pregnancy, where there are many developmental 
changes occurring and even slight changes to hormone levels could impact the growing fetus. 
Further studies are needed to understand these associations better to protect the mother and her 
fetus. 
Exposure biomarkers and birth outcomes. Aim 2 of this dissertation examined the effect of 
phenols, parabens and triclocarban on birth outcomes. I first looked at the average exposure of 
each exposure biomarker across three study visits, and then examined windows of susceptibility 
by stratifying the models by study visit. We found that BP-3, MPB and PPB were associated 
with an increase in gestational length. The associations with MPB, PPB and BPA were strongest 
at the first study visit indicating earlier time points are more vulnerable to changes in gestational 
length. BP-3 associations did not differ by study visit. Triclocarban was suggestively associated 
with a decrease in gestational length, and the association was also stronger at earlier time points 
in pregnancy. Associations with triclosan, on the other hand, differed by fetal sex. Triclosan was 
associated with an increase in gestational length among male fetuses, and a decrease in 
gestational length among female fetuses. We wanted to look into differences in preterm birth 
(spontaneous versus placental), but were limited by the sample size. Furthermore, most of our 
significant associations indicated an increase in gestational length, rather than a decrease. 
None of the exposure biomarkers were associated with birthweight; there were however 
associations with birth size. Parabens were protective of SGA, but were not associated with 
LGA. Triclosan was associated with a higher odds of SGA, and BP-3 was associated with a 
higher odds of LGA, and these associations were strongest at 20-24 weeks gestation. The 
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relationship between BPS and birth size differed by study visit. At 16-20 weeks gestation, BPS 
was associated with LGA; however, at 24-28 weeks gestation, BPS was associated with SGA. To 
date, no other studies have looked into the association between BPS and birth outcomes in 
humans, and this finding of opposite directions of associations by time point needs to be verified 
by future studies as our significant results could be due to chance. Nevertheless, this finding 
highlights the importance of investigating effects of endocrine disruptors at different time points 
during pregnancy. It can also help explain why results in this area of research can vary from one 
study to another.  
Few studies have looked into the relationships between these exposure biomarkers and birth 
outcomes. One study examined the association between BP-3 and gestational length, and 
reported a decrease in gestational length, in conflict with our results [5]. However, as previously 
mentioned, it appears that the timing of exposure is important in determining the outcome. In the 
mentioned study, BP-3 was measured at delivery, whereas our measurements were conducted at 
up to 28 weeks, i.e. the beginning of the third trimester. Similarly, studies that looked at the 
association between BPA and gestational length also measured BPA concentrations at delivery, 
all of which reported a decrease in gestational length with higher concentrations of BPA [5–7], in 
contrast to our finding of an increase in gestational length at 16-20 weeks gestation. These 
studies that look at BPA concentrations at time of delivery also risk reverse causation. Higher 
risk pregnancies involve more invasive medical care, leading to higher BPA exposure through 
medical equipment. Thus, the shortened gestational length could result in higher BPA 
concentrations rather than BPA leading to that adverse change. There was one study that looked 
at BPA levels at a similar time point to our study, and also reported an increase in gestational 
length with higher maternal plasma concentrations of BPA [8]. 
Previous reports on parabens were more in line with our results. Geer et al. also reported a 
protective effect on preterm birth [9], similar to our findings. We detected a decrease in SHBG 
and an insignificant decrease in estriol in association with paraben biomarkers in Aim 1. 
Estrogens increase steadily during pregnancy, and play a role in gestational length by stimulating 
uterine prostaglandins and contractions [10,11]. Therefore, it is possible that a decrease in these 
hormones by parabens could influence this important rise that triggers parturition, leading to a 
longer gestational length. Parabens have also been reported to increase birthweight and birth 
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length, which could indicate an increase in birth size [12,13]. While we did not report an increase 
in birth size with paraben biomarkers, we did observe a protective effect against SGA at the 20-
24 weeks gestation time point.  
There were no previous studies that looked into triclocarban’s impact on gestational length. 
However, triclocarban was associated with an increase in T3 in Aim 1. A previous report found 
that high levels of T3 at similar time points to the study visits reported in PROTECT was 
associated with an increased odds of preterm birth [14]. Therefore, our finding could indicate a 
potential mediating effect of T3 in the association between triclocarban and decreased gestational 
length. 
With regards to our association between gestational length and triclosan, four other studies also 
reported on significant associations between triclosan and birth outcomes among boys only [15–
18]. Fetal sex can impact the gestational environment, and cause different birth outcomes. For 
example, preterm births due to pre-eclampsia are more common in female infants versus male 
infants [19], and there are differences in placentation by fetal sex that could lead to adverse birth 
outcomes [20]. Thus, it is plausible that the interaction between triclosan and fetal sex could lead 
to different birth outcomes, possibly mediated by an androgenic effect from triclosan [34]. In 
fact, as reported in CHAPTER III, triclosan was associated with an increase in maternal 
testosterone levels in the PROTECT cohort. 
The analyses included in Aim 2 is the largest human study to date to look at the relationship 
between phenols, parabens and triclocarban in relation to birth outcomes that includes several 
time points. While there were many strengths to this study, there were some limitations. Similar 
to the limitations pertaining to Aim 1, the variation of concentrations of these exposure 
biomarkers over time may introduce potential bias. We also had a smaller sample size for some 
of the emerging phenols of concern, such as BPA replacement chemicals, and triclocarban as 
they were added to the analytical panel part-way through the study. Unlike most other studies in 
this area, however, we were able to explore windows of susceptibility over a number of birth 
outcomes. Additionally, even though our sample sizes were smaller for some analytes, we are 
among the first to explore associations with some emerging chemicals of interest. Our population 
had an exceptionally high concentration of triclocarban as compared to other populations, 
allowing us to study this association in a vulnerable population. While further studies are 
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required to substantiate our results, the work presented in Aim 2 provides evidence to caution 
parents about the kind of products used during pregnancy. 
Interaction between exposure biomarkers and psychosocial stress. Aim 3 expanded the analysis 
of Aim 2 by exploring the interaction between exposure biomarkers and psychosocial stress 
indices on gestational length. Interactions between chemical and non-chemical stressors are 
important to consider in deepening our understanding on how the environment impacts humans. 
Stress can impact the human body via similar mechanisms of action to those proposed for 
phenols, parabens and triclocarban, leading to multiple “hits” on a system, eventually increasing 
the allostatic load sufficiently to cause an adverse effect.  
Four psychosocial indices were available from the PROTECT cohort, including perceived stress, 
depression, social support and a life events survey (LES). Only interactions with the LES score 
were statistically significant, and the rest of Aim 3 focused on the results of these interactions. 
The LES score was further divided into only the positive life events and the negative life events.  
Associations with BPS, triclocarban, MPB and PPB were strongest when the total LES scores 
were negative, indicating that gestational length was most affected in the presence of higher 
concentrations of the exposure biomarkers, as well as overall negative life events. In Aim 2, 
associations between the average BPS and triclocarban concentrations were not significantly 
associated with gestational length; however, Aim 3 reports significant associations in the 
presence of negative life events. Associations between BP-3 and gestational length were not 
modified by LES. In the examination of negative life events alone, women with medium and 
high scores of Negative LES had stronger associations between the exposure biomarkers and 
gestational length. The association between triclocarban and gestational length was strongest 
when the Positive LES score was low, indicating the lack of positive life events modified the 
association more so than the presence of negative life events. 
None of the psychosocial indices were independently associated with gestational length in our 
dataset. Therefore, this indicates that the presence of psychosocial stress was not sufficient to 
illicit a response. It was only in the presence of both higher concentrations of exposure 
biomarkers and negative scores of Total LES that we observe up to five-day changes in 
gestational length. These results support the multiple hit theory described in Error! Reference 
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source not found.. Aim 3 further highlights the importance of examining the impact of multiple 
stressors on health, rather than looking at individual chemicals or other stressors in silo.  
Given the relationships observed between the exposure biomarkers and hormones in Aim 1, it is 
possible that the associations observed in Aims 2 and 3 were at least partly mediated through 
endocrine disruption. Life events is used as a proxy measure for maternal stress, and maternal 
stress has been implicated to negatively impact the maternal-placental-fetal hypothalamic-
pituitary-adrenal axis [21,22]. A pertinent hormone in stress-caused responses is cortisol, which 
is mediated by levels of CRH. While cortisol and CRH are part of the HPA axis, they also 
influence thyroid hormones part of the HPT axis [23], and are influenced themselves by 
reproductive hormones such estrogens and progesterone [24]. This complex interplay of 
hormones make it difficult to disentangle how the combined effect of exposure biomarkers and 
stress could in unison impact gestational length, but it does speak to the potential vulnerability in 
the system in the case of multiple hits. For example, excess stress increases levels of cortisol, 
which is implicated in stimulating preterm birth [25]. Cortisol, however, also inhibits T4 to T3 
deodination; T3 is another hormone implicated in stimulating preterm birth [14]. As previously 
mentioned, none of the stress indices were associated with gestational length in this cohort. As 
shown in Aim 1, triclocarban was associated with an increase in T3. Thus, it may be possible that 
the combined effect of an increase in cortisol via negative life events, as well as an increase in 
T3 via triclocarban caused a sufficient allostatic overload, leading to a significant decrease in 
gestational length. 
The associations with parabens were especially difficult to interpret. Parabens were associated 
with an increase in gestational length; however, maternal stress is associated with a decrease in 
gestational length. Parabens were associated with a decrease in estriol, while stress is associated 
with an increase in CRH [26] and subsequent increase in estriol [11]. Additionally, parabens 
have antimicrobial properties which could decrease inflammation, while stress is associated with 
an increase in inflammation [27]. Because of these opposite biological effects, I would have 
expected to see no effect on gestational length with high levels of stress and paraben exposure. 
This conflicting finding could indicate that parabens affect gestational length through a different 
mechanism than the one proposed, or it could indicate that interaction between stressors act 
differently than in the presence of each stressor alone. This was also observed in an animal study 
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that exposed rats to various stressors across two generations, and also observed different effects 
on birth outcomes with different combination of stressors [28].   
Aim 3 was the first study to look at the interaction between this set of exposure biomarkers and 
psychosocial stressors. A unique strength of this study was its exploration of positive, as well as 
negative life events. Most studies examine the effect of negative events and/or maternal stress 
without exploring the buffering effects of positive life events. This study the importance of 
looking at both in understanding the modifying effect of stress on chemical exposures and birth 
outcomes. While the robust sample size allowed us to look for interactions effectively, there 
were some limitations to the study. The timing of maternal stress could influence the effect on 
the fetus [26]; however, we did not have data on when the life event took place apart from 
happening sometime between the beginning of pregnancy and the mid-way through the second 
trimester. Similarly, we had no data on the participants’ psychosocial profiles past this time 
point. Given this, we had to rely on average biomarker concentrations as our exposure proxies. 
The three time points used to calculate the average concentration is more robust than using a 
single time point, but the models resemble a cross-sectional design. 
Future Research Recommendations 
These results add to the growing evidence on the risk of phenol, paraben and triclocarban 
exposure on adverse birth outcomes. While this dissertation examines these associations in a 
large cohort, future studies are required to validate our findings. Of note, we found differences 
across the associations by time point in pregnancy, so future studies should include more time 
points to look for potential windows of vulnerability, and confirm our findings.  
I originally proposed to estimate the extent to which hormones mediate the associations between 
the exposure biomarkers and gestational length. However, the effect estimates of the associations 
between the biomarkers and gestational length were relatively small, and the mediation analysis 
would have further diluted the estimates, making it difficult to observe meaningful results. There 
were also no associations between any of the hormones and gestational length in our dataset, 
possibly due to the smaller sample size for which hormone levels have been measured. Thus, 
future studies should look to estimate this mediation in a larger sample size. Furthermore, 
evidence suggests hormone trajectories provide better prediction of pregnancy health as 
compared to point estimates due to the large variation in hormone levels between women. High 
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variation also exists within women, and our models did not adjust for these diurnal hormone 
changes. Future studies should try to incorporate more time points that are further apart to better 
estimate hormone trajectories and their subsequent mediating effects on pregnancy health. Other 
pathways should also be considered. Associations between phenols and parabens in relation to 
inflammation and oxidative stress have been observed, and could also explain the adverse effects 
observed in this cohort. Other pathways could also include epigenetic changes. Further studies 
are required to demonstrate the pathways involved.  
There has been a push to examine chemical mixtures, rather than studying the effects one 
chemical at a time. The chemicals included in this dissertation (as well as many others not 
included) are ubiquitous in our anthropogenic environment. Therefore, it is imperative that future 
work looks at the combined effect of these chemicals on health to understand the implications of 
any possible interactions.  
In addition to looking at chemical mixtures, interactions between chemical and non-chemical 
stressors is another largely untapped area of research in the area of endocrine disruptors. This 
dissertation examines the interaction with psychosocial stressors, but there are other equally 
important stressors than could modify associations between chemical exposure and health. In the 
context of Puerto Rico specifically, the data collected for this dissertation occurred prior to 
Hurricane Maria. Thus, stress will contribute to health even more so now, and studying the 
effects of this stress will be important in implementing effective strategies to improve overall 
health and well-being of the Puerto Rican population.  
Finally, the majority of research on endocrine disruptors has focused on the biology and statistics 
of the issue. However, more studies on practically reducing exposure to such chemicals are 
required. Some researchers have attempted to study the effect of switching personal care 
products and making dietary changes, but results on the efficacy of such changes have varied 
[29–31].  
Public Health Impact 
Exposure to phenols, parabens and triclocarban may contribute to changes in gestational length, 
including the high preterm birth rate in Puerto Rico. There has been a push to educate and 
communicate these risks to the general public in order to reduce exposure. There is some 
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evidence supporting lower concentrations of exposure biomarkers after switching certain 
products [29–31], and this dissertation supports the need for such programs. 
However, there are several issues with the approach of relying on public education alone. First, 
education does not necessarily lead to behavior change. In spite of high risk perception, change 
in cosmetic use among pregnant women did not occur [32]. Second, products that avoid use of 
endocrine disrupting chemicals tend to be cost-prohibitive and can exclude those of lower 
socioeconomic status. In fact, there is evidence of higher concentrations of phthalates in less 
educated pregnant women with lower incomes [33]. Therefore, there is concern regarding 
burdening those with lower socioeconomic status with guilt in the case of an inability to change 
the products they use.  
A better approach would be to make the safety of all products a priority and requirement. 
Currently, it has been difficult to apply policies to limit the use of these endocrine disruptors 
given industry’s push to raise doubt on their health impacts. Instead, a more comprehensive 
approach to chemical safety may be a better route. Green chemistry principles have been 
introduced to consider the health and environmental safety of chemicals during the initial 
chemical engineering design and process. Such initiatives may be difficult to implement, but 
would be highly worthwhile in the future, given the burden of impact hazardous chemicals have 
on population health. Thus, this research grows our understanding of the impacts and potential 
pathways involved in phenols, parabens and triclocarban exposure on pregnancy, thereby, 
helping to create overall safer chemicals.  
The results pertaining to the modifying effect of maternal stress on this population in Puerto Rico 
is especially relevant today. Hurricane Maria, a Category 5 Hurricane, hit Puerto Rico in late 
2017, leading to catastrophic damage. Many were left without electricity, running water and/or 
homeless, and remain in need today. The data collected as part of this dissertation were collected 
prior to the event, and do not reflect the effects post-hurricane, but can serve as a baseline for 
future comparisons. Based on this analysis, in addition to the direct effects of Hurricane Maria 
on the health of the Puerto Rican population, the elevated levels of stress as a result of Hurricane 
Maria created a biological state more vulnerable to various stressors, including chemical 
exposures. Chemical exposures were likely to be especially elevated due to the destruction of 
buildings, increased consumption of canned foods, increased cooking over open fires, and other 
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coping strategies. Thus, maternal and fetal health will be especially affected from this event. In 
addition to the continued emergency assistance the Puerto Rican population requires, 
interventions should be put in place to alleviate the effects of these multiple stressors on pregnant 
women.  
Overall Conclusions 
In conclusion, this dissertation provides evidence for the endocrine disrupting properties of 
phenols, parabens and triclocarban during pregnancy, which could potentially mediate the 
relationship between the exposure biomarkers and birth outcomes. Additionally, this dissertation 
provides evidence for a modifying effect of psychosocial stress, where negative life events can 
strengthen associations between exposure biomarkers and gestational length. This body of work 
significantly improves upon the body of knowledge in this area of research by utilizing a large 
prospective cohort study, and by exploring the modifying effect of psychosocial factors during 
pregnancy. This is also the first study to include this breadth of exposures and birth outcomes in 
a cohort of pregnant women. Thus, these results provide a strong argument for the role of 
phenols, parabens and triclocarban in the risk of adverse birth outcomes, and can be used to 
support stronger policies in the future. 
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Figure VI.1: Depiction of hormone pathways during pregnancy. Bolded hormones are hormones studied in this dissertation. SHBG rises and falls 
with thyroid hormones. Some evidence supports testosterone’s role in initiating parturition, but it is unclear how. CRH is produced by 
hypothalamus and placenta, and has an important role in setting biological clock of pregnancy duration. CRH is also produced by the 
hypothalamus with maternal stress to stimulate cortisol production. Phenols, parabens and triclocarban are associated with changes in these 
hormones during pregnancy, which could affect gestational length.  
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